Volume 31, issue 3 by Canadian Medical Association
Western University
Scholarship@Western
Canadian Journal of Surgery
5-1-1988
Volume 31, issue 3
Canadian Medical Association
Follow this and additional works at: https://ir.lib.uwo.ca/cjs
Part of the Surgery Commons
This Book is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Canadian Journal of Surgery by an
authorized administrator of Scholarship@Western. For more information, please contact tadam@uwo.ca, wlswadmin@uwo.ca.
Recommended Citation
Canadian Medical Association, "Volume 31, issue 3" (1988). Canadian Journal of Surgery. 187.
https://ir.lib.uwo.ca/cjs/187
The E 
Canadian j 
Journal (2
of Surgery (t
n1
OR SWALLOW 
EASILY
WITH CITRUCEL 
THE NEW 
BULK-FORMING 
LAXATIVE.
The way powdered bulk­
forming laxatives mix, 
look and (most impor­
tantly) taste means some 
patients cut down on 
their doses or skip them 
altogether.
NewCitrucel has all 
the laxative effectiveness 
and fibre of the leading 
brand! It mixes quickly, 
has a smooth taste and 
goes down easily so most 
of your patients will take 
it every day
So recommend Citrucel. 
A proven laxative that 
tastes great, without the grit
Citrucel,
M£THYlCtUUlOSt
ALL THE FIBRE. 
WITHOUT THE GRIT.
MERRELL DOW PHARMACEUTICALS (CAMDA) INC.
MEMBER
paab)
r
* *
k
►
Fo r p re sc r ib in g  in fo rm atio n  se e  page  197
VOLUME 31, NUMBER 3
journalcanadiende chirurgie
LIST OF CONTENTS
QUILL ON SCALPEL
Defunctioning Colostomy: an Outmoded Operation?
L.D. MacLean
139
Colonoscopy After Resection for Bowel Cancer -  Is It Already Too Late to Answer the Questions?
C.J. Wright
140
SURGEONS’ UPDATE
Royal College Statement on Informed Consent; Task Force Formed to Analyse Use of Health Care Services in Ontario; 142
Princess Margaret Hospital’s New Radiotherapy Unit Approved
L. Williamson
HOW I DO IT
Ivalon Sponge Wrap Operation
P.H. Gordon
143
CANADIAN ASSOCIATION OF CLINICAL SURGEONS
Cyclosporin A Metabolites Suppress T-Cell Proliferation by Concanavalin A and in a Mixed Lymphocyte Reaction 145
M. Abecassis, P.Y. Wong, N. Mason, F. Cheung, A.V. Mee, E.H. Cole, B. Langer, Z. Cohen, G.A. Levy
Prognostic Factors in Colorectal Carcinoma of Young Adults 150
M.C. Taylor, D. Pounder, N.H. Ali-Ridha, A. Bodurtha, E.C. MacMullin
Profound Hypothermia and Circulatory Arrest in Excision of Renal Cell Carcinoma Invading the Vena Cava
T.E. Theman, R.A. Stauffer, J.B. Lennert, C.D. Saunders
153
CANADIAN SOCIETY FOR VASCULAR SURGERY
Symposium on Mesenteric Ischemia
1. Acute Intestinal Ischemia 157
W.G. Jamieson
2. Chronic Mesenteric Ischemia 159
C.R. Lye
3. Colonic Ischemia After Aortic Reconstruction 162
P.D. Fry
ORIGINAL ARTICLES
Methyldopa Hypersensitivity Can Mimic Acute Toxic Enteritis
B.A. Young, M.J. Girotti
165
VOLUME 31, NO. 3 M AY 1988 /THE CANADIAN JOURNAL OF SURGERY 137
LIST OF CONTENTS Cont'd
Primary Resection and Anastomosis of Lesions Obstructing the Left Colon
R.G . G oo da ll, M. P ark
167
Treatment of Experimental Peritonitis With Intraperitoneal 
Povidone-iodine Solution
M. O g u z , M. B e k te m ir, M. D u lge r, R. Yalin
169
Multiorgan Failure in Critically III Patients
G .E . D a rlin g , J.H . D u ff, R .A. M u s ta rd , R.J. F in le y
172
Lipomas of the Colon: a Clinicopathologic Review
B .J. F lancock, A. V a jcn e r
178
Early Results With the J-Pouch Procedure in Children
D.E. W esson
182
Effects of Immobilization and Continuous Passive Motion on Postoperative Muscle Atrophy in Mature Rabbits
W .J A . D hert, S .W . O 'D ris c o ll, B.J. van  Royen, R .B. S a lter
185
Colonoscopy in the Follow-up of Patients With Colorectal Carcinoma
C -A . V as ilevsky , P.FI. G o rd o n
188
Demographic and Medical Characteristics of Adult Head Injuries in a Canadian Setting
W .G . S now , M.S. M a ca rtn e y -F ilg a te , M .L . S c h w a rtz , P.S. K lo n o ff, B .A . R id g le y
191
Preservation of the Spleen Using Human Fibrin Seal
S.W . C h u n g , A .G . N agy
195
A Review of Intra-articular Knee Injuries in Racquet Sports Diagnosed by Arthroscopy
H.J. M a rans, D .K. K e n n e d y , T.G . K avan agh , T .A . W rig h t
199
HISTO RY O F SURGERY
Further Remembrances of That Revered Anatomist, Dr. J.C. Boileau Grant
C .L .N . R ob inson
203
Books Received 158
SESAP V Question 166
SESAP V Critique 194
Book Reviews 202
Classified Advertising 206
Advertisers’ Index 206
Notice of Change of Address/Avis de changement d’adresse 206
138 VOLUME 31, NO. 3 M A Y  1988 /THE CANADIAN JOURNAL OF SURGERY
QUILL ON SCALPEL
This section provides a medium through which Canadian 
surgeons can declare themselves, briefly and informally, on 
the day-to-day affairs of surgery.
Defunctioning Colostomy: an Outmoded Operation?
For many years primary resection 
with anastomosis has been the treat­
ment of choice for lesions causing 
total obstruction of the right colon. It 
has the attraction of removing the 
lesion, anastomosing to collapsed, 
albeit unprepared, colon using small 
intestine that can be decompressed by 
milking the liquid contents back or in­
to the portion of bowel to be resected.
In marked contrast, surgeons have 
been much less inclined to resect such 
lesions in the left colon and to per­
form primary anastomosis.
We were all influenced by the low 
mortality (8%)‘ reported as early as 
the 1940s when right transverse colos­
tomy was performed for obstructing 
left colonic lesions; previously, when 
cecostomy had been used, the death 
rate for large-bowel obstruction was 
50%.2 After a totally diverting colosto­
my and before definitive resection it 
is possible to cleanse the colon com­
pletely so that a wider resection can
be performed if carcinoma is the 
cause of obstruction.
In our teaching, we have always 
emphasized the hazardous nature of 
large-bowel obstruction, which can be 
a “closed loop” type with urgent need 
for decompression. Modern textbooks 
suggest right transverse colostomy3 as 
the initial treatment for obstructing 
lesions of the left colon, but if resec­
tion is preferred primary anastomosis 
is not recommended.4-5 A one-stage 
procedure with primary anastomosis 
has been proposed but with total ab­
dominal colectomy and ileorectal 
anastomosis in order to avoid using 
distended colon in the anastomosis.5-7
A randomized prospective trial 
comparing resection and immediate 
anastomosis with traditional manage­
ment in two or three stages has not 
been done for obstructing lesions of 
the left colon.
In this issue of the Journal (pages 
167 and 168), Goodall and Park, in
a remarkable report on 40 patients 
with totally obstructing left colonic 
lesions, advise immediate resection 
with colocolostomy. During the peri­
od of the study, 1981 to 1986, 20 
other patients with total obstruction 
were treated at their hospital, by ei­
ther the Hartmann procedure or anas­
tomosis with protective colostomy. Of 
the study group of 40 patients, 30 had 
carcinoma, 9 diverticulitis and 1 vol­
vulus as the cause for the obstruction. 
In three patients perforations had oc­
curred and in two an intraperitoneal 
abscess existed at the time of surgery.
Two patients died — one, aged 84 
years, of myocardial infarction, the 
other, aged 89 years, of pneumonia — 
a death rate of 5%. Morbidity was 
acceptable and could probably have 
been diminished even further, as the 
authors state, by using delayed prima­
ry wound closure.
This is not a randomized trial and 
the authors do not tell us the fate of
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the 20 patients with left colonic ob­
struction treated differently during 
this same period. The results could 
not have been much better. It is 
gratifying to see these impressive re­
sults, especially in the elderly who can 
be overwhelmed by the necessities of 
care of a colostomy.
In patients with cancer as the cause 
of obstruction some might prefer a 
two- or three-stage operation in order 
to obtain a wider resection and possi­
bly a better long-term survival. How­
ever, obstructing cancers are usually 
more advanced lesions. A prospective 
trial supporting the concept that a 
wider resection on prepared bowel 
increases survival rate in this setting 
has also not been done. One retro­
spective study of primary versus 
staged resection for obstructing left 
colonic cancers reported 5-year sur­
vival rates of 63% and 33% respective­
ly.8 These differences are significant 
but may indicate that the more favou­
rable lesions with a better prognosis 
were treated by primary resection.
In the report by Goodall and Park 
the colonic anastomosis is protected 
by aspirating the contents of the colon 
at surgery and packing the proximal 
opening with Gelfoam to prevent 
fecal material from coming into con­
tact with the anastomosis during the 
initial phases of healing. In another 
study,9 an intracolonic device, Colo- 
shield (Deknatel, Lake Success, NY) 
has been used for the same purpose in 
28 patients with diverticulitis and
perforation who underwent one-stage 
colectomy and colocolostomy. Of 
these 28 patients, 18 had paracolic 
abscesses and 10 generalized peritoni­
tis at the time of surgery. There were 
no anastomotic leaks and no deaths.
Should a transverse colostomy be 
used to protect a left-sided anastomo­
sis? There may be some argument for 
this if the resection is elective, bowel 
preparation was possible and the 
anastomosis is technically difficult. It 
is not rational to do a protective 
colostomy after emergency resection 
and anastomosis when the large bowel 
proximal to the anastomosis and dis­
tal to the colostomy is heavily con­
taminated and likely to cause major 
peritonitis if there is a disruption of 
the anastomosis. Local drainage and 
colostomy for perforated diverticulitis 
are known to be associated with a 
high death rate (10% to 48%).10-n
We must conclude that defunction­
ing colostomy without resection is 
now rarely indicated even in totally 
obstructing and perforated left colonic 
lesions.
Lloyd  D. M acLean, m d , frcsc 
Coeditor,
Canadian Journal of Surgery
Surgeon-in-Chief,
Royal Victoria Hospital,
687 Pine Ave. W,
Montreal, PQ 
H3A 1A1
References
1. Dennis C: Treatment of large bowel obstruction; 
transverse colostomy — incidence of incompetency 
of ileocecal valve; experience at the University of 
Minnesota Hospitals. Surgery 1944; 15: 713-734
2. WANGENSTEEN OH: Intestinal Obstructions: Physio­
logical, Pathological and Clinical Considerations 
With Emphasis on Therapy, 3rd ed, Thomas, Spring- 
field, 111., 1955: 475
3. COHN I jr , Nance EC: The colon and rectum. In 
Sabiston DC JR (ed): Textbook o f Surgery: The 
Biological Basis o f Modern Surgical Practice, 13th 
ed, Saunders, Philadelphia, 1986: 996
4. SCHROCK TR: Large intestine in current surgical 
diagnosis and treatment. In Way LW (ed): Current 
Surgical Diagnosis and Treatment, 7th ed, Appleton 
& Lange, Los Altos, Calif., 1985: 593
5. Fry RD, Kodner IJ, Rauh SM: Colon and rectum. 
In Davis JH (ed): Clinical Surgery, Mosby. St. 
Louis, 1987: 1546
6. Fry RD, Fleshman JW jr, Kodner IJ: Abdominal 
colectomy with ileorectal anastomosis. South Med J  
1984; 77:711-714
7. Ramming KP, Haskell CM: Colorectal malignan­
cies. In Haskell CM (ed): Cancer Treatment, 2nd 
ed, Saunders, Philadelphia, 1985
8. FIELDING LP, Wells BW: Survival after primary 
and after staged resection for large bowel obstruction 
caused by cancer. Br J  Surg 1974; 61: 16-18
9. Ravo B, MISHRICK a , ADDEI K, et al: The treat­
ment of perforated diverticulitis by one-stage in­
tracolonic bypass procedure. Surgery 1987; 102: 
771-776
10. MacLaren IF: Perforated diverticulitis: a survey of 
75 cases. J R  Coll Surg Edinb 1957; 3: 129-144
11. eng K, Ranson JH, Localio SA: Resection of the 
perforated segment. A significant advance in treat­
ment of diverticulitis with free perforation or ab­
scess. Am J  Surg 1977; 133: 67-72
Colonoscopy After Resection for Bowel Cancer — Is It 
Already Too Late to Answer the Questions?
At the time of primary resection of a 
colorectal carcinoma, the entire colon 
should be examined carefully, even in 
areas remote from the primary tu­
mour, and all coexisting polyps and 
synchronous cancers should be re­
moved. At follow-up, the colon should 
be routinely examined to treat meta­
chronous cancers at an early stage and 
to remove all polyps when they are 
small, before cancer develops. This 
should benefit the patient by reducing
the occurrence of second cancers and 
the overall death rate. There are a 
large number of “shoulds” in the 
foregoing statements and the paper in 
this issue of the Journal by Vasilevsky 
and Gordon, entitled “Colonoscopy 
in the follow-up of patients with colo­
rectal carcinoma” (pages 188 to 190), 
helps us to examine at least one of 
these critically.
There appears to be increasing ac­
ceptance by general surgeons of the
case management method described 
above. It is an attractive concept that 
the entire colon can be completely 
“cleaned” of benign and malignant 
masses at the time of primary resec­
tion of a carcinoma and subsequently 
kept “clean” by repeated colonos­
copy, with obvious patient benefit. 
There is no question that the more 
often and the more rigorously the 
colon is examined, the more lesions 
will be discovered and diagnosed than
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would otherwise be possible, or that 
the majority of these small lesions can 
be removed endoscopically. The un­
answered questions concern which 
regimen of surveillance should be fol­
lowed, which methods of colonic ex­
amination should be used and to what 
extent these programs benefit the pa­
tients. As in so many areas of modern 
medicine, the acceptance of regular 
follow-up protocols has occurred far 
ahead of the evidence for their bene­
fits. Even when the answers to these 
questions are clear, we still must an­
swer the last (and most difficult) ques­
tion in coming to a management deci­
sion — that is, do the benefits out­
weigh the costs?
Our understanding of the natural 
history of colorectal polyps and their 
relationship to carcinoma is at present 
inadequate to permit a definite rec­
ommendation on the desirable fre­
quency of follow-up after primary re­
section of colorectal cancer. The con­
tribution by Vasilevsky and Gordon 
does help us to assess the relative 
benefits of colonoscopy as opposed to 
radiology. All of their patients had 
normal barium enema findings and 
the subsequent findings at colonos­
copy would, presumably, have been 
missed until at least the time of the 
next follow-up examination. In sum­
mary, they found 2 anastomostic re­
currences, 2 metachronous cancers 
and 22 neoplastic polyps (of which 10 
were greater than 1 cm in size) in 
their 100 patients. The study design is 
open to the criticism that only single­
contrast barium enema examination 
was performed, and their statement 
that this is the examination most 
commonly performed (rather than 
double-contrast barium enema) is no 
longer true for most major centres.
A pros and cons list may be drawn 
up for colonoscopy versus barium 
enema examination in postoperative 
surveillance of the colorectum. Nei­
ther method is an enjoyable experi­
ence for the patient, but the compli­
ance with suggested follow-up pro­
grams is high. Complete colonoscopy, 
a procedure described as “difficult” in 
25% of cases by highly experienced 
colonoscopists,1 was achieved in 94% 
of the patients in the current series. 
Barium enema study achieves about 
the same level of completeness over­
all.2 Colonoscopy and double-contrast 
barium enema have about the same 
rate of false-negative results (about 
10%), but colonoscopy has no false­
positive results.3 Colonoscopy can cer­
tainly detect lesions smaller than can 
be seen on double-contrast barium 
enema examination, but, as the au­
thors discuss in detail, the clinical
importance of small polyps is a major 
question. Perforation is rare and 
bleeding uncommon after colonos­
copy and even more so after barium 
enema. A major advantage of colonos­
copy is its operative capability. If one 
must choose between the two tech­
niques, colonoscopy seems to have 
the edge. Why not use colonoscopy 
and double-contrast barium enema to­
gether? This would raise the sensitiv­
ity to near 100%.4 This question can 
only be answered in relation to the 
overall benefit-cost equation, which 
is the key issue.
Cost-benefit analysis of an inter­
vention is always difficult, because 
different people will always take the 
same data and come to totally differ­
ent conclusions based on different 
values. There is no doubt that too few 
cancers are found on follow-up by 
colonoscopy to justify the costs and 
hazards of the intervention, but what 
about the polyps? A rate of 25 polyps 
in 100 patients would seem adequate 
to justify the procedure, but this is 
where we have the final missing link 
in the chain. The evidence that colo­
rectal polyps are associated with colo­
rectal cancer is strong,5 but more evi­
dence is desperately required on the 
actual clinical benefit that may be 
expected by removing them prophy- 
lactically. Unfortunately, the answer 
to this question has been pre-empted 
by many surgeons and gastroenterolo­
gists who have adopted protocols that 
have been advocated prematurely. 
Not only is this question suitable for a 
randomized prospective trial, but the 
large number of patients that could be 
collected in a comparative study in a 
relatively short time would ensure a 
valuable answer. There is an ideal 
opportunity here for a collaborative 
research protocol to be organized by a 
Canadian general surgical organiza­
tion such as the Canadian Association 
of General Surgeons or the Canadian 
Association of Clinical Surgeons. The 
question is circumscribed, important 
and answerable. The protocol would 
require randomization of patients 
after primary resection into two 
groups, one managed on the basis of 
subsequent signs and symptoms and 
the other managed by regular colonos­
copy in addition. Unfortunately, it 
may already be too late for surgeons 
and gastroenterologists to comply 
with such a study because of en­
trenched clinical behaviour. Compli­
ance can be expected only if we ac­
knowledge that we do not know the 
answer to the question.
Large fees are generated by endos­
copy and there is a medical-political 
minefield here in terms of appropriate
and possible contraction of indica­
tions for the procedures. Health econ­
omists and government agencies 
should recognize the need for research 
funding on issues like this, and physi­
cians should recognize the need for 
adequate evaluation of protocols be­
fore mass implementation — there we 
have another couple of “shoulds” to 
add to the list. Without proper evalu­
ation we cannot even begin to address 
the benefit versus cost issue; we don’t 
even know whether we are causing net 
harm to our patients regardless of the 
dollars and resources aspects of cost.
We desperately need to know the 
answer to these questions: does annu­
al colonoscopic follow-up of patients 
after primary resection of colorectal 
cancer reduce mortality; if so, by how 
much? It simply will not do to claim 
that the answer is obvious because 
polyps can be detected and removed 
at colonoscopy. Any suggested proto­
col for unpleasant, costly and poten­
tially dangerous intervention such as 
colonoscopy requires validation. We 
often lament the progressive reduc­
tion in bench surgical research, but 
here is an example of the prime im­
portance of evaluative research for 
which the majority of surgeons are 
most suited. To acknowledge igno­
rance, however, is a prerequisite to 
seeking the required knowledge. Let 
us not dig the trenches around clinical 
behaviour so deep that it becomes 
completely impossible to evaluate it. 
Let us not pretend that the answers to 
the questions are so obvious that even 
asking them is inappropriate.
C harles J. W r ig h t , mb, ch  b. m sc ,
FRCSC, FRCS, FRCS(EDIN)
Member,
Editorial Board,
Canadian Journal o f Surgery
Department o f  Surgery,
University Hospital,
University o f  Saskatchewan,
Saskatoon, Sask.
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know 
who's doing what and why. Surgeons are interested in what other surgeons are doing in 
research, education, practice and administration. Surgery is a vibrant specialty, and, as 
its practitioners, you must be the source as well as the readers of this column.
Royal College Statement on Informed Consent
Complying with legal requirements 
for obtaining a patient’s consent be­
fore medical treatment does not en­
sure that acceptable ethical standards 
have been met, advises the Biomedi­
cal Ethics Committee of the Royal 
College of Physicians and Surgeons of 
Canada, since “higher standards of 
informed consent than those required 
by law may be appropriate”. In a 
recently released statement by the 
Royal College, the principles of in­
formed consent are discussed, guide­
lines for procedures for obtaining a 
patient’s consent provided and a set 
of maxims outlined.
Because in our society so much 
value is placed on the rights of the 
individual, to entrust the physician 
with absolute authority would not be 
acceptable. Therefore, patients have
the right to make decisions concern­
ing their medical care after receiving 
sufficient information from their phy­
sician. This, of course, applies only to 
patients who are able to take the 
responsibility and who wish to do so. 
The Committee recommends proce­
dures to follow in other instances: a 
competent patient cannot make a de­
cision or leaves it to the physician to 
make a decision; a patient is incompe­
tent (e.g., an infant, unconscious or 
severely retarded); a patient is in­
competent and it is an emergency 
situation; a patient’s competence is 
uncertain.
Copies of the statement are avail­
able from the Communications Sec­
tion of the Royal College of Physi­
cians and Surgeons of Canada in Ot­
tawa.
health resources, such as: physician 
services in offices, hospitals and other 
settings, technology, changing demo­
graphics, legislation and the political 
process, changing malpractice climate 
and growing public education and 
awareness.
•  Initiating studies to determine 
what resources and structures are 
necessary to provide optimal health 
care.
•  Developing short- and long-term 
plans designed to achieve efficient use 
of medical services without compro­
mising their quality.
The chairman of the nine-member 
task force is former Deputy Minister 
of Health Graham Scott. Quarterly 
reports will be submitted to the Min­
istry of Health and to the OMA, and 
there will be an annual review of the 
task force’s progress by the two bo­
dies.
Task Force Formed to Analyse 
Use of Health Care Services in 
Ontario
Ontario Health Minister Elinor Ca- 
plan and Ontario Medical Association 
(OMA) President Hugh Scully an­
nounced recently that the Ministry of 
Health and the OMA have formed a 
task force to study the use of medical 
services in the province.
The task force has been formed to 
look for answers to a worrying prob­
lem — the rising cost of health care in 
Ontario. Said Health Minister Ca- 
plan, “I have been concerned about 
the demands on our health care sys­
tem and the use of medical services 
since I took over this portfolio.”
Contributions to this column are welcome. 
Please send your material to: Miss Laurel 
Williamson, Canadian Journal o f  Surgery, 
PO Box 8650, Ottawa, Ont. K1G 0G8.
One of the task force’s goals is to 
identify the factors that influence 
both how the health care system is 
used and how demand on resources is 
created, such as increasing requests 
for services from patients, physician 
behaviour, or the use of more sophis­
ticated diagnostic and treatment 
methods.
When these influencing factors 
have been identified and documented, 
the second goal of the task force can 
be achieved — to formulate a series of 
recommendations that will reinforce 
“sound practices” and “modify any 
behaviour that has resulted in inap­
propriate use of the health care sys­
tem in Ontario”.
The task force intends to achieve 
its goals by the following means:
•  Gathering and analysing data 
provided by the Ministry, the OMA 
and other sources, including research 
literature.
•  Using this information to identi­
fy the factors that influence the use of
Princess Margaret Hospital’s 
New Radiotherapy Unit 
Approved
Toronto’s Princess Margaret Hospi­
tal, the largest cancer treatment, re­
search and teaching centre in Canada, 
has received approval from Ontario’s 
Ministry of Health to proceed with 
plans for a new radiotherapy unit to 
be housed in the basement of Mount 
Sinai Hospital. Construction of the 
unit will begin in April 1989 and is 
the first step in the reconstruction of 
the Princess Margaret Hospital, which 
by 1995 should be situated at its new 
location adjacent to Mount Sinai Hos­
pital on University Avenue. There 
will be 16 radiotherapy machines op­
erating at the new hospital, including 
the 4 in the Mount Sinai unit. The 
Princess Margaret Hospital currently 
operates nine radiotherapy machines.
Laurel Williamson
142 VOLUME 31, NO. 3 M A Y  1988 /  THE CANADIAN JOURNAL OF SURGERY
HOW I DO IT
A section on surgical technique, supervised by Dr. N.M. Sheiner
P hilip  H. Gordon, md, frcsc, facs
Ivalon Sponge Wrap Operation
Numerous operations have been de­
scribed for the many distressing 
symptoms of rectal procidentia. In the 
good-risk patient, the Ivalon (supplied 
by Downs Surgical Canada Ltd., 
Cooksville, Ont.) wrap operation de­
scribed by Wells' has been effective. 
There are several variations of this 
operation2-6 and the technique I have 
found satisfactory is as follows.
Technique
With the patient in the supine posi­
tion the bladder is catheterized and 
the skin prepared with a suitable anti­
septic. The abdomen is entered 
through an infraumbilical transverse 
incision. The table is tilted to the 
Trendelenburg position to facilitate 
packing the abdominal viscera into 
the upper abdomen. Taking care to 
protect the ureters, the surgeon incises 
the peritoneum on each side of the 
rectosigmoid, beginning about 5 cm 
above the pelvic brim (Fig. 1). The 
presacral space is entered at the level 
of the sacral promontory and the 
rectum is gently and fully mobilized 
from the sacral hollow to the level of 
the coccyx (Fig. 2), avoiding the pre­
sacral nerves (Fig. 3). To permit ante­
rior mobilization, the lateral peritone­
al incisions are extended distally to 
join each other in the deepest portion 
of the cul-du-sac (Fig. 4). With the 
rectum grasped in the left hand, a 
plane of dissection is achieved with 
the fingers of the right hand. Dissec­
tion in this plane need not be exten-
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sive as a deep cul-de-sac is a charac­
teristic of most cases of complete 
rectal procidentia, and the seminal 
vesicles or vaginal vault is easily 
reached. The lateral stalks, or at least 
their upper portion on each side, are 
divided between clamps and ligated 
with an absorbable suture. If  the rec­
tum is not fully mobilized, redundant 
rectum below the point of fixation 
may cause the prolapse to recur. 
Throughout the procedure, meticu­
lous hemostasis is essential since he­
matoma formation may predispose to 
infection of the sponge.
A rectangular sheet of previously 
sterilized Ivalon is then moistened in 
normal saline to make it pliable. 
Three sutures of a material such as 
2-0 Prolene or 2-0 Vicryl on a non­
cutting needle are then passed 
through the Ivalon sponge, the presa­
cral fascia and then back through the 
Ivalon sponge (Fig. 5). The distal 
suture should be placed as low as 
possible, deep in the pelvis. The 
sponge is then “railroaded” into the 
pelvis and the sutures are tied (Fig. 6).
The mobilized rectum is drawn up­
ward and placed in front of the Ivalon
FIG. 1 — Peritoneum incised on both 
sides of rectosigmoid, beginning 5 cm above 
pelvic brim.
sheet, the lateral ends of which are 
folded to encompass approximately 
three-quarters of the circumference of 
the rectum. The residual gap is essen­
tial to prevent constriction of the 
lumen. Excess Ivalon is excised and a 
series of three 3-0 Prolene or 3-0
Fig. 2a
Fig. 2b
FIG. 2 — (a) Mobilization of rectum 
accomplished by gentle manual dissection, 
avoiding presacral plexus of veins, (b) Sa­
gittal view. Dissection carried down toward 
tip of coccyx, preserving mesorectum.
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FIG. 3 — Lateral incisions joined in anterior cul-de-sac. Presacral neural plexus should be left intact.
FIG. 4 — Blunt or sharp dissection frees anterior rectal wall. Peritoneum of anterior cul-de-sac is retracted superiorly.
FIG. 5 — Sheet of Ivalon sponge sewn to presacral fascia with interrupted 2-0 poly­propylene suture material on round needle. Rectum is retracted forward away from sacrum.
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FIG. 6 — Three polypropylene sutures hold Ivalon immobile against presacral fas­cia.
Vicryl sutures is used on each side to fasten the lateral limbs of the sponge to the anterior aspect of the rectum 
(Fig. 7).The sponge is extraperitonealized by closing the pelvic peritoneum with 
continuous 3-0 chromic catgut (Fig. 8). No drains are used. Postoperative- ly, fluids are given intravenously until ileus has resolved. Nasogastric suction is usually not necessary. The Foley 
catheter is removed on day 2. It is essential to ensure that the patient 
does not strain at defecation, so as soon as oral feeding is tolerated, a bulking agent in the form of a psylli­
um seed preparation is given, supple­
mented by Milk of Magnesia as neces­sary.
All figures are reproduced by permission from N yhus LM, Baker RJ: Mastery o f Surgery, Little, Boston 1984: 1045-1050.
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Canadians all over are 
waiting for the gift of 
a life-saving transplant.
The Kidney 
Foundation of Canada 
urges you to sign an 
organ donor card.
The 
Kidney 
Foundation 
of Canada
Improving the odds. On life.
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Cyclosporin A Metabolites Suppress T-Cell Proliferation by 
Concanavalin A and in a Mixed Lymphocyte Reaction
To ascertain if cyclosporine metabo­
lites (CMs) have immunosuppressive 
activity, bile, whole blood and urine 
taken from patients after cholecystec­
tomy and from a liver transplant recipi­
ent on cyclosporin A (CsA) were as­
sayed to determine their effect on T- 
cell proliferation induced by con­
canavalin A (Con A) and in a two-way 
mixed-lymphocyte response. Bile and 
whole blood from the liver transplant 
patient completely suppressed Con A 
proliferation and the mixed lymphocyte 
response (MLR) at dilutions at which 
normal bile and whole blood have no 
suppressive activity, but no such activ­
ity was noted from the urine. The CMs 
were separated into six peaks (frac­
tions) by high-pressure liquid chroma­
tography (HPLC). Metabolites were 
identified by internal standards and 
HPLC/mass spectrophometric analy­
sis. Cyclosporine metabolite fractions
2 and 3 from bile and blood had im­
munosuppressive activity similar to 
parent CsA whereas fractions 5 and 6 
demonstrated less but substantial im­
munosuppressive activity. Fractions 2,
3 and 5 demonstrated an ability to
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inhibit two-way MLR similar to parent 
CsA; the other metabolite fractions 
were able to inhibit the MLR but to a 
lesser extent.
These results demonstrate that a 
number of CMs have immunosuppres­
sive effects similar to those of the 
parent compound, and this may ac­
count for the lack of correlation be­
tween whole blood CsA levels and 
immunosuppressive activity.
Afin d'etablir si les metabolites de la 
cyclosporine possedent une activite 
immunosuppressive, la bile, le sang 
entier et I'urine de patients qui eurent 
a subir une cholecystectomie et ceux 
d'un greffe du foie traite a la cyclospo­
rine A ont ete doses d'apres leurs 
effets sur la proliferation des lympho­
cytes T provoquee par la conacavaline 
A et sur la reponse bi-directionnelle de 
lymphocytes en culture mixte. La bile 
et le sang entier du greffe du foie ont 
completement supprime la prolifera­
tion provoquee par la conacavaline A 
et la reponse des lymphocytes en cul­
ture mixte a des dilutions auxquelles la 
bile et le sang entier normaux n'exer- 
cent aucune activite immunosuppres­
sive; toutefois, aucune activite n'a ete 
decelee dans I'urine. Les metabolites 
de la cyclosporine ont ete separes d'a­
pres six pics d'elution (fractions) par 
chromatographie liquide a haute per­
formance (HPLC). Les metabolites ont 
ete identifies a I'aide de standards 
internes et par HPLC/spectrophotome- 
trie de masse. Les fractions 2 et 3 de 
la bile et du sang possedaient une 
activite immunosuppressive semblable 
a celle du produit pere, alors que les 
fractions 5 et 6 demontraient une acti­
vite moindre mais quand meme impor- 
tante. Les fractions 2, 3 et 5 mon- 
traient une activite semblable a celle 
de la cyclosporine A contre la reponse 
bi-directionelle des lymphocytes en 
culture mixte. Les autres fractions
metaboliques etaient capables d'inhi- 
ber la reponse des lymphocytes en cul­
ture mixte mais a un degre moindre.
Ces resultats demontrent que cer­
tains des metabolites de la cyclospor­
ine possedent des effets immunosup- 
presseurs semblables a ceux du pro­
duit pere et ceci peut expliquer le peu 
de correlation observe entre les taux 
de cyclosporine A dans le sang entier 
et I'activite immunosuppressive.
Cyclosporin A (CsA) is a biologically 
active product of the fungus Tri- 
choderma polysporum.' It is a chemi­
cally neutral, extremely hydrophobic, 
cyclic polypeptide composed of 11 
amino acids.2 Previous studies using 
tritiated CsA demonstrated that the 
molecule is rapidly and extensively 
metabolized mainly through the mono­
oxygenase cytochrome P450 system 
in man and that the liver is the major 
site of its elimination.3-4 Over 50% of 
an intravenously administered dose of 
CsA is excreted in bile, predominant­
ly in metabolite form, and less than 
0.1% is excreted as parent CsA.5 In 
contrast, less than 6% of the adminis­
tered dose excreted in the urine con­
tains more than 99% cyclosporine me­
tabolites (CMs).5 Recent studies have 
shown that biogradation of CsA pro­
duces a relatively small number of 
metabolites, some of which have been 
isolated from blood, bile and urine 
from both experimental animals and 
humans.5-8 Most are lipophilic, as in­
dicated by their occurrence in the 
ether phase of liquid extraction, al­
though polar metabolites have been 
described. The cyclic endecapeptide 
structure of CsA is preserved in all 
identified metabolites.3-5
Cyclosporin A is unique in that it is 
not cytotoxic and is selective in its 
immunosuppressive effects, having 
particular influence on T-cell func-
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tion.9-12 Although the precise mecha­
nism of action is controversial, it has 
been suggested13-14 that the major im­
munosuppressive property of CsA 
stems from inhibitory effects on inter- 
leukin-2 (IL-2) receptor expression on 
activated T cells. Others15-16 have de­
scribed an inhibitory effect on DNA 
synthesis due to selective blockage of 
IL-2 production, rather than IL-2 re­
ceptor generation. The immunosup­
pressive effects of CsA on immune 
cells in vitro can be measured by the 
inhibition of T-lymphocyte prolifera­
tive responses induced by mitogens 
(e.g., concanavalin A [Con A], phy­
tohemagglutinin [PHA]) and in a 
mixed lymphocyte response (MLR).
Little is known about the effects of 
CMs on immune responses. Maurer3 
found that CMs had low immunosup­
pressive effects when compared with 
CsA. However, Fidelus and Fergu­
son17 suggested that a second im­
munosuppressive agent, other than 
parent CsA, exists in plasma. More 
recently Freed and colleagues18 have 
reported that some purified CMs and 
CMs isolated from the blood of renal 
transplant patients have immunosup­
pressive properties. Because of these 
conflicting reports we undertook 
studies to identify CMs in bile, blood 
and urine from an orthotopic liver 
transplant patient, to determine their 
effects on Con A-induced prolifera­
tion and on a MLR and to compare 
their immunosuppressive activity 
with that of the parent compound 
(CsA).
Methods
Patients
Blood and urine were collected 
from six, normal, healthy, control 
patients after cholecystectomy and 
from a patient who underwent or­
thotopic liver transplantation for he­
patocellular carcinoma. Bile was col­
lected daily from the liver transplant 
patient and those who had undergone 
cholecystectomy. The former was oth­
erwise healthy and receiving CsA in­
travenously (7.5 mg/kg daily) and me- 
thylprednisolone (10 to 20 mg/d) to 
control rejection. All samples were 
collected daily and stored at -70°C 
until assayed.
Cells
Peripheral blood mononuclear cells 
(PBM) were collected from the venous 
blood of healthy control subjects, 
aseptically drawn into 50 ml conical 
tubes containing 1.5 ml of 0.5 M 
citrate buffer at pH 5.0. The blood
was centrifuged at 2200 g for 20 
minutes and the plasma removed. 
The cells were then diluted 4:1 with 
RPMI 1640 medium (Flow Laborato­
ries, Mississauga, Ont.) and centri­
fuged over Ficoll Hypaque gradients 
(1.074 g/L) at 2200 g for 12 minutes 
at 22°C, as previously described.19 
Mononuclear cells were removed at 
the interface (less than 1% polymor­
phonuclear cells), washed three times 
with RPMI 1640 and resuspended at 
a concentration of 2 X 106 PBM/ml in 
RPMI 1640 which had been supple­
mented with 10% fetal calf serum 
(Flow Laboratories) and 4 mM gluta­
mine (Gibco Scientific, Burlington, 
Ont.).
Isolation of Cyclosporin A and 
Cyclosporine Metabolites
One part bile (10 ml), blood (10 ml) 
or urine (50 ml) was extracted with 
two parts diethyl ether (Fisher Scien­
tific Co., Toronto, Ont.) three times. 
The ether extracts were combined and 
evaporated to dryness under vacuum 
at 45 °C. The residue was reconstitut­
ed in 400 m 1 of the solvent system, 
acetonitrile:methanol:water (50:20:20) 
and chromatographed by high-pres­
sure liquid chromatography (HPLC). 
Two methods of HPLC separation 
were used. In the first, a 15-cm uBon- 
dapak/C18 column and model M-45 
pump (Waters Associates, Milford, 
Mass.) were used to separate CsA 
from its metabolites. Of the reconsti­
tuted residue 400 /A was subjected to 
chromatography on the C l8 column 
at 50°C with a flow rate of 1.5 
ml/min. Cyclosporine metabolites and 
CsA were collected in the first and 
second 10 ml respectively. The pres­
ence of metabolites and CsA was de­
termined by radioimmunoassay20 and 
the samples were dried under vacuum 
at 45°C. In the second method, two 
Beckman “ultrasphere-ocytl” 5-/tm re­
versed phase columns (4.6 mm X 250 
mm) were connected in tandem to 
further separate CMs. Again 400 #tl of 
the reconstituted residue was injected 
and run at a flow rate of 1.0 ml/min 
at 70°C, and 0.5-ml fractions were 
collected. The presence of CMs was 
determined again by radioimmunoas­
say, and six fractions were pooled and 
evaporated to dryness. In the Con A 
proliferation assay, separate fractions 
were redissolved in RPMI 1640 con­
taining 0.1% Tween 20 (Sigma Chem­
ical Co., St. Louis, Mo.).
Concentrations of fractions con­
taining known CMs were calculated 
by utilizing data on the cross-reactivi­
ty of the different metabolites in the 
Sandoz cyclosporine radioimmunoas­
say as documented in the product 
monograph (Table I).
Mitogenic Response to 
Concanavalin A
The proliferative response of PBM 
was assessed by culturing 4 X 105 cells 
with 5 ug/ml of Con A (Sigma Chemi­
cal Co.) for 72 hours in 96 well 
microtitre plates (Falcon 3040, Micro­
test II, Becton-Dickinson, Lincoln 
Park, NJ) at 37°C in a 5% carbon 
dioxide atmosphere in 200 jitl of 
RPMI 1640 supplemented with 10% 
fetal calf serum and 4 mM glutamine. 
Cells were cultured alone or with 
increasing concentrations of CM or 
CsA. One uCi of 3H-methyl thymidine 
(3HTdR) (25 Ci/mmol) (Amersham 
Corp., Toronto, Ont.) was added for 
the final 18 hours of culture. Cells 
were harvested onto fibreglass filters 
with a minimash II cell harvester 
(Microbiological Associates, Bethes- 
da, Md). The uptake of 3HTdR was 
quantitated by placing the filters in 5 
ml of scintillation fluid consisting of 
10 ml of Omnifluor (New England 
Nuclear, Boston, Mass.) per 3.785 L 
toluene (Aquasol II, New England 
Nuclear) and by counting in a Beck­
man scintillation counter (Beckman 
Instruments Inc., Schiller Park, 111.). 
The mean counts of stimulated cul­
tures were corrected for uptake of 
control unstimulated cultures.
Data Analysis
Data were statistically analysed 
using the Student’s /-test, and a p 
value of less than 0.05 was considered 
significant.
Results
Isolation and Fractionation of 
Cyclosporine Metabolites and 
Cyclosporin A
Cyclosporines, identified by radi-
Table I— Relationship of Cyclosporin A (CsA) 
and Cyclosporine Metabolites (CMs) in 
Radioimmunoassay (RIA)
Concentrations True concentration 
CsA/CM by RIA (/ug/ml) (/xg/ml)
CsA 100 910
CM1 100 1000
CM8 100 1000
CM9 100 1000
CM10 100 1000
CM 17 100 670
CM18 100 710
Cross-reactivity of CMs in the RIA to parent 
CsA is described in the Sandimmune RIA kit 
(Sandoz Pharmaceuticals, Dorval, PQ).
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oimmunoassay, were extracted from 
blood, bile and urine of the liver 
transplant patient and separated into 
total CM and CsA fractions by HPLC 
method 1. When the same fluids were 
fractionated by method 2 and 
analysed by radioimmunoassay, seven 
peaks (fractions) of cyclosporines 
were obtained, corresponding to the 
six fractions of CMs and the parent 
CsA (fraction 7) (Fig. 1).
Identification of CMs (7, 18 and 
21) was accomplished by using inter­
nal purified CM kindly provided by 
G. Maurer, Sandoz, Basel, Switzer­
land. Metabolites 1, 8, 9, 10 were 
identified by HPLC/mass spectromet- 
ric analysis as previously described21 
(Table II).
Utilizing the data from Table I, 
true concentrations of parent CsA and 
those fractions containing known 
CMs were determined as shown in
FIG. 1 — Isolation of cyclosporin A 
(CsA) and cyclosporine metabolites (CMs) 
from liver transplant patient. Cyclosporine 
metabolites (fractions 1 to 6) and CsA 
(fraction 7) were isolated from (A) 10 ml of 
bile, (B) 20 ml of blood and (C) 50 ml of 
urine and separated by high pressure liquid 
chromatography (HPLC) method 2. Con­
centrations of cyclosporines were deter­
mined by radioimmunoassay and are ex­
pressed as cyclosporine-relative equivalents 
(ng/ml of HPLC effluent).
Table II. Based on these data, the 
concentration of total cyclosporines in 
the bile of the liver transplant patient 
was 27- and 128-fold greater than that 
of blood and urine respectively. Con­
centrations could not be established 
for fractions 1 and 4, which did not 
contain known CM.
Bile fractions 3 and 5 accounted for 
80% of total cyclosporines, with CsA 
accounting for less than 1% of the 
total (Fig. 1A, Table II). Blood con­
tained significantly (p = 0.007) lower 
concentrations of CsA and CMs, but 
in contrast to bile, parent CsA consti­
tuted a substantially greater propor­
tion of the total cyclosporines (3.5%). 
Of the CMs in blood, 82% was local­
ized to fractions 3 and 5, similar to 
that seen in bile (Fig. IB, Table II). 
Small amounts of CMs and CsA were 
detected in urine; however, 90% of 
the CMs were equally distributed in 
fractions 2, 3 and 5, and parent CsA 
was 1% of the total (Fig. 1C, Table II). 
No cyclosporines, as measured by ra­
dioimmunoassay, were detected in 
bile, blood or urine extracted with 
diethyl ether from control subjects.
Effect of Cyclosporine Metabolites and 
Cyclosporin A on Concanavalin A 
Proliferation
Marked stimulation of proliferative 
activity in human PBM, as reflected 
by 3HTdR uptake, in response to Con 
A was noted. Maximum proliferation 
(115 282 ± 12 840 cpm) was seen at 5 
Mg/ml of Con A, as previously de­
scribed.22 Bile, whole blood and urine 
were assayed for their ability to inhib­
it the Con A proliferative response. 
Bile from controls significantly (p < 
0.01) inhibited the Con A prolifera­
tive response up to a 1:32 dilution 
(Fig. 2A). In contrast, bile from the 
liver transplant patient (to a 1:1024 
dilution) completely suppressed the 
Con A proliferative response, suggest­
ing the presence of additional inhibi­
tory compounds (Fig. 2A). Whole 
blood from normal controls inhibited
Con A proliferation to a dilution of 
1:64, whereas whole blood from the 
liver transplant patient fully sup­
pressed Con A proliferation to a dilu­
tion of 1:1024 (Fig. 2B). In contrast, 
no inhibitory activity was detected in 
urine from either the controls or the 
liver transplant patient (Fig. 2C). 
Total CMs isolated from bile and 
blood exhibited dose-dependent sup­
pression of Con A proliferation. The 
immunosuppressive activity of the 
CM fraction was similar to that of the 
parent CsA fraction in both fluids, 
indicating that a substantial portion 
of the immunosuppressive effect of 
cyclosporine was related to CMs.
The six CM fractions obtained 
from bile and blood by HPLC method 
2 demonstrated dose-dependent inhi­
bition of the Con A proliferative re­
sponse (Figs. 3 and 4). However, dif­
ferent CM fractions exhibited differ­
ent degrees of suppressive activity. 
Relative potency was expressed as the 
concentration required for 50% inhi­
bition of Con A-induced proliferation 
(Table III). However, as fractions 1 
and 4 did not contain known CMs, 
their concentrations could not be es­
tablished accurately; thus, relative po­
tency could not be determined. By 
this analysis fractions 2 (CMs 8 + 9) 
and 3 (CM 10) from bile and blood 
had similar potency to parent CsA. In 
contrast, peaks 5 and 6 had substan­
tially less (5- to 20-fold) immunosup­
pressive activity (Table III). Fractions 
1 and 4 had substantial immunosup­
pressive activity; however, their con­
centrations could not be established 
because their structure is unknown. 
Thus, relative potency could not be 
determined.
Discussion
The fungal metabolite cyclosporin 
A (CsA) is a powerful immunosup­
pressant and is now the major drug 
used to prevent rejection after organ 
transplantation. There is evidence 
that CsA is metabolized extensively
Table II— Cyclosporin A (CsA) and Cyclosporine Metabolites (CMs) in the Bile, Blood and Urine of
a Liver Transplant Patient
CsA/CM Bile, mq/L Whole blood, Mg/L* Urine, Mg/L
Total cyclosporines 
Fractions
237 687 887 1860
1 Unknownt — — —
2 CMs 8, 9 33 520 86 570
3 CMs 9, 10 93 600 200 700
4 Unknownt — — —
5 CMs 17, 1 97 695 528 500
6 CM 18 12212 43 70
7 CsA 660 31 20
‘ For comparison the blood level for CsA by radioimmunoassay was 880 Mg/L. 
fAs these metabolites have not been identified, concentrations could not be assigned.
VOLUME 31, NO. 3 MAY 1988 /  THE CANADIAN JOURNAL OF SURGERY 147
by hydroxylation and N-demethyla- 
tion,3-23 and the structure of the me­
tabolites suggests the involvement of 
the hepatic microsomal cytochrome 
P-450-dependent mono-oxygenase 
system.3-5-23 The liver appears to be 
the major site of CsA metabolism as 
well as the primary excretion site by 
way of bile and thence fecal elimina­
tion.8 Enterohepatic recirculation of 
CsA has been suggested by the ap­
pearance of two phases of CsA in 
radioimmunoassay pharmacokinetic 
profiles.17 It has been noted that upon 
restoration of the integrity of the bili­
ary system, CsA requirements are re­
duced.24 This could be explained by 
improved intestinal absorption of 
CsA as well as reabsorption of CMs in
RECIPROCAL OF BILB DILUTION
RECIPROCAL OF WHOLE BLOOD DILUTION
(C)
oo
2 4 8 16 32 04 120 250 512 1024
RECIPROCAL OF URINE DILUTION
FIG. 2 — Effects of bile, whole blood and 
urine from normal control subject and liver 
transplant patient on concanavalin A (Con 
A)-induced proliferation of peripheral blood 
mononuclear cells (PBM). Dilutions of (A) 
bile, (B) w-hole blood and (C) urine from 
normal control (crosses) and liver trans­
plant patient on CsA (squares) were as­
sayed for their ability to inhibit Con A- 
induced proliferation of PBM.
bile possessing immunologic activity. 
Supportive of a role for CMs is a 
recent report25 that bile contains pri­
marily crossreactive metabolites with 
low concentrations of parent CsA.
Several CMs have been identified 
by chromatography. Two major oxi­
dative metabolites, 17 and 18, have 
been isolated from urine, bile and 
blood, and both appear to express less 
immunosuppressive activity than 
CsA.3 Lensmeyer and Fields26 de­
scribed the presence of a compound 
in whole blood from a renal trans­
plant patient on CsA which cross- 
reacted in the Sandoz radioim­
munoassay. It appeared to be local­
ized to red blood cells, with very little 
detected in plasma. Fidelus and Fer­
guson17 also reported the presence in 
the serum of renal allograft patients 
who were on cyclosporine of a factor 
that possessed potent immunosup­
pressive activity. Freed and col-
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FIG. 3 — Effect of CM and CsA extracted from bile of liver transplant patient on Con 
A-induced proliferation. Cyclosporine metabolites (fractions 2, 3, 5 and 6) and CsA 
(fraction 7) isolated from bile of liver transplant patient were assayed for their ability to 
inhibit Con A-induced proliferation of PBM.
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FIG. 4 — Effect of CsA and CM isolated from whole blood of liver transplant patient 
on Con A-induced proliferation. Cyclosporine metabolites (fractions 2, 3, 5 and 6) and CsA 
(fraction 7) were extracted from whole blood of liver transplant patient and assessed for 
their ability to inhibit Con A-induced proliferation of PBM.
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leagues18 recently reported that puri­
fied CMs 1, 17 and 21 have potent 
immunosuppressive activity in vitro 
and that CMs isolated from the blood 
of a renal transplant patient also ex­
hibited significant immunosuppres­
sive activity.
Our present studies were undertak­
en to document the presence by 
HPLC and radioimmunoassay of 
CMs in bile, blood and urine from a 
patient who had undergone orthotop­
ic liver transplantation and to deter­
mine whether these metabolites pos­
sessed immunosuppressive activity.
Bile and whole blood from the liver 
transplant patient suppressed Con A- 
induced proliferation in dilutions at 
which normal bile and whole blood 
had no such effects, suggesting the 
presence of one or more inhibitory 
factors. Diethyl ether-soluble factors 
were isolated from bile, blood and 
urine and analysed for the presence of 
cyclosporines by radioimmunoassay. 
Although they all contained cyclospo­
rines, immunosuppressive activity 
could be detected only in blood and 
bile with bile having significantly (p < 
0.008) more activity. High-pressure 
liquid chromatography and radioim­
munoassay of diethyl ether-soluble 
material confirmed the presence of 
CMs and CsA in all three body fluids, 
with the highest concentrations in bile 
as previously reported.8-25 Significant 
(p = 0.002) immunosuppressive activ­
ity was found in both fractions of 
CMs and the parent CsA fraction.
This suggests that, in vivo, CMs exert 
a marked immunosuppressive effect. 
Separation of the metabolites by 
HPLC method 2 yielded six CM frac­
tions, two of which appeared to have 
immunosuppressive activity, similar 
to that of parent CsA. Two other 
fractions, 1 and 4, were also potent 
but cannot be assessed further until 
their structure is known.
Freed and colleagues18 recently re­
ported that CMs 1 and 17 had signifi­
cant immunosuppressive activity, but 
that CM 8 showed little activity in 
both the Con A proliferation and 
MLR assays. As CM fraction 2 in our 
study showed significant immunosup­
pressive activity and contained CMs 8 
and 9, CM 9 would also appear to 
inhibit both MLR and Con A prolifer­
ation.
Our radioimmunoassay method of 
assessing CMs does not allow for de­
tection of those that are nonreactive 
in the radioimmunoassay. The pres­
ence of such metabolites will only be 
confirmed using tracer techniques and 
comparing these simultaneously to ra- 
dioimmunoassasy-positive metabo­
lites. Indeed Maurer and associates,5 
using tracer techniques, identified 17 
metabolites, all of which retained 
their basic endecapeptide structure. 
This suggests that each of the six CM 
fractions we identified may indeed 
contain many more distinct metabo­
lites. It is apparent that CMs are 
present in the blood of transplant 
patients in much greater amounts
than CsA, but this has not been ap­
parent due to differences in reactivity 
in the CsA radioimmunoassay.
We excluded methylprednisolone 
as the immunosuppressive factor in 
our transplant patient, both by failing 
to detect it in diethyl ether-extracted 
blood and bile, and by the fact that 
immunosuppression of Con A prolif­
eration could only be detected at 
pharmacologic concentrations (1 
Mg/ ml).
The observation that urinary CMs 
have no immunosuppressive activity, 
while similar fractions from bile and 
whole blood are strongly inhibitory, is 
intriguing. Although the urinary CMs 
are recovered from the HPLC column 
in the same fractions as bile and 
blood, they may not be identical in 
chemical structure. Conjugation could 
impair immunosuppressive activity, 
and although conjugated metabolites 
have not previously been detected,3-4 
this does not exclude their presence in 
this clinical setting. Finally, as previ­
ously reported,3-8-25 only very small 
amounts of CMs were recovered from 
the urine of the transplant patient, 
and in order to recover the CMs, large 
volumes of urine (50 to 100 times the 
volume of bile) needed to be extract­
ed; this may result in recovery of 
substances from the urine that could 
interfere with the immunosuppressive 
properties of the CMs.
Although in this study data from 
only one allograft recipient are pre­
sented, we have now isolated similar 
CM fractions from the whole blood of 
a renal allograft recipient that had 
similar immunosuppressive activity, 
but only when used at higher concen­
trations (unpublished data). The vari­
ability in immunosuppressive activity 
may be related to differences in CsA 
metabolism from patient to patient. 
Furthermore, we have now demon­
strated that three CM fractions isolat­
ed from bile and two CM fractions 
isolated from blood can inhibit a 
mixed lymphocyte response similar to 
that of parent CsA, adding strength to 
the concept that CMs have potent 
immunosuppressive properties (Table 
IV). It is interesting that the im­
munosuppressive activity of some 
CMs differed in the two different 
assays; however, this has been ob­
served for other immunosuppressive 
agents.
In summary, we report that bile 
and blood from a liver transplant 
patient contain CMs that have signifi­
cant immunosuppressive activity, re­
sults that may help to explain why 
patients with similar blood levels of 
CsA often exhibit different degrees of 
immunosuppression. Furthermore, it
Table III— Relative Inhibition of Concanavalin A-Induced Proliferation by Cyclosporin A (CsA) and
Cyclosporine Metabolites (CMs)
Concentration of CMs for 50%
Cyclosporine
fractions
inhibition, ng/ml
Metabolite Bile Blood
1 Unknown* — —
2 8, 9 100 250
3 10 300 100
4 Unknown* — —
5 17, 1 2700 1000
6 18 5000 2000
7 CsA 270 160
•These metabolites have not been identified and thus concentrations cannot be assigned.
Table IV— Relative Inhibition of a Mixed Lymphocyte Response by Cyclosporin A (CsA) and 
Cyclosporine Metabolites (CMs)
Cyclosporine
fractions
Concentration of CMs for 50% 
Inhibition, ng/ml
Metabolite Bile Blood
1 Unknown* — —
2 8 ,9 90 180
3 10 75 70
4 Unknown* — —
5 17, 1 50 50
6 18 1000 500
7 CsA 50 30
•These metabolites have not been identified and thus concentrations cannot be assigned.
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is conceivable that susceptibility to 
nephrotoxicity may reflect different 
patterns of CsA metabolism. Experi­
ments are now under way to charac­
terize these metabolites and deter­
mine their effects in other in-vitro 
and in-vivo immunologic assays. 
These studies should improve our un­
derstanding of the biologic behaviour 
of CsA.
We thank Mr. Lai Sum Fung and Aniel 
Menon for their technical assistance and 
Charmaine Jaglal for typing.
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Prognostic Factors in Colorectal Carcinoma of Young
Adults
To determine why the prognosis for 
colorectal cancer in young adults is 
poor, survival and prognostic factors in 
patients under 40 years of age were 
compared with those in patients be­
tween 40 and 50 years of age. In a 
10-year period, 122 patients less than 
50 years of age (88 between 40 and 
50 years) presented at the Victoria 
General Hospital in Halifax, NS, with 
colorectal cancer. Their charts were 
retrospectively reviewed. Follow-up 
was obtained for all patients.
Of the 34 patients younger than 40  
years, 71 % (24) were men compared
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with 38% (33) of older patients. Symp­
toms, their duration and the location of 
primary tumours were similar in the 
two groups. Patients younger than 40  
years presented with advanced lesions 
(Dukes' stages C and D) in 67% of 
cases compared with 52% of the older 
group. Mucinous tumours were twice 
as common in patients less than 40 
years old (p = 0.036) and actuarial 
survival rates were lower at all stages 
for the same group.
The authors conclude that the poor­
er prognosis in patients less than 40 
years of age is not due to late symp­
tom reporting or delay in diagnosis, but 
to more aggressive disease.
Afin de determiner pourquoi le pronos- 
tic du carcinome recto-colique chez les 
patients jeunes est mauvais, la survie 
et les facteurs pronostiques des mala- 
des de moins de 40 ans ont ete com­
pares a ceux de patients de 40 a 50 
ans. Sur une periode de 10 ans, 122 
patients de moins de 50 ans (dont 88 
entre 40 et 50 ans) ont ete recus au
Victoria General Hospital de Halifax, 
NE, souffrant de cancer recto-colique. 
Les dossiers medicaux ont ete etudies 
retrospectivement. Un suivi a pu etre 
obtenu pourtous les patients.
Sur les 34 patients de moins de 40  
ans, 71 % (24) etaient des hommes, 
comparativement a 38% (33) pour les 
patients plus ages. Les symptdmes et 
leur duree, et la localisation des tu- 
meurs primitives etaient les memes 
dans les deux groupes. Les patients 
ages de moins de 40 ans presentaient 
des lesions avancees (stades C e t D a  
la classification de Dukes) dans 67% 
des cas, comparativement a 52% pour 
les patients plus ages. Les tumeurs 
mucineuses etaient deux fois plus 
frequentes chez les patients de moins 
de 40 ans (p = 0.036) et la survie 
actuarielle etait plus faible a tous les 
stades pour ce meme groupe.
Les auteurs concluent que le plus 
sombre pronostic des patients de 
moins de 40 ans n'est pas du a un 
retard a signaler les symptomes ou a 
un delai de diagnostic, mais piutot a 
une maladie plus agressive.
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Colorectal carcinoma is most com­
monly seen in older patients, the peak 
incidence occurring in the seventh 
decade of life.1 However, it has been 
reported that in 8% of cases the pa­
tient is younger than 40 years2 and in 
1 % younger than 30 years.3 There has 
been a long-standing impression that 
patients under 40 years old have a 
poor prognosis.45 However, in recent 
studies identical survival rates were 
found for patients both under and 
over 40 years of age,6-9 while others
Table 1— Sex D is tr ib u tio n
G roup M e n W o m e n
1 2 4 10
2 3 3 5 5
T o ta ls 5 7 6 5
confirmed a worse prognosis for the 
younger group.10-13 We undertook a 
retrospective study to determine if 
patients less than 40 years of age have 
a worse prognosis than those between 
40 and 50 years, and also to compare 
the two groups in terms of symptoms 
and their duration, pathologic charac­
teristics of the tumour and clinical 
stage.
Patients and Methods
We reviewed the charts of all pa­
tients less than 40 years of age admit­
ted to the Victoria General Hospital 
in Halifax between Jan. 1, 1974 and 
Dec. 31,1984 with colorectal carcino­
ma.
The patients were divided into two
Tab le  I I - -P re s e n t in g  S y m p to m s  a nd  S ig n s*
S y m p to m /s ig n G roup  1, no. (%) G roup  2 , no. (% )
A b d o m in a l pain 8 ( 2 4 ) 3 5  (40)
R ecta l b leeding 1 5 ( 4 4 ) 3 6 ( 4 1 )
C hange o f bow e l h ab it 1 4 ( 4 1 ) 3 4  (39)
O b s tru c tio n 5 ( 1 5 ) 1 0 (1 1 )
A n e m ia 2  (6) 9 (1 0 )
W e ig h t loss 3 (9) 11 (13)
M ass 1 (3) 7 (8)
M isce llaneous 2  (6) 5 (6)
N one 2  (6) 4  (5)
•N o n e  o f the  d iffe re n ce s  w e re  s ig n ifica n t.
T a b le  III— D u ra tio n  o f S y m p to m s *
D ura tio n , m o G roup  1, no. (% )t G roup 2 , no. (% ) $
<  1 1 0 (2 9 ) 3 0  (34)
1 - 3 2  (6) 1 5 (1 7 )
4 - 6 11 (3 2 ) 2 0  (23)
7 - 1 2 2  (6) 1 2 (1 4 )
>  12 4 ( 1 2 ) 4  (5)
U n kn o w n 3  (9) 3 (3)
* N o  s ig n ifica n t d iffe re n ce s  b e tw e e n  th e  groups.
| 2  w e re  a s y m p to m a tic . 
$ 4  w e re  a s y m p to m a tic .
Tab le  IV — L o ca tio n  o f  P rim a ry  T u m o u r*
Loca tion G ro u p  1, no. (%) G roup  2 , no. (% )
C ecum  and ascend ing  co lon 5 ( 1 5 ) 1 5 (1 7 )
T ransverse  co lon 1 (3) 7 (8)
D escend ing  colon 4 ( 1 2 ) 9 (1 0 )
S ig m o id 1 3 (3 8 ) 3 3  (38)
R ectum 11 (3 2 ) 2 9  (33)
U n k n o w n 1 (3) 0  (0)
* N o  s ig n if ic a n t d iffe re n ce s  b e tw e e n  th e  groups.
Tab le  V — D u ke s ' S ta g e *
Stage G ro u p  1, no. (%) G roup  2 , no. (% )
A  -  co n fin e d  to  b o w e l w a ll 0  (0) 3  (3)
B -  p e n e tra ting  serosa l su rface 11 (32) 3 9  (44)
C -  p o s itive  nodes 1 4 ( 4 1 ) 2 9 (3 3 )
D -  d is ta n t m e ta s ta se s 9 ( 2 6 ) 1 7 (1 9 )
* N o  s ig n ifica n t d iffe re n ce s  b e tw e e n  th e  groups.
groups: group 1, 34 patients who were 
less than 40 years of age at the time of 
diagnosis and group 2, 88 patients 
aged 40 to 49 years. The two groups 
were compared with respect to diag­
nosis, duration of symptoms, present­
ing symptoms, location of the primary 
tumour, Dukes’ stage, pathological 
findings and survival. The current 
status of all patients was noted from 
ongoing hospital charts or the files of 
the Nova Scotia Tumour Registry, or 
by contacting the attending physician. 
The date and cause of death were 
available for all who died. Follow-up 
of living patients ranged from 15 
months to 135 months (mean 44 
months for group 1 and 47 months for 
group 2). One pathologist (N.H.A.) 
examined the 82 original specimens 
available for review. The histologic 
grade, depth of invasion, lymph-node 
involvement and presence or absence 
of mucin were assessed for each le­
sion. A tumour was judged to be 
mucinous if it met the criteria of 
Symonds and Vickery.14 The x2 test 
was used to assess apparent differ­
ences, and actuarial survival rates 
were calculated. A p value of less than 
0.05 was considered significant.
Findings
The sex distribution of the 122 
patients (Table I) was highly signifi­
cant (p = 0.002).
Symptoms and signs of colorectal 
carcinoma in the two groups were 
similar (Table II). In both, abdominal 
pain, rectal bleeding and change of 
bowel habit were the most common 
complaints. Table III shows the dura­
tion of symptoms; in group 1, 74% 
had been symptomatic for less than 6 
months compared with 78% in group 
2.
There was a predominance of left- 
sided primary tumours (Table IV) — 
82% in group 1 and 81% in group 2 
were distal to the splenic flexure. One 
patient in group 1 had two synchro­
nous primaries as did five patients in 
group 2.
The Dukes’ staging was recorded at 
the time of diagnosis for all patients 
(Table V). No patients in group 1 but 
three in group 2 had stage A lesions.
On the other hand, more advanced 
disease (stages C and D) was seen in 
group 1 (67%) than group 2 (52%), 
although the difference was not sig­
nificant (p = 0.18). Table VI shows 
5-year survival rates for each Dukes’ 
stage; again, the differences were not 
significant. Of 12 patients with rectal 
tumours in group 1, 2 survived 5 
years, compared with 14 of 31 in
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group 2, an insignificant difference. 
There was no difference in survival 
between the groups for patients with 
colonic tumours.
There was an overall similarity in 
the histologic grading of the tumours. 
Moderately differentiated lesions 
were present in 70% of group 1 and 
82% of group 2 patients; the remain­
der were equally divided between 
poorly and well-differentiated tu­
mours. The incidence of predisposing 
conditions was low — one group 1 
patient with ulcerative colitis and an­
other with polyposis coli and in group 
2 two patients with polyposis coli.
With respect to actuarial survival 
(Fig. 1), group 1 had a lower propor­
tion surviving at all intervals, most 
apparent in years 1 to 3. The number 
surviving at each interval was inade­
quate to prove statistical significance, 
but we can infer a poorer prognosis 
for younger patients from the consis­
tently lower proportion surviving.
A review of the surgical specimens 
showed general agreement with the 
initial pathology reports. On re­
examination of lymph nodes, five pa­
tients initially classified as having 
Dukes’ B lesions were found to have 
Dukes’ C. Classifications of lesions as 
mucinous or nonmucinous were not 
changed as a result of specimen re­
examination. When the initial slides 
were not available, the findings on the 
original pathology report were used. 
In group 1 there were 13 mucinous 
and 21 nonmucinous lesions, while 
group 2 had 16 mucinous and 72 
nonmucinous lesions (p = 0.036) (Ta­
ble VII).
Although retrospective evaluation 
of their overall health is difficult, the 
fact that both groups of patients were 
composed of relatively young people 
(mean ages 32.3 and 46.5 years) 
should limit the importance of this 
factor. All patients who died of natu­
ral causes did so as a result of colorec­
FIG. 1 — Actuarial survival.------ =
under 40 years of age (group 1), —  = 40 to 
50 years of age (group 2).
tal carcinoma (one committed sui­
cide).
Discussion
There has been a long-standing im­
pression that young patients with co­
lorectal carcinoma have a poorer 
prognosis than their older counter­
parts as noted by Ezzo and col­
leagues13 in 1958. A study in 19744 
found that the 5-year survival for 
those under age 35 was 17.5%. Sugar- 
baker and colleagues5 concluded that 
age less than 30 years is associated 
with a particularly poor prognosis. A 
number of recent papers on the sub­
ject do not agree with this conclusion; 
a British study6 found that age 40 
years was not synonymous with a 
poor prognosis. Although they had a 
higher incidence of more anaplastic 
lesions, younger patients tolerated 
emergency surgery better and overall 
had an improved prognosis.
To limit the factor of better toler­
ance we reviewed two groups close to 
each other in age. Although the num­
bers are too small to show significant 
differences in actuarial survival, the 
trend to a poorer prognosis is clear.
An interesting observation is that 
mucin-secreting tumours were twice 
as prevalent in the younger group; 
38% of group 1 patients had mucin­
ous tumours, compared with 18% of 
group 2 (p = 0.036). Bedikian and 
colleagues10 found an increased rate of 
mucin-secreting tumours in patients 
under 40 years of age. A study of 62 
patients11 found that colorectal carci­
noma was a more virulent disease in 
patients under the age of 40 years, 
with a higher incidence of poorly 
differentiated lesions and mucin- 
secreting tumours. Adolescents with 
far advanced colorectal carcinoma
have an extremely high percentage of 
mucinous lesions.1-15
Two Scandinavian studies that re­
viewed all cases of colorectal carcino­
ma in Denmark8 and Sweden9 over 
more than 20 years found that prog­
nosis was not affected by age at pre­
sentation; interestingly, there was no 
difference in histologic type between 
younger and older patients. The previ­
ously cited study6 from Britain also 
found no histologic difference in the 
tumours of both groups. It is interest­
ing that European studies show a 
similar survival for younger and older 
patients, while American studies tend 
to reveal a poorer prognosis in youn­
ger patients, especially when there is 
an increased incidence of mucinous 
tumours; our results reflect the Ameri­
can pattern.
Fifteen percent of colorectal tu­
mours produce large quantities of 
mucin and are associated with a par­
ticularly poor prognosis. The 5-year 
survival for such patients is 34%, 
compared with 53% for those with 
nonmucinous lesions. The poor prog­
nosis may relate to either an increased 
water absorption by the mucus, en­
couraging malignant cell dispersal, or 
a mucopolysaccharide coating on the 
cells interfering with immunologic 
recognition of the malignant cells.14
Safford and colleagues7 found that 
stage of the tumour at the time of 
diagnosis, rather than patient age, was 
the most accurate prognostic determi­
nant. A report on United States mili­
tary personnel found that patients 
under 30 years of age with Dukes’ A 
or B lesions had the same prognosis as 
older patients, but those with stage C 
lesions had a much poorer outlook.16 
Patients in Hong Kong under 40 years 
old17 were found to have a higher 
number of Dukes’ C and D lesions. In
Tab le  V I— Five-Year S urv iva l B y  D uke s ' Stage*
S ta g e G roup 1, n o . /to ta l (%) G roup 2 , n o ./to ta l (%)
A 0  (0) 3 /3  (1 0 0 )
B 5 /7  (7 1 ) 1 7 /3 0  (5 7 )
C 3 /1 2 ( 2 5 ) 1 1 /2 5  (4 4 )
D 0 /8  (0) 0 /1 7  (0)
O vera ll 8 /2 7  (3 0 ) 3 1 / 7 5 t  (4 1 )
‘ D a ta  n o t y e t availab le  on  a large enough n u m b e r to  p ro v e  s ta tis tic a l s ig n ificance . 
fN o .  fo llo w e d  up fo r  5 years.
Tab le  V II— M u c in o u s  T u m o u rs
T y p e  o f tu m o u r G roup 1, no. (%) G roup 2 , no. (%)
M u c in o u s * 13 (3 8 ) 16 (1 8 )
N o n m u c in o u s 21 (6 2 ) 7 2  (82)
T o ta ls 3 4 ( 1 0 0 ) 8 8 (1 0 0 )
•D iffe re n c e  is s ig n if ic a n t (p =  0 .0 3 6 ).
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our study, advanced lesions were seen 
more commonly in younger patients, 
but the difference was not significant. 
The histologic grade of the tumour in 
both age groups was similar.
The majority opinion is that the 
poor prognosis in younger patients is 
due to late reporting of symptoms and 
failure of physicians to investigate 
their complaints thoroughly.1015 Sim- 
stein and associates,12 in their review 
of military personnel with colorectal 
carcinoma, found no evidence of a 
delay in diagnosis. Other investiga­
tors10 have reported an average of 3 
months between onset of symptoms 
and diagnosis. Rosato and col­
leagues18 noted a greater interval be­
tween onset of symptoms and diagno­
sis in the young, but this did not lead 
to a poorer prognosis. Moreover, it 
has been established that there is no 
correlation between a delay in treat­
ment and survival from colorectal 
carcinoma. Associated disorders such 
as ulcerative colitis, familial polyposis 
and familial nonpolyposis syndromes 
have been suggested as contributing 
factors in colorectal cancer, but re­
views to date report a very small 
number of patients with these culpa­
ble conditions present simultaneously.
An interesting and unexpected 
finding in our study was that colorec­
tal carcinoma in those under 40 years 
of age was much commoner in men.
Most reports do not indicate this 
difference; some in fact show higher 
numbers of women,20 while in others 
there is essentially no difference.2-6 
The one study that had a much higher 
number of men was that of US Army 
personnel.7
Conclusions
Patients under 40 years of age with 
colorectal carcinoma have a poorer 
prognosis than those aged 40 to 50 
years, due to a tendency toward ag­
gressive tumours that present as ad­
vanced lesions and to a larger number 
of mucinous tumours in these pa­
tients.
We thank Dr. D. Rathbone for assis­
tance with the chart review and Dr. P. Roy 
for assistance with the statistical analysis.
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Profound Hypothermia and Circulatory Arrest in Excision 
of Renal Cell Carcinoma Invading the Vena Cava
Two patients with renal cell carcinoma 
invading the inferior vena cava to the 
level of the right atrium underwent 
complete excision of their renal tu­
mours. Clearance of the caval exten­
sion was accomplished using cardio-
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pulmonary bypass, profound hypo­
thermia and circulatory arrest. The use 
of these techniques visually improved 
the operative field without extending 
operating time. Profound hypothermia 
and circulatory arrest do not increase 
postoperative morbidity or mortality 
and offer the best opportunity for cure.
Deux patients porteurs de carcinomes 
des cellules renales envahissant la 
veine cave inferieure au niveau de 
I'oreillette droite, ont subi une excision 
complete de la tumeur renale. Le net- 
toyage de I'extension cave a ete reali­
se grace a une circulation extracorpo- 
relle, une hypothermie profonde et un
arret circulatoire. L'emploi de ces 
techniques a permis de degager le 
champ operatoire sans prolonger la 
duree de I'intervention. L'hypothermie 
profonde et I'arret circulatoire n'aug- 
mentent pas la morbidite et la mortali- 
te postoperatoires et ameliorent les 
chances d'obtenir une guerison com­
plete.
Renal cell carcinoma is an aggressive, 
locally invasive tumour that tends to 
invade the renal veins and subse­
quently the inferior vena cava.1-5 The 
best opportunity for cure is offered by 
complete removal of the renal mass 
and its local extension.3-15 It is a 
formidable undertaking for a surgeon
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to embark on excision of a renal mass 
with extension into the inferior vena 
cava reaching to the heart. We recent­
ly experienced two such cases and 
found the technique of profound hy­
pothermia and circulatory arrest to be 
a safe and useful adjunct, facilitating 
resection of the intravascular compo­
nent.
Case Reports
Case 1
Routine urinalysis in a 67-year-old 
woman in June 1986 revealed microscopic 
hematuria. A subsequent intravenous pye- 
logram demonstrated a right renal mass 
and inferior vena cavography a tumour 
obstruction to the level of the diaphragm. 
Computed tomography and echocardiogra­
phy confirmed the presence of a thrombus 
extending from the right renal vein to the 
right atrial-caval junction (Fig. 1). There 
was no evidence of metastases on physical 
examination, chest x-ray film or computed 
tomography of the chest and abdomen.
This patient gave a history of long­
standing hypertension, treated with pro­
pranolol, hydrochlorthiazide and prazosin. 
She had undergone a hysterectomy and a 
cholecystectomy without complications.
The only abnormal findings on physical 
examination were palpable right flank full­
ness and a blood pressure of 205/100 mm 
Hg. There was no clinical evidence of 
caval obstruction. On admission her hemo­
globin level was 9.62 mmol/L, leukocyte 
count 6.9 X 109/L, blood urea nitrogen 
level 5.35 mmol/L (urea) and serum creati­
nine value of 88.4 /umol/L (all within 
normal limits). An SMA-12 biochemical 
analysis was normal. Urinalysis showed 
microscopic hematuria.
Just before operation, intravenous, radi­
al artery and pulmonary artery catheters 
were inserted. General endotracheal anes­
thesia was induced using isoflurane, fenta- 
nyl citrate and pancuronium bromide.
A small roll was placed under the right 
flank and the patient’s skin prepared with 
Betadine solution. A two-team approach 
was used, the urology team performing a 
right subcostal incision and the thoracic 
team a median sternotomy.
The right renal artery was ligated and 
the renal veins were isolated. The renal 
mass was widely dissected, removing the 
kidney within Gerota’s fascia and dividing 
the ureter well away from the mass. Re­
gional lymph nodes and the right adrenal 
gland were also taken en bloc.
After renal dissection, the patient was 
fully heparinized and cannulated for car­
diopulmonary bypass, using an aortic arch 
cannula, a superior vena caval cannula and 
a right femoral cannula. Sodium pentothal, 
1.5 g intravenously, was administered over 
a period of 8 minutes. Cardiopulmonary 
bypass was begun using a membrane oxy­
genator and roller pump, and the pa­
tient’s body temperature was lowered to 
18°C as her head was packed in ice. The 
aorta was cross-clamped and cold blood 
cardioplegia was given at 20-minute inter­
vals to protect the myocardium. When the 
cooling process was completed, the pa­
tient’s blood was diverted into the pump 
oxygenator and the inferior vena cava and 
right atrium were opened widely.
The tumour was carefully and complete­
ly removed from within the inferior vena 
cava. Its entire length from the renal veins 
to the right atrium could easily be visual­
ized by this approach. After excision of the 
caval mass, the vein was liberally irrigated 
with sterile water.
After cavotomy closure, cardiopulmo­
nary bypass was reinstituted and the pa­
tient gradually rewarmed. During this peri­
od, hemostasis was assured in the bed of 
the excised renal tumour. Once the patient 
was weaned from cardiopulmonary bypass 
and the heparin effect reversed with prot­
amine sulfate, the wounds were closed 
routinely and she was moved to the inten­
sive care unit.
The total bypass time was 74 minutes 
with 40 minutes of aortic cross-clamp 
time. The time of circulatory arrest, how­
ever, was only 25 minutes.
The patient had no neurologic sequelae. 
She required eight units of packed red cells 
and four units of fresh frozen plasma 
during the postoperative period.
When she was discharged home on post­
operative day 9 she had normal renal 
function and a hemoglobin level of 6.95 
mmol/L. She was still well 22 months later.
Case 2
A 72-year-old woman was seen by her 
family physician for nonspecific chest and 
abdominal pains. There was no history of 
hematuria. She had lost 2.3 kg in weight 
over the preceding 2 months while dieting. 
She was taking guanethidine, ranitidine 
and chlorothiazide.
Abdominal ultrasonography revealed a 
right renal mass. Intravenous pyelography 
and computed tomography (Fig. 2) of the 
abdomen demonstrated a right renal tu­
mour (7 cm in diameter) with extension 
into the right renal vein and inferior vena 
cava. Bone scanning and computed tomog­
raphy of the chest gave normal results. 
Echocardiography showed the tip of a 
caval thrombus close to the right atrium.
Her medical history included hyperten­
sion, cholecystectomy, stroke (with recov-
FIG. 1 — Case 1. Preoperative abdomi­
nal computed tomogram demonstrating 
large right renal mass extending into inferi­
or vena cava.
ery), myocardial infarction and arthritis of 
her knees. She was an obese woman with 
evidence of peripheral arterial disease and 
varicose veins. On admission she had a 
hemoglobin level of 7.88 mmol/L, leuko­
cyte count of 5.4 X 109/L, blood urea 
nitrogen level 5.0 mmol/L (urea) and a 
serum creatinine value of 79.6 /tmol/L.
She underwent resection of a right renal 
cell carcinoma, using the method described 
in Case 1, except that we found it neces­
sary to cannulate only the right atrium for 
venous access.
Adherence of the tumour thrombus 
made it necessary to resect 8 cm of inferior 
vena cava, which was reconstructed using 
a pericardial patch.7 The total bypass time 
was 68 minutes with 49 minutes of circula­
tory arrest.
Postoperatively, the patient had no 
major complications; she required 12 units 
of packed red cells and 2 of fresh frozen 
plasma and she had anorexia secondary to 
a prolonged ileus. She was depressed for 
several days, but there was no detectable 
neurologic deficit.
The patient was discharged home on 
postoperative day 12 with a hemoglobin 
level of 5.8 mmol/L and normal renal 
indices. She was placed on a 3-month 
course of Coumadin to prevent thrombosis 
of the inferior vena caval patch graft and 
was still well 16 months postoperatively.
Discussion
Invasion of the inferior vena cava 
by renal cell carcinoma is reported to 
occur in 4% to 10% of patients.1-15 
Tumour extension to the right atrium 
is less common.4-7-9-11 Several tech­
niques have been described for re­
moving renal tumours that involve 
the renal veins and inferior vena ca­
va,10-14 but when the tumour throm­
bus extends to or above the dia­
phragm, the problems are much grea­
ter.4-915 Intraoperative hazards in­
clude tumour embolization into the 
right heart or lungs, massive bleeding 
or incomplete clearance of the throm­
bus. Cardiopulmonary bypass, pro­
found hypothermia and circulatory 
arrest provide a clear, dry operative
FIG. 2 — Case 2. Preoperative abdomi­
nal computed tomogram showing tumour 
thrombus within enlarged inferior vena 
cava.
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field with excellent visualization of 
the entire suprarenal inferior vena 
cava, maximizing the opportunity for 
complete tumour resection.6
One potential hazard associated 
with this technique is the effect of 
cardiopulmonary bypass and pro­
found hypothermia on hemostasis.16 
With the aid of packed red cells and 
specific clotting factors, we have not 
found bleeding to be a problem using 
this method. It is also possible that 
the routine postoperative use of des­
mopressin could further reduce peri­
operative blood loss.17 There is con­
cern that circulatory arrest may cause 
a serious neurologic deficit. The 
“safe” time limit for circulatory arrest 
is controversial,1819 but it would seem 
that the time should be kept under 40 
minutes whenever possible. Whether 
certain anesthetic and pharmacologic 
maneuvers can be employed to pro­
tect the brain during circulatory arrest 
is unclear at present. As Hickey and 
Anderson20 have noted, “the inci­
dence of significant neurologic seque­
lae using modern techniques is diffi­
cult to distinguish from the incidence 
of cardiopulmonary bypass-related 
neurologic complications”.
The use of pentothal, 15 to 30 
mg/kg, with profound hypothermia 
has been shown to produce an isoelec­
tric electroencephalogram, thereby de­
creasing cerebral oxygen consumption 
to 50% of that at normothermia.21'22 
To optimize cerebral protection, both 
patients received 20 mg/kg of pento­
thal 10 minutes before circulatory ar­
rest. Potential side effects from the 
pentothal, such as prolonged sedation 
and myocardial depression, were not 
evident. Both patients remained he- 
modynamically stable during the 
rapid pentothal administration; nei­
ther required vasopressors at the end 
of cardiopulmonary bypass and both 
were extubated the morning after sur­
gery.
Renal cell carcinoma is an aggres­
sive lesion in which surgical extirpa­
tion remains the only treatment.16 
Poor prognostic features of this dis­
ease include invasion of the peri­
nephric fat, lymph-node involvement 
and histologic evidence of spindle-cell 
formation.23’24 Until recently, it was 
believed that inferior vena caval in­
volvement conferred a poor progno­
sis, a view strengthened by the staging 
system of Robson and associates,25 
which defines renal vein and inferior 
vena caval involvement as a stage III 
lesion. Other studies have indicated 
that caval involvement may not be as 
serious as lymph-node invasion, and 
that survival of a patient with caval 
involvement alone may approximate 
that of a patient with a stage I le­
sion.23'24
These data reflect the aggressive 
nature of this disease, yet a carefully 
planned, well-executed operation of­
fers the best opportunity for cure or 
palliation. We believe that the addi­
tion of cardiopulmonary bypass, pro­
found hypothermia and circulatory 
arrest significantly increases the ease 
of the operative procedure with ac­
ceptable morbidity.
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Symposium on Mesenteric Ischemia
W.G. Jamieson, md, frcs, frcsc, facs
1. Acute Intestinal Ischemia
Massive acute intestinal ischemia, an 
intra-abdominal catastrophe, is associ­
ated with a high death rate. Only with 
early diagnosis and prompt aggressive 
management can this rate be reduced.
The key to diagnosis is suspicion 
followed by intelligent interpretation of 
physical findings, awareness of the 
importance of elevated leukocyte 
count and inorganic phosphate levels 
and of acidosis, and more liberal use of 
superior mesenteric angiography in 
cases of possible intestinal ischemia.
A "golden period" exists in which the 
bowel may be revascularized without 
tissue loss, so the aim should be to 
make the diagnosis more often during 
this period and to restore intestinal 
blood flow promptly.
L'ischemie massive intestinale aigue, 
veritable catastrophe intra-abdomina- 
le, est reliee a une mortalite elevee. 
Seuls un diagnostic precoce et une 
intervention agressive rapide permet- 
tent de reduire ce taux.
La clef du diagnostic tient dans sa 
presomption, puis dans ('interpretation 
intelligente de I'examen physique, 
dans la reconnaissance de ('importan­
ce d'un compte leucocytaire eieve, des 
taux de phosphate inorganique et 
d'une acidose, et dans une utilisation
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plus repandue de I'angiographie 
mesenterique superieure dans tous les 
cas d'ischemie intestinale possible. II 
existe un "intervalle privilegie" au 
cours duquel I'intestin peut etre revas- 
cularise sans qu'il y ait de perte tissu- 
laire. On doit done tendre a faire le 
diagnostic durant cette periode et a 
retablir la circulation sanguine intesti­
nale promptement.
Acute mesenteric ischemia has been the bete noire of acute abdominal conditions. The impending in- traperitoneal catastrophe is out of keeping with the patient’s often vague complaints, the paucity of physical findings and the lack of diagnostic help from routine laboratory investi­gations and plain abdominal x-ray films.
The subject I shall discuss is mas­sive acute intestinal ischemia; I shall not consider small areas of necrosis, ischemic colitis, necrotizing enteroco­litis of children, celiac or inferior mesenteric artery problems.
Etiology
There are three possible causes of acute mesenteric ischemia: embolism, thrombosis and nonocclusive mesen­teric insufficiency.An embolus to the superior mesen­teric artery accounts for 25% to 30% of cases of acute intestinal ischemia.1 Most (90% to 95%) emboli arise from the heart, usually because of atrial fibrillation, but also from mural thrombus in the left ventricle. Other sources of emboli may be atheroscle­rotic plaques and vegetation or thrombi on valves. The embolus lodges in the superior mesenteric ar­tery a few centimetres from its origin and usually spares the middle colic artery and proximal jejunal branches,
giving a classic distribution of isch­emia at the time of laparotomy.Thrombosis of the superior mesen­teric artery, usually associated with aortic atherosclerosis, occurs at the origin of the vessel and involves all branches of the superior mesenteric artery, including the middle colic and early jejunal branches. The gut be­comes ischemic from the duodenum to the middle of the transverse colon.Nonocclusive mesenteric insuffi­ciency is the term used for cases with no mechanical blockage of the superi­or mesenteric artery. In the majority of such patients a major contributing factor, such as cardiac failure or ar­rhythmia, digitalis abuse, hemocon- centration following diuretic therapy and other systemic debilitating diseas­es, leads to a reduction in cardiac output and subsequently in mesenter­ic flow. The true frequency of this problem remains unknown because the underlying cause is often correct­ed with return of blood flow and 
function of the gut.
Diagnosis
The key to early diagnosis is suspi­cion, especially during the first few hours when the findings are only vague abdominal pain with diffuse tenderness, anorexia and abdominal fullness.The classic picture of obvious car­diac disease, sudden severe abdomi­nal pain and spontaneous defecation is usually not present. I believe the onset often is insidious and early diagnosis is most difficult.Help may be obtained from a triad of laboratory observations.•  The leukocyte count is usually grossly elevated.2•  Metabolic acidosis is usually present; our group likes to call this “inappropriate acidosis” as the pa-
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tient has no other obvious cause of 
the acid-base upset and early on is not 
as ill as the acidosis would indicate.3
•  We have shown that the level of 
serum inorganic phosphate is substan­
tially elevated in peripheral blood, at 
a time when prompt restoration of 
mesenteric blood flow is gut-sparing. 
In 20 of our cases the finding of an 
elevated serum phosphate level has 
been an accurate reflection of gut 
ischemia.46
I recommend that if there is any 
chance of intestinal ischemia, the 
serum phosphate level, leukocyte 
count and pH should be measured. If 
these are abnormal, the patient should 
quickly undergo superior mesenteric 
artery angiography and appropriate 
action should be taken.
With nonocclusive mesenteric in­
sufficiency suspicion again is the key. 
A patient with a deteriorating cardiac 
problem and vague abdominal com­
plaints whose abdomen feels “doughy” 
should undergo the same laboratory 
investigations followed by angiogra­
phy. If the supenor mesenteric artery 
spasm is not treated, the cardiac prob­
lem is magnified and often irrevers­
ible.
Treatment
Superior Mesenteric Artery Embolus
Embolectomy and resection of the 
necrotic bowel should be performed 
promptly. Attention to the source of 
the embolus and elimination of the 
cause is mandatory. Metabolic acido­
sis, if present, should be corrected. As 
soon as the diagnosis is made, heparin 
should be given systemically to help 
prevent a second embolus from dis­
lodging and to stop propagation of the 
clot within the superior mesenteric 
artery.
Some7 believe that the angiographic 
catheter should be left in the superior 
mesenteric artery and used to infuse 
papaverine (60 mg/h) because spasm 
is associated with the embolus and its 
extraction.
The superior mesenteric artery is 
found at the base of the mesentery as 
it courses over the third part of the 
duodenum. The embolus is removed 
using a small Fogarty catheter, the 
artery is irrigated distally with hepari­
nized saline and the arteriotomy is 
closed. Obviously necrotic bowel 
should be resected and the viability of 
the remaining bowel examined. 
Doppler probes are available8 and flu­
orescein dye tests have been helpful.8 
We use observation and Doppler ex­
amination.
Areas of bowel that are of question­
able viability should be examined at a 
“second look” operation 24 hours 
after the first.9 There are no tests to 
determine small areas of necrotic 
bowel and too much is at stake to 
adopt a “wait and see” attitude.
Superior Mesenteric Artery 
Thrombosis
•  An elevated serum inorganic 
phosphate level in peripheral blood 
may be an early key to diagnosis in 
the patient with minimal abdominal 
findings.
•  Superior mesenteric angiography 
should be used liberally if there is any 
possibility of acute intestinal isch­
emia.
Ischemic bowel extending from 
proximal jejunum to the splenic flex­
ure is diagnostic of superior mesenter­
ic artery thrombosis.
The same urgency is required for 
this condition as for embolism — that 
is, prompt surgery; I have had no 
experience with fibrinolytic agents.
After the artery has been isolated, it 
is opened at a soft spot. Removal of 
the thrombus with a Fogarty catheter 
may be attempted, but often it is to 
no avail. I believe that a simple by­
pass (aorta-superior mesenteric artery 
or iliac artery-superior mesenteric ar­
tery) using vein or synthetic material 
is the operation of choice. Aortic su­
perior mesenteric endarterectomy, 
distal superior mesenteric artery-iliac 
artery anastomosis and axial aorta- 
superior mesenteric artery grafting 
have all been done with good results. 
As with the superior mesenteric artery 
embolus, the bowel is observed, re­
sected if necessary and a second look 
laparotomy done, if indicated.
Nonocclusive Mesenteric Ischemia
Pharmacologic treatment is the 
mainstay of management in these pa­
tients. The angiographic catheter is 
left in the origin of the superior mes­
enteric artery and papaverine (60 
mg/h) is infused for 24 hours. Repeat 
angiography is done and if the 
splanchnic circulation is normal, the 
catheter is removed.
If there is residual spasm, vasodila­
tor therapy is continued for an addi­
tional 24 hours. During this 24- to 
48-hour period, aggressive cardiac re­
suscitation is carried out.10
Comment
Early diagnosis is mandatory for 
successful management of mesenteric 
ischemia.
A number of points should be em­
phasized.
•  The condition, if treated early, 
will give excellent results with no loss 
of bowel.
•  Visible peritonitis with mesen­
teric ischemia usually indicates ne­
crotic bowel.
•  The leukocyte count is usually 
elevated.
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2. Chronic Mesenteric Ischemia
Although chronic mesenteric ischemia 
is an infrequent, even rare, condition 
and a busy vascular surgeon may en­
counter only one such patient in a 
year, the associated morbidity and 
mortality are high, especially if the 
condition is not recognized. General 
and vascular surgeons must bear in 
mind the triad of postprandial pain, 
weight loss and diarrhea. Patients 
with mesenteric ischemia are at high 
risk and generally have diffuse periph­
eral vascular disease. Although sur­
gery is hazardous, successful repair 
can result in long-term survival with­
out morbidity. The author favours 
antegrade supraceliac bypass grafting 
over infrarenal grafting which is tech­
nically more difficult.
L'ischemie mesenterique chronique 
est peu frequente, voire rare. Un chi- 
rurgien vasculaire occupe peut n'en 
recontrer qu'un seul cas annuellement. 
Neanmoins, la morbidite et la mortalite 
qui y sont rattachees sont elevees, 
surtout quand I'affection n'est pas ra- 
pidement reconnue. Les chirurgiens 
vasculaires et generaux doivent garder 
a I'esprit la triade: douleur post-pran- 
diale, perte de poids et diarrhee. Les 
patients qui souffrent d'ischemie 
mesenterique sont des sujets a risque 
et ils ont generaiement une vasculopa- 
thie peripherique disseminee. Meme si 
la chirurgie est risquee, une reparation 
reussie peut resulter en une survie
From the Department o f  Surgery, Health 
Sciences Centre, University o f  Manitoba, 
Winnipeg, Man.
Presented as part o f a symposium on mes­
enteric ischemia at the 9th annual meeting 
o f the Canadian Society for Vascular Sur­
gery, held in conjunction with the 56th 
annual meeting of the Royal College of 
Physicians ana Surgeons o f Canada, Win­
nipeg, Man., Sept. 12, 1987
Accepted for publication Jan. 5, 1988
Reprint requests to: Dr. C.R. Lye, Associate 
Professor, Department o f Surgery, Health 
Sciences Centre, 700 William A ve., Winni­
peg, Man. R3E 0Z3
prolongee, exempte de morbidite. 
L'auteur prefere un pontage supra- 
coeliaque anterograde a une derivation 
sous-renale, laquelle est technique- 
ment plus difficile a realiser.
Chronic mesenteric ischemia is un­
common, but the associated morbidi­
ty and mortality are high. It is a 
manifestation of atherosclerotic occlu­
sive disease, usually involving a com­
bination of two or three of the follow­
ing: the celiac axis and superior and 
inferior mesenteric arteries. Rarely, 
fibromuscular disease in the young or 
Buerger’s disease in the adult may be 
causative, and very occasionally pa­
tients will have symptoms with single­
artery involvement (usually the supe­
rior mesenteric artery). Interestingly, 
women are affected more frequently 
than men. The atherosclerotic lesion 
usually involves the proximal cen­
timetre of the vessel and may be 
considered an extension of adjacent 
aortic atheroma. Although atheroscler­
otic involvement of the aortic ori­
fices of the visceral vessels is com­
mon, the functional effects of single- 
and even double-vessel lesions are 
limited, due to the excellent potential 
collateral pathways that exist between 
the celiac axis and the superior mes­
enteric artery (pancreatoduodenal ar­
teries), and the superior mesenteric 
and inferior mesenteric arteries (the 
arc of Riolan and marginal artery of 
Drummond). Usually all three vessels 
are involved in the symptomatic pa­
tient. The ensuing ischemia results in 
postprandial pain and often malab­
sorption, both of which may lead to 
weight loss. Malabsorption may lead 
to diarrhea which is often fatty. The 
end result, as noted by Dunphy,1 is 
often gut infarction and death.
Clinical Presentation and Diagnosis
Pain is virtually universal in pa­
tients with chronic mesenteric isch­
emia. It usually develops 10 to 30 
minutes after eating. It may be steady
or colicky, is usually periumbilical 
and often varies in duration with the 
type and amount of food ingested. 
The patient learns to avoid large 
meals and may experience sitophobia, 
resulting in weight loss which may be 
massive and mimic carcinomatosis. 
In extreme cases, abdominal pain may 
be virtually continuous, analogous to 
rest pain in the extremity, and the 
clinical picture can merge into one of 
acute mesenteric ischemia. Although 
diarrhea is the classic form of bowel 
disturbance, it occurs in only 50% of 
patients. Constipation may also occur.
Physical findings are few. Weight 
loss is usually marked. Generalized 
atherosclerotic occlusive disease is 
frequent and an epigastric bruit is 
usually present.
The correct diagnosis is generally 
not made until the patient has had 
symptoms for many months. General 
abdominal x-ray films are of little 
value. Assessment of gut function 
with xylose uptake and fecal fat mea­
surements is useful if the findings are 
positive, but they are frequently nor­
mal. Diagnosis depends on the clini­
cal picture and awareness and is con­
firmed by angiography. Although 
frontal aortography usually demon­
strates collateral channels, lateral 
views are essential to delineate the 
proximal celiac and superior mesen­
teric lesions.
Treatment
Treatment is by surgical reconstruc­
tion. Although we have had short­
term success in one instance of bal­
loon angioplasty of the superior mes­
enteric artery, there is no reason to 
expect that the outcome of angioplas­
ty of stenoses at the origins of the 
visceral vessels will differ from the 
rather dismal results seen in similar 
lesions of the renal arteries.
Reconstructive techniques have 
been many and varied. Local short 
endarterectomy and patching through 
an anterior transabdominal approach 
can be applied to any of the visceral 
vessels and has stood the test of time.
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Thromboendarterectomy of the supe­
rior mesenteric artery can be accom­
plished either above, through the gas- 
trohepatic ligament, or below, 
through the ligament of Treitz. The 
retroperitoneal “ trap door” approach 
recommended by Stoney and associ­
ates2 affords an excellent repair, 
which can include the renal arteries 
when necessary, but demands a high 
level of technical expertise and famil­
iarity with the anatomy involved. It is 
not for the occasional operator.
Because of its relative simplicity,
the bypass graft remains the choice of 
most surgeons. Here the major choice 
lies between an infrarenal or su- 
praceliac location for the origin of the 
graft. In our experience, and that of 
others,3 the long retrograde infrarenal 
graft taken through the mesentery to 
the middle of the superior mesenteric 
artery, whether vein or prosthesis, is 
difficult to position and is susceptible 
to both early and late occlusion, often 
with disastrous results. A short retro­
grade infrarenal graft to the proximal 
superior mesenteric artery, where pos­
sible, is more durable. This may be 
technically more difficult, particularly 
in the patient who has previously 
undergone aortic surgery. Our proce­
dure of choice is the antegrade su- 
praceliac graft that can be brought 
down either in front or behind the 
pancreas to the middle of the superior 
mesenteric artery. In the very thin 
patient with a mobile pancreas it is 
possible to retract the pancreas inferi- 
orly and accomplish the entire repair 
through the divided gastrohepatic lig­
ament. This is a durable procedure,
An emerging
IN THE MANAGEMENT
fprobably because of the axial orienta- 
K * tion of the graft. If the celiac axis is
involved as well as the superior mes- 
>• enteric artery, the proximal anasto­
mosis may be placed across the celiac 
'  axis as a patch angioplasty. This tech-
4  ^ nique is equally applicable to the
previously reconstructed aorta, and 
A the aorta at the supraceliac level is
} usually free of atheroma. If a su-
i A praceliac graft is to be combined with
infrarenal aortic surgery, the visceral 
A > repair should be done as the initial
step.
*  t___________
standard
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OF COMMUNITY-ACQUIRED INFECTIONS
Symptoms of mesenteric ischemia 
may be difficult to identify in the 
abdomen postoperatively, and for this 
reason angiography is mandatory if 
there is any concern in the first few 
days after surgical repair. In any 
event, angiographic assessment of the 
visceral vessels should be obtained 
before the patient is discharged from 
hospital.
Successful reconstruction is associ­
ated with alleviation of symptoms 
and the patient’s return to his usual 
weight. As with other reconstructions,
late occlusion can occur, and later 
abdominal symptoms should be ag­
gressively investigated to forestall po­
tential gut infarction.
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3. Colonic Ischemia After Aortic Reconstruction
Colonic ischemia after aortic recon­
struction is rare, but when it occurs in 
its worst form it carries a 50% death 
rate. The etiology and pathogenesis of 
this condition demonstrate that in 
many instances it may be prevented. 
Early recognition, particularly of the 
transmural ischemic injury, is essen­
tial.
Numerous techniques used during 
surgery for assessing the adequacy of 
colonic perfusion have been evaluated 
and found to be cumbersome and inac­
curate in terms of predicting colonic 
ischemia. Recent experience with the 
use of the pulse oximeter appears 
promising in identifying patients with 
inadequate colonic perfusion who may 
then be candidates for reimplantation 
of the inferior mesenteric artery.
L'ischemie colique consecutive a une 
reconstruction de I'aorte est rare. Tou- 
tefois, lorsqu'elle survient, elle en- 
traine, dans sa forme la plus grave, 
une mortalite de 50%. L'etiologie et la 
pathogenese de cette affection 
demontrent que dans plusieurs cas elle 
pourrait etre prevenue. Son identifica­
tion precoce est essentielle. particu- 
lierement lorsqu'on est en presence 
d'une lesion ischemique transmurale.
On a evalue plusieurs techniques 
utilisees en salle d'operation pour eta- 
blir la capacite de perfusion colique. 
Ces techniques sont souvent lourdes 
et elles manquent de precision pour 
predire l'ischemie colique. L'utilisation 
recente de I'oxymetre a impulsion 
parait prometteuse pour identifier les
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patients souffrant d'une perfusion 
colique insatisfaisante qui pourraient 
etre candidats a une reimplantation de 
I'artere mesenterique inferieure.
Colonic ischemia after aortic proce­
dures is mainly iatrogenic. In its worst 
form, ischemic colitis complicating 
aortic surgery carries a 50% mortality. 
It is apparent, however, that vascular 
surgeons now have the techniques to 
recognize the potential for this condi­
tion and to avoid it completely.
Historical Perspective
Only 2 years after Dubost and col­
leagues1 resected the first aortic aneu­
rysm in 1952, Moore2 reported the 
first case of ischemic colitis after aor­
tic reconstruction. Since then, numer­
ous case reports and series have been 
published.3-6
These series provide evidence of 
marked differences in the incidence of 
this condition.36 In retrospective 
studies, an occurrence rate of 2% has 
been found, usually associated with 
an unfavourable outcome; in prospec­
tive series, the frequency was from 7% 
to 35% mainly because of better diag­
nosis through colonoscopy in the 
postoperative period. In 75% of cases 
the condition is associated with liga­
tion of the inferior mesenteric artery 
during aneurysm resection; the other 
25% occur during aortoiliac recon­
struction for claudication.
A 12% incidence of ischemic colitis 
is associated with ruptured abdominal 
aortic aneurysm in retrospective 
studies. However, routine postopera­
tive colonoscopy will reveal demon­
strable mucosal changes in 60%.. The 
death rate for elective aortic proce­
dures has declined to approximately 
2% and a similar incidence of clinical­
ly overt ischemic colitis would not be 
considered high. However, for the 
number of aortic procedures that are 
done in Canada, for example, 2% 
represents a sizable number of pa­
tients and 50% of them will die of 
complications associated with isch­
emic colitis.
Johnstone and Scobie,7 reporting 
on the Canadian Society for Vascular 
Surgery Multicentre Study of Aneu­
rysmectomy, demonstrated one of the 
lowest rates of this complication ever 
recorded — 0.6% in 666 patients — 
but the series excluded patients with 
ruptured aneurysms. In this series the 
inferior mesenteric artery was reim­
planted in 4.8% of patients and car­
ried a greatly increased incidence of 
hemorrhage postoperatively. Twelve 
percent of patients had complete ex­
clusion of the hypogastric vessels, and 
in this group the frequency of both 
diarrhea alone and ischemic colitis 
was markedly increased.
In the four patients who had isch­
emic colitis, wound infection, paralyt­
ic ileus and renal dysfunction were 
also common, as might be expected. 
Two died, giving a death rate that was 
consistent with those of other pub­
lished series.
Etiology
Although most documented cases of 
ischemic colitis are associated with 
ligation of the inferior mesenteric ar­
tery during the aortic procedure, asso­
ciated factors contribute significant­
ly.3-6 Arrthymias affecting cardiac 
output, aortic clamp time, colonic 
distension, hypogastric exclusion, hy­
povolemia and retractor injuries have 
all been cited as contributing causes.3 4
As well, operative measures will 
prevent complications. Improper liga­
tion of the inferior mesenteric artery 
distal to its first bifurcation could be 
prevented by transfixion within the 
sac of the aneurysm. Limiting manip­
ulation of the aneurysm may prevent 
trash colon and trash foot. Also, if it 
is considered necessary to evacuate 
the retroperitoneal hematoma from 
the mesentery, it should be done from 
the lateral aspect rather than through 
the sigmoid mesentery. Hypogastric 
flow should be preserved whenever 
possible and this is feasible in 90% of 
cases.
To avoid unnecessary reconstruc­
tion of the inferior mesenteric artery, 
particularly when the hypogastric ves-
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sels are not going to be reperfused, 
measurement of colonic perfusion by 
one of several techniques should be 
considered.
Anatomical Considerations
If the principal cause of ischemic 
colitis is ligation of the inferior mes­
enteric artery and the problem is fail­
ure to recognize this dominant vessel, 
the solution must lie in attempting to 
predict the patient who requires re­
construction of the hemodynamically 
important inferior mesenteric artery 
at the time the initial aortic procedure 
is performed.
Collateralization between the supe­
rior mesenteric artery, its midcolic 
branch and the hypogastric arteries 
through the middle and inferior rectal 
arteries and the superior rectal branch 
of the inferior mesenteric artery is 
well known. The origin of the inferior 
mesenteric artery and its first branch,
FIG. 1 — Barium enema demonstrating 
stricture resulting from type B ischemic 
insult.
FIG. 2 — Aortogram demonstrating me­
andering mesenteric vessel after aortic re­
construction.
3 to 4 cm from the aorta, can vary, 
and the presence of a particularly 
large abdominal aortic aneurysm can 
shorten this distance considerably. Li­
gation in this event can readily in­
clude the superior rectal branch or the 
ascending branch of the inferior mes­
enteric artery which together form 
part of a meandering mesenteric ves­
sel. Many pseudonyms have been at­
tached to this vessel, perhaps explain­
ing the confusion related to the true 
functional anatomy of the region.
Potentially present in 60% of the 
general population, the meandering 
mesenteric vessel is identified in 30% 
of angiograms performed for occlu­
sion or aneurysmal disease and is a 
cardinal sign, the implications of 
which the surgeon must not overlook.
Classification
Experience has taught us to differ­
entiate three clinicopathological types 
of ischemic insult, each characterized 
by different prognostic features.
Type A is associated with a con­
tained, generally mild, mucosal injury 
from which the patient should recover 
normally. This is the most common 
type and the one most likely to be 
seen during colonoscopy done after 
aortic reconstruction.
Type B (Fig. 1) indicates an isch­
emic insult to mucosa and underlying 
muscularis; the latter lesion may pro­
duce long-term problems with insidi­
ous diarrhea and possibly stricture 
formation.
Type C represents the transmural 
ischemic injury, usually producing 
fairly obvious signs within a short 
time. Clinical signs, however, may be 
masked in the early postoperative pe­
riod, delaying the diagnosis and re­
sulting in increased mortality. Overt 
sepsis, gangrene of the colon and per­
foration are anticipated sequelae.
Clinical Recognition
Acute clinical awareness of isch­
emic colitis contributes to an early 
diagnosis, but with a frequency of 
only 2% this is not always easy to 
achieve, many cases not being detec­
ted as soon as they could be.
Early after aortic surgery, patients 
may exhibit pain, guarding, febrile 
episodes, oliguria and leukocytosis, 
features that are also typical of isch­
emic colitis.
Although bloody diarrhea is recog­
nized as pathognomonic of this condi­
tion, it may not become evident for 
several days after the initiating insult. 
The decision to intervene surgically is 
never easy. Intervention too early
may result in an unnecessary laparot­
omy at best or an unnecessary colonic 
resection with all its attendant risks at 
worst.
Intervention too late in a patient 
with a type C lesion is associated with 
" 90% mortality. One can argue 
strongly in favour of routine colonos­
copy in the postoperative period. 
Even performed at the bedside, it has 
been shown to be sensitive in identify­
ing early mucosal changes. The diag­
nosis can be ruled out in a sick patient 
if colonoscopy performed to the level 
of the descending colon demonstrates 
a normal appearance.
Barium enemas in the presence of 
ischemic colitis are fraught with the 
danger of perforation and subsequent 
peritonitis and are to be condemned.
Prevention
The key to prevention lies in recog­
nizing the basic vascular abnormality. 
This can be achieved by identifying 
preoperatively patients most at risk 
for ischemic colitis and confirming 
during surgery any altered blood flow 
to the colon.
Angiography
It is important that vascular radiol­
ogists place their catheters high 
enough in the aorta to demonstrate 
patency of the superior mesenteric 
artery. If this vessel is not demon­
strated angiographically,5 one cannot 
be certain about its complicity in the 
blood supply of the colon.
If a meandering mesenteric vessel 
is demonstrated (Fig. 2), it may indi­
cate obstruction of either the celiac or 
superior mesenteric artery. If, howev­
er, it appears on the superior mesen­
teric artery injection, the risk of pro­
ducing ischemic colitis by ligating the 
origin of the inferior mesenteric ar­
tery is minimal, unless ligation occurs 
too far distally, which might happen 
in association with a particularly large 
aneurysm. Although angiography is 
standard for assessing aortoiliac dis­
ease, it is not for aneurysmal disease. 
In fact, we may be moving away from 
not only standard angiography but 
also intravenous and intra-arterial 
digital subtraction angiography. In 
our efforts to reduce risk factors we 
have become more selective in our 
use of contrast studies,5 using them 
only when we are concerned about 
aneurysmal involvement of the renal 
arteries, associated renovascular hy­
pertension and claudication. Howev­
er, this may prevent us from obtain­
ing important information about vis­
ceral blood flow.
VOLUME 31, NO. 3 MAY 1988 / THE CANADIAN JOURNAL OF SURGERY 163
When digital subtraction angiogra­
phy is used, it will seldom provide 
adequate information regarding flow 
in the mesenteric arteries.
The accepted standard in many 
centres is now computed tomography, 
but magnetic resonance imaging is 
starting to play a similar role. Al­
though either approach adds to the 
surgeon’s knowledge of specific anato­
my pertinent to the aneurysm, both 
fail to provide information about vis­
ceral flow. Duplex scanning of the 
superior mesenteric artery in conjunc­
tion with computed tomography or 
magnetic resonance imaging may cor­
rect this shortfall.
Assessing Perfusion of the Colon
It seems clear that prevention lies 
in recognizing the potential for isch­
emic colitis in the individual patient 
and that the ability to predict clinical­
ly the adequacy of colonic perfusion is 
unreliable. Current techniques for as­
sessing perfusion in the operating 
room tend to be time-consuming, 
cumbersome, subject to equipment 
and human error and, thus, unreli­
able.
Isotope scanning,8 although relia­
ble, is cumbersome in the operating 
room. It could be more informative in 
the recovery period in questionable 
cases. Surface temperature determina­
tions and dye injection are generally 
considered unreliable. Measurements 
of stump pressure and the inferior 
mesenteric artery systolic ratio have 
been found helpful59 and are good 
predictors of adequate colonic perfu­
sion when the stump pressure exceeds 
40 mm Hg or when the ratio exceeds 
0.4:1.
These measurements can be diffi­
cult to obtain, however, particularly 
in aneurysmal disease where the in­
ferior mesenteric artery at its origin is 
occluded in 45% of cases.
Mucosal pH measurement with in­
traluminal balloon catheters in the 
colon, as described by Fiddian-Green 
and associates,10 is a sensitive and 
reliable means of assessing and pre­
venting ischemic colitis. However, it 
is also cumbersome and is unlikely to 
be available outside tertiary or quater­
nary care hospitals.
Thus, we need instrumentation that 
is sensitive, reliable, inexpensive, not 
time-consuming and readily available 
in regional hospitals where aneurysm 
surgery is usually carried out.
The pulse oximeter is standard 
equipment for the anesthetist in any 
hospital likely to undertake aortic sur­
gery. It accurately measures pulsatility 
and oxygen saturation and, although
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normally attached to an appendage 
such as finger or nose, it readily 
adapts to the surface of the colon or 
small bowel.
Once the pulse oximeter is calibrat­
ed by the anesthetist at the start of 
surgery, movement of it between the 
finger and colonic surface back to the 
digit will not change its accuracy. 
Under normal circumstances of ade­
quate perfusion, the recordings made 
by the anesthetist should mimic those 
obtained from the colon or small bow­
el. The oximeter probe is placed in a 
sterile sleeve and is passed into the 
operative field to be attached to the 
segment of bowel in question. Arterial 
pulsatility and transcolonic oxygen 
saturation can be measured before 
and after aortic reconstruction or dur­
ing temporary clamping of the inferi­
or mesenteric artery or iliac vessels.
Ouriel and colleagues11 described 
their findings using this technique in 
30 consecutive patients who under­
went aortic reconstruction. In two 
patients who demonstrated loss of 
pulsatility with unmeasurable transco­
lonic oxygen saturation but without 
signs at surgery of impaired perfusion 
in the colon, classic evidence of mu­
cosal ischemic changes was seen on 
colonoscopy and clinical signs of mild 
colitis were noted in the postoperative 
period. This test, although carried out 
in a small group of patients, appeared 
to be accurate in predicting viability 
of the colon and the need for revascu­
larization of the patent inferior mes­
enteric artery.
Protocol for Identifying the Potentially 
Ischemic Colon
If one could reliably identify the 
subset of patients who, depending on 
inferior mesenteric artery blood flow, 
are clearly at particularly high risk for 
ischemic colitis, selective inferior 
mesenteric artery revascularization 
could be performed and adequate co­
lonic perfusion restored in this group 
of patients.
The following protocol is suggested.
•  Preoperative ultrasonography, 
which generally has routinely been 
done, should be followed by comput­
ed tomography or magnetic resonance 
imaging in the case of an aortic aneu­
rysm, with angiography being added 
in selected cases. Angiography clearly 
is obtained in all cases of aortoiliac 
disease but must in addition show 
details of the superior mesenteric ar­
tery.
•  Patients with aneurysms who do 
not undergo angiography should have 
duplex scanning of the origin of the 
superior mesenteric artery.
At the time of aortic reconstruction 
when the possibility of colonic isch­
emia is present, several options are 
available but are not necessarily 
equally desirable.
•  First, one may proceed with 
reimplantation of the inferior mesen­
teric artery. This increases the operat­
ing time and adds the risk of anasto­
motic complications. It is an ap­
proach that I do not believe is justi­
fied as a routine add-on procedure. 
My belief has been confirmed by the 
Canadian Aneurysm Study.12
•  Second, one may ignore the pos­
sibility of colonic ischemia and pro­
ceed with aortic reconstruction. If the 
colon is not going to be assessed and 
monitored during surgery, colonos­
copy should be carried out routinely 
in the postoperative period.
•  Third, my own preference is to 
either measure inferior mesenteric 
stump pressure or use the pulse oxi­
meter to assess perfusion. If colonic 
perfusion is adequate, the primary 
aortic procedure may be performed. If 
the hypoperfusion of the colon is 
confirmed, the inferior mesenteric ar­
tery should be reconstructed using 
one of several well-established meth- 
ods.4’6'9
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Methyldopa Hypersensitivity Can Mimic 
Acute Toxic Enterocolitis
The most widely known hypersensitiv­
ity reaction of methyldopa, a drug 
commonly used in the treatment of 
hypertension, is seroconversion to a 
positive result of a direct Coombs' test 
that may lead to a hemolytic anemia. 
The authors report a case of an infre­
quently noted, but serious, hypersensi­
tivity reaction to methyldopa, mani­
festing primarily as acute toxic entero­
colitis. A 63-year-old woman was ad­
mitted to hospital and underwent ag­
gressive and prolonged investigation of 
enterocolitis. Withdrawal of methyl­
dopa gave immediate relief of intesti­
nal problems. Rechallenge precipitated 
a return of symptoms within 14 hours. 
It is recommended that periodic blood 
counts and liver function tests be done 
on patients treated with methyldopa 
for hypertension. If any abnormalities 
are noted the drug should be discontin­
ued.
La reaction d'hypersensibilite le mieux 
connu de la methyldopa, un medica­
ment couramment utilise dans le trai- 
tement de I'hypertension systolique, 
est I'induction d'un test direct de 
Coombs positif, resultat qui peut con- 
duire a une anemie hemolytique. Les 
auteurs signalent le cas d'une reaction 
d'hypersensibilite a la methyldopa, 
reaction rarement observee mais 
serieuse qui se manifeste principale- 
ment par une enterocolite toxique ai- 
gue. Une femme de 63 ans, fut hospi- 
talisee pour des examens pousses et 
prolonges des causes de I'enterocolite. 
L'arret de la methyldopa a entrafne un 
soulagement immediat des problemes 
intestinaux. Une nouvelle exposition a 
precipite le retour des symptomes en
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moins de 14 heures. II est recomman- 
de de soumettre les patients traites a 
la methyldopa pour hypertension a des 
numerations cellulaires et a des epreu- 
ves fonctionnelles hepatiques periodi- 
ques. Si des anomalies sont obser- 
vees, la medication doit etre interrom- 
pue.
Current management regimens for ar­
terial hypertension may include the 
use of methyldopa, alone or in combi­
nation with other antihypertensive 
medications. The most commonly re­
ported hypersensitivity reaction asso­
ciated with this drug is seroconver­
sion, giving a positive direct Coombs’ 
test result in 20% of patients, which 
may lead to hemolytic anemia in 
0.02% of cases.1
Methyldopa may rarely cause hy­
persensitivity reactions such as fever, 
hepatitis, colitis, pancreatitis and 
myocarditis,1 reactions that are infre­
quently noted in standard references 
and hence can be overlooked. As a 
result, patients may undergo extensive 
and unwarranted clinical investiga­
tions. We report a case of methyldopa 
hypersensitivity.
Case Report
A 63-year-old woman was admitted to 
the general surgical service of the Toronto 
General Hospital with a provisional diag­
nosis of acute enterocolitis. She had been 
receiving antihypertensive (nadolol) and 
thyroid supplement (L-thyroxine) medica­
tions until 1 month before admission with 
no adverse effects. Because of an upper 
respiratory tract infection, erythromycin 
ethylsuccinate was prescribed. Broncho- 
spasm became an increasing problem, ne­
cessitating sustained-release theophylline 
(200 mg twice daily) and methyldopa (250 
mg twice daily) and withdrawal of the 
nadolol. The patient’s respiratory symp­
toms resolved and the theophylline was 
discontinued. Two weeks after the first 
dose of methyldopa, she experienced diar­
rhea, vomiting, undulating fever, chills and 
debilitating headaches. These symptoms 
persisted for 10 days and she returned to
the hospital. On readmission her vital 
signs were within normal limits, except for 
mild pyrexia (38°C orally). There was 
generalized abdominal tenderness but no 
other evident abnormalities. Notable labo­
ratory findings included eosinophilia 0.17 
X 109/L (normal 0.01 to 0.06 X 109/L) and 
an increased alkaline phosphatase level of 
118 U/L (normal less than 80 U/L). Stan­
dard abdominal x-ray films revealed a 
large amount of air scattered throughout 
the intestinal tract, compatible with a diag­
nosis of paralytic ileus. Appropriate stool 
cultures grew no important pathogens. In 
particular there was no Clostridium diffi­
cile toxin. Proctosigmoidoscopy, abdomi­
nal ultrasonography and barium c~enia 
examinations gave normal results. In hos­
pital, the patient continued to have undu­
lating fever with a body temperature 
reaching 40°C, chills, persistent vomiting 
and diarrhea. Because of a transient drop 
in her blood pressure, below 100 mm Hg 
systolic, methyldopa was withheld. For the 
first time since admission her chills and 
fever abated. The methyldopa was discon­
tinued with subsequent resolution of the 
nausea and diarrhea. After 5 days the 
patient enjoyed good health. We were sus­
picious of a drug reaction so a test dose 
(250 mg) of methyldopa was administered 
to the patient, with a return of acute 
nausea, chills, fever and abdominal dis­
comfort within 14 hours. She was dis­
charged, free of symptoms, on hospital day 
14.
Discussion
Fever with methyldopa has been 
reported to occur in approximately 
3% of patients receiving the drug.1 It 
usually develops within the first 3 
weeks of therapy, and in some cases is 
associated with eosinophilia and ab­
normal results of one or more liver 
function tests (e.g., serum alkaline 
phosphatase, serum transaminases, bi­
lirubin and prothrom bin tim e).2 Our 
patient demonstrated fever and liver 
function abnormalities in addition to 
a pronounced eosinophilia.
There are reports o f methyldopa 
causing colitis and prolonged diar­
rhea, but fever has not been noted in
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these cases.3-4 An extensive review5 
from the Swedish Adverse Reaction 
Reporting Program in 1978 summa­
rized reactions to methyldopa report­
ed over a 10-year period. In this 
review, 159 patients had a fever; of 
these, 13 had moderately elevated 
serum transaminase levels, 8 skin 
manifestations, 4 gastrointestinal 
complaints and 2 had eosinophilia. 
Gastrointestinal symptoms were re­
ported in another 17 patients, diar­
rhea being the most common com­
plaint. The onset of fever within 3 
weeks of drug administration was also 
noted. The temperatures were high 
and returned to normal within a cou­
ple of days of discontinuing methyl­
dopa therapy. Several patients under­
went provocative tests and fever de­
veloped within 12 hours of drug ad­
ministration.5 Our patient demon­
strated a combination of these clinical 
events. She was also challenged with 
the drug and her symptoms recurred 
within 14 hours.
The occurrence of serious adverse 
reactions with methyldopa is low, but 
they may cause serious morbidity, 
unwarranted investigations and result 
in hospitalization. Rapid recovery 
after drug withdrawal is the rule, al­
though deaths have been reported due 
to severe hemolysis or liver failure.
When methyldopa is used to treat 
hypertension, periodic blood counts 
and liver function testing are manda­
tory. If jaundice or abnormalities of 
liver function are noted, the drug 
should be discontinued. The onset of 
fever and enterocolitis within 3 weeks 
of initiation of methyldopa therapy 
should alert the physician to the pos­
sibility of an adverse drug reaction.
We thank Mr. John K. Murdoch, B 
Sc(Phm), Drug Information Services, To­
ronto General Hospital, for his help in 
researching and preparing the background 
on adverse drug reactions.
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SESAP V Question
112. Overwhelming sepsis after splenectomy has been recognized since 1952.
Which of the following statements about this phenomenon is NOT true?
(A) Progression from onset to death may occur in a matter of hours
(B) Most fatal episodes occur less than two years after splenectomy
(C) Pneumococci have been isolated in approximately 50% of the fatal 
cases.
(D) Patients who have had their spleen removed for hematologic 
disease have a greater risk for overwhelming sepsis than those who 
have splenectomy for trauma
(E) Postsplenectomy sepsis has not been reported in patients with 
splenosis or accessory spleens
For the critique of Item 112 see page 194.
(Reproduced by permission from S PS A P V Syllabus; Surgical Education and 
Self-Assessment Program No. 5. For enrolment in the Surgical Education and 
Self-Assessment Program No. 5, please apply to the American College of 
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Primary Resection and Anastomosis of Lesions 
Obstructing the Left Colon
It is becoming apparent that primary 
resection and anastomosis of the left 
colon for colonic obstruction is a feasi­
ble operation.
This paper reviews 750 colonic re­
sections at the Queen Elizabeth Hospi­
tal of Montreal, of which 40 were 
performed on unprepared bowel in pa­
tients with obstructed left colonic le­
sions.
The pre- and postoperative hospital 
stay was greatly reduced. The death 
rate was 5% and complication rate 
40%. Follow-up results suggest this 
procedure is safe and that an adequate 
cancer operation can be carried out. It 
should be stressed that not all ob­
structing left colonic lesions can be 
treated with a one-stage procedure 
and that the Hartmann procedure or a 
protective colostomy can always be 
used if the situation warrants it.
Dans les cas d'obstruction colique, il 
semble maintenant possible de prati- 
quer une resection primaire et une 
anastomose du colon gauche.
Cet article passe en revue 750 
resections coliques qui ont ete prati- 
quees a I'Hopital Reine Elizabeth de 
Montreal. De ce nombre, 40 cas ont 
ete effectues sur des intestins non 
prepares, chez des patients souffrant 
d'une obstruction colique gauche.
Le sejour hospitalier pre et post- 
operatoire a ete grandement reduit. 
La mortalite fut de 5% et le taux de
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complications de 40%. Les controles 
ulterieurs indiquent que cette inter­
vention est sure et qu'elle permet de 
realiser une chirurgie anticancereuse 
satisfaisante. On doit souligner qu'une 
intervention en un seul temps ne peut 
pas etre realisee dans tous les cas 
d'obstruction colique gauche et qu'une 
operation de Hartmann ou une colosto- 
mie de protection peuvent toujours 
etre utilisees quand la situation 
I'exige.
The treatment of left colonic lesions by a staged procedure is tedious and time-consuming. Moreover, the 5-year 
survival rate1 is very low (16%). Treatment by extended right hemico­lectomy,2 subtotal colectomy or total colectomy3-4 is radical, the procedures requiring considerable skill and resec­tion of a great deal of normal colon in most cases. The argument that the terminal ileum has a richer blood supply than the colon may be true, but results still show that a considera­ble number of leaks occur. Fielding and Wells5 reported that patients with primary resection had a higher 5-year survival than those with staged resec­tions.
In the 6 years 1981 to 1986, 750 colonic resections were performed at the Queen Elizabeth Hospital in Mon­
treal. Of these, 40 were emergency primary resections with anastomosis for obstruction or ruptures of the left colon. It should be noted that not every case was treated this way; in 12 cases the Hartmann procedure6 was used and in 8 others a protective colostomy was performed when the anastomosis or some other condition made this seem more prudent.
Indications and Contraindications
We believe that all patients with obstructive lesions of the left colon should be considered possible candi­dates for primary resection and anas­tomosis with the following exceptions:
•  Those with systemic disease.(a) Severe medical disease that would not allow a further 45 minutes of surgery.
(b) Prolonged steroid therapy.(c) Inflammatory bowel disease.•  Those with local problems in the pelvis and sigmoid colon that pre­clude mobilization of the rectum and 
sigmoid.(a) Diffuse metastases in pelvis.(b) Phlegmonous diverticulitis.(c) Previous radiotherapy.(d) Ischemic changes of bowel.(e) Necrotic sigmoid volvulus.
Patients
This series consisted of 40 patients (26 women, 14 men) between the ages of 34 and 93 years (average 67.9 years) (Table I).Of the 40 patients, 30 had carcino­ma, 9 diverticulitis and 1 necrotic volvulus of the sigmoid. In three cases there were associated perforations and in two an abscess was present. The 
stages of the 30 carcinomas were 14 
Dukes’ B, 8 Dukes’ C and 8 Dukes’ D.
Preoperative Assessment
In addition to nasogastric suction and intravenous therapy, appropriate preoperative x-ray films were ob­tained and laboratory investigations carried out. The lower rectum was emptied by gentle enemas and the colon assessed either using a flexible sigmoidoscope or by colonoscopy to confirm the level of the lesion and to obtain a biopsy if possible. Barium
Table 1— Age o f the 4 0  Patients in the S tudy
Age, yr No.
3 0 -  4 0 1
41 -  5 0 5
51 -  6 0 8
61 -  70 12
71 -  80 9
81 -  9 0 4
91 -  100 1 I
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enema examination was done only if 
the diagnosis could not be made by 
colonoscopy. Most patients were 
taken to the operating room within 48 
hours of admission.
Many antibiotics were used periop- 
eratively in the early cases, including 
combinations of gentamicin, clin­
damycin, Flagyl and tobramycin. The 
last 16 patients were given cefoxitin 
(2 g intravenously on call to the oper­
ating room and then postoperatively 
every 6 hours for 5 days) and this has 
proved satisfactory.
Operative Technique
Under general anesthesia, the pa­
tient is placed in a modified lithoto­
my position and the rectum examined 
to make sure it is clean and empty. If 
fluid is present a rectal tube is put in 
place.
The appropriate segment of colon 
containing the lesion is mobilized. 
The colon distal to the tumour is then 
transected and a swab placed in the 
lumen to prevent leakage. A large 
rectal tube is inserted through a dou­
ble pursestring suture placed in the 
proximal distended colon close to the 
tumour and attached to suction. Copi­
ous amounts of normal saline are 
used to empty the proximal bowel as 
much as possible. The distended 
colon above the tumour is milked 
proximally with the fingers. When the 
resection area is empty, pressure is 
applied by the thumb and index finger 
to occlude the fragile bowel. A clamp 
is then placed across the colon just 
proximal to the double pursestring 
suture holding the rectal tube. The 
anterior surface of the colon is opened 
proximal to the clamp and Gelfoam 
rapidly packed into the lumen to 
avoid any spillage. We have found 
this most effective in keeping the 
anastomotic area clean. The decom­
pressed proximal lumen is then anas­
tomosed to the distal lumen. If any 
doubt exists as to the integrity of the 
anastomosis, the peritoneal cavity can 
be flooded with saline and the rectum 
distended with air using a bulb sy­
ringe. The Gelfoam will obstruct the 
lumen proximal to the anastomosis to
Table II— C o m p lica tio n s
C o m p lic a tio n No.
U r in a ry  o b s tru c tio n  or in fe c tio n 4
W o u n d  in fection 3
A te le c ta s is  or p ne u m o n ia 3
S m a ll-b o w e l o b s tru c tio n 2
W o u n d  dehiscence 1
M y o c a rd ia l in fa rc tio n 1
D e e p -ve in  th ro m b o s is 1
R ena l failure 1
allow good assessment of any air leak. 
The Gelfoam passes with the first 
bowel movement. Before abdominal 
closure, the peritoneal cavity is irri­
gated with large quantities of normal 
saline until clean. The abdomen is 
usually closed without drainage but if 
a Hemovac drain is necessary it is 
removed within 48 hours. Skin clo­
sure depends upon the extent of con­
tamination, but usually it is wise to 
leave the skin open, with sutures 
placed ready for closure later. A single 
gauze pad soaked in 3% saline is 
placed in the open wound.
In 20 patients whose wound was 
closed primarily, 3 had wound infec­
tions. In 20 others the wound was left 
open and closed 5 days postoperative­
ly with no infection.
The mean operating time was 109 
minutes.
Postoperative Care
All patients were managed by naso­
gastric suction, intravenous adminis­
tration of fluids, sedation and Foley 
catheterization. They were kept in the 
intensive care unit on average for 48 
hours. Antibiotic coverage with cefox­
itin, 2 g intravenously every 6 hours 
for 5 days, gave excellent results. The 
wound was cleansed with 3% saline 
three times daily, and moist gauze 
was left in the open wound. Patients 
were mobilized as rapidly as possible. 
The Foley catheter on average was 
removed between day 2 and day 5, 
depending on the patient’s condition.
Wound closure was usually on day
5 and the patient was discharged 
home on day 7 or 8 if there were no 
complications. The mean postopera­
tive stay in our series was 14.6 days.
Extent of Resection
Of our 40 patients 6 underwent left 
hemicolectomy, 26 sigmoid resection,
6 rectosigmoid resection (below 18 
cm) and 2 subtotal colectomy. One 
subtotal colectomy was for a synchro­
nous carcinoma of the cecum and 
obstructing sigmoid lesion. On sig­
moidoscopy, this patient was noted to 
have a polyp in the rectum, and we 
thought subtotal colectomy was the 
appropriate treatment. The second 
case was an obstructing carcinoma of 
the sigmoid with perforation of the 
cecum.
Complications (Table II)
There were two deaths. An 
84-year-old man suffered a myocardi­
al infarction on postoperative day 7, 
followed by renal failure, and he died
on day 11. The second was a weak, 
senile, 89-year-old man who had ne­
crotic volvulus of the sigmoid. A 
wound infection, dehiscence and 
pneumonia developed and he died 
when treatment was withdrawn at his 
family’s request.
Of the other complications, the 
four cases of urinary obstruction or 
infection probably occurred because 
the Foley catheter was withdrawn too 
soon in these elderly men. The two 
patients with small-bowel obstruction 
both required surgery. Of note is that 
five of the complications occurred in 
the two patients who died.
Comments
Disparate diameter of bowel lumen 
was not a problem in our series as the 
lumen rapidly returns to reasonable 
dimensions following decompression 
and irrigation of the bowel. Necrotic 
sigmoid volvulus is associated with a 
very poor result in our hands and 
requires further assessment.
From our study it would seem that 
in patients with lesions obstructing 
the left colon, resection with primary 
anastomosis can be performed with a 
reasonable death rate of 5%. Many of 
these patients are elderly and would 
have a hard time enduring two or 
three procedures. The morbidity of 
40% could be lowered by leaving all 
wounds open. Cefoxitin is satisfactory 
for controlling sepsis. Gelfoam 
packed in the proximal lumen will 
avoid spillage in the obstructed colon 
after decompression by irrigation. 
The Gelfoam passes through the anas­
tomosis with little problem. However, 
not all cases of left colonic obstruc­
tion are suitable for a one-stage opera­
tion, and the Hartmann procedure or 
a protective colostomy are still some­
times indicated.
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cost effective
prophylactic
alternative
in contaminated 
or potentially 
contaminated 
gastro-intestinal 
surgery
Claforan .. was superior 
in preventing infectious 
morbidity and side effects 
and reduced hospital 
drug costs compared 
directly with multidose 
regimens of cefazolin 
or cefoxitin (p value not 
statistically significant)
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Action
In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium) 
a semi-synthetic cephalosporin antibiotic, results from inhibition of cell wall 
synthesis.
Indications and Clinical Uses
Treatm ent: CLAFORAN (cefotaxime sodium) may be indicated for the treatment 
of infections caused by susceptible strains of the designated micro organisms 
in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by 
Streptococcus pneumoniae (formerly Dipiococcus pneumoniae), other streptococci 
(excluding enterocci, e.g. S. faecalis), Straphylococcus aureus (penicillinase and 
non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fec tions : caused by Escherichia coli, unspecified Klebsiella 
species (including K. pneumoniae), Proteus mirabilis, indole positive Proteus, Ser- 
ratia marcescens and Staphylococcus epidermidis. Also, uncomplicated gonor­
rhea caused by N. gonorrhoeae including penicillin resistant strains. 
Bacteremia /  S ep ticem ia : caused by Escherichia coli, unspecified Klebsiella 
strains and Serratia marcescens.
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non­
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli, 
Proteus mirabilis and indole positive Proteus.
Intra-abdominal in fec tions: caused by Escherichia coli, and unspecified Kleb­
siella species.
Gynecological in fec tions : including pelvic inflammatory disease, endometritis 
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus 
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostrep- 
tococcus strains and some strains of Bacterotdes fragilis. In several cases, although 
clinical cures were achieved, bacteriological follow-up was not available. 
Clinical experience with CLAFORAN in anaerobic infections is limited. CLAFORAN 
has been used with some success in wound and intra-abdominal infections against 
some strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas. 
In the treatment of infections encountered in immunosuppressed and granulo­
cytopenic patients, results of therapy with CLAFORAN have not been impressive. 
CLAFORAN should not be considered in the treatment of enterococcal infections, 
i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order 
to isolate and identify the causative organisms and to determine their suscep­
tibilities to CLAFORAN. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re evaluated once these results 
become available.
Prophylactic U se : The administration of CLAFORAN periopeiatively (pieoperative- 
ly, intraoperatively and postoperatively) may reduce the incidence of certain infec 
tions in patients undergoing elective surgical procedures (eg. abdominal or vaginal 
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified 
as contaminated or potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased 
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative 
use of CLAFORAN may also reduce the incidence of certain postoperative infections 
Effective use for elective surgery depends on the time of administration (see Dosage 
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation 
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin) 
is recommended.
If there are signs of infection, specimens for culture should be obtained for iden­
tification of the causative organism so that appropriate therapy may be instituted. 
Contraindications
CLAFORAN is contraindicated in patients who have shown hypersensitivity to 
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics. 
Warnings
Before therapy with CLAFORAN is instituted, it must be carefully determined whether 
the patient has had previous hypersensitivity reactions to cefotaxime, 
cephalosporins, penicillins or other drugs. CLAFORAN should be given with caution 
to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including 
CLAFORAN should be administered with caution to any patient who has 
demonstrated some form of allergy, particularly to drugs. If an allergic reaction 
to CLAFORAN occurs, the drug should be discontinued and the patient treated 
with the usual agents (e.g. epinephrine, antihistamine, pressor-amines or 
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins 
(and other broad spectrum antibiotics); therefore, it is important to consider its 
diagnosis in patients who develop diarrhea during the administration of CLAFORAN. 
This colitis can range from mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor­
mal flora of the colon and may permit overgrowth of Clostridium difficile or other 
Clostridia. It has been established that a toxin produced by Clostridium difficile 
is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of CLAFORAN and replace­
ment with a suitable specific antibiotic. Moderate to severe cases should be manag­
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis 
is not relieved by discontinuance of CLAFORAN administration or when it is severe, 
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis 
(e.g. vancomycin) or other suitable therapy may be indicated. Other possible causes 
of colitis should also be considered (see Adverse Reactions).
Precautions
CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals 
with a history of lower gastrointestinal disease particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently, 
use of the drug in pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child-bearing potential requires that the anticipated 
benefits be weighed against the possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be 
exercised when the drug is administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible 
organisms. Constant evaluation of the patient’s condition is essential. If super­
infection occurs, therapy should be discontinued and appropriate measures taken. 
Although CLAFORAN rarely produces alterations in kidney function, evaluation 
of renal status is recommended, especially in severely ill patients receiving high 
doses.
Patients with markedly impaired renal function should be placed on the special 
dosage schedule recommended under Dosage and Administration, because nor­
mal dosage in these individuals is likely to produce excessive and prolonged serum 
antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment 
with the cephalosporin group of antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing 
substances but not with the use of specific glucose oxidase methods. 
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are: 
Hypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflam­
mation with intravenous administration. Pain, induration and tenderness after in­
tramuscular injection. Gastrointestinal (1.7%): Colitis, diarrhea, nausea and 
vomiting. Symptoms of pseudomembranous colitis can appear during or after 
CLAFORAN treatment. Hemic and Lymphatic System ( <  1%): Mild, reversi 
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some 
patients developed positive direct Coomb’s test during treatment with CLAFORAN. 
Genitourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient 
elevations in SGOT, SGPT, serum LDH and serum alkaline phosphatase levels 
have been reported. Kidney ( <  1%): Increased serum creatinine and BUN have 
occasionally been observed. Central Nervous System (0.2%): Headache. 
Symptoms and Treatment of Overdosage 
Since no case of overdosage has been reported to date with CLAFORAN, no 
specific information on symptoms or treatment is available. Treatment of over­
dosage should be symptomatic.
Dosage and Administration
CLAFORAN (cefotaxime sodium) may be administered intramuscularly or in­
travenously after reconstitution (see Table with recommended mode of reconstitution 
according to route of administration).
Dosage
Adults
The dosage of CLAFORAN should be determined by susceptibility of the causative 
organisms, severity of the infection and condition of the patient.
Guidelines for Dosage of CLAFORAN (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated
Gonorrhea
1 1 g IM (single dose)
Uncomplicated
infections
2 1 g every 12 hours 
IM or IV
Moderately 
severe to severe 
infections
3-6 1-2 g every 
8 hours IM or IV
Very severe 
infections (e.g. 
septicemia)
6-8 2g every 
6-8 hours IV
Life-threatening
infections
up to 12 2g every 
4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated 
surgery, recommended doses are as follows.
(a) 1 g IM or IV administered V2 to 1V2  hours prior to the initial surgical incision 
to ensure that adequate antibiotic levels are present in the serum and tissues 
at the start of surgery
(b) 1 g IM or IV administered IV 2 to 2 hours following the first dose; for lengthy 
operative procedures, additional intraoperative doses may be administered, if 
necessary, at appropriate intervals (1 1/ 2  to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period. 
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. 
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours 
after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, 
the recommended daily dose is 50 to 100 mg / kg IM or IV of body weight divid­
ed into 4 to 6 equal doses, or up to 180 m g/kg /day for severe infections. 
For body weights 50 kg or more, the usual adult dosage should be used. 
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a minimum of 48 to 72 
hours after the patient defervesces or after evidence of bacterial eradication has 
been obtained; a minimum of 10 days of treatment is recommended for infec­
tions caused by Group A beta-hemolytic streptococci in order to guard against 
the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical 
appraisal is necessary during therapy of chronic urinary tract infections and may 
be required for several months after therapy has been completed; persistent in­
fections may require prolonged treatment. Doses less than those recommended 
should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on 
sex, weight, and age of the patient) may be used to convert these values into 
creatinine clearance.
Males: Weight (kg) x  (140 -  age) Females: 0.85 x above value 
72 x  serum creatinine
Administration
Intram uscular: CLAFORAN should be injected well within the body of a relatively
large muscle such as the upper outer quadrant of the buttock (i.e gluteus max- 
imus); aspiration is necessary to avoid inadvertent injection into a blood vessel. 
In travenous: The intravenous route is preferable for patients with bacteremia, 
bacterial septicemia, or other severe or life-threatening infections, or for patients 
who may be poor risks because of lowered resistance resulting from such 
debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, 
or malignancy, particularly if shock is present or impending.
For bolus administration a solution containing 1 or 2 g of CLAFORAN can be 
injected over a period of 3 to 5 minutes Using an infusion system, it may also 
be given over a longer period of time through the tubing system by which the 
patient may be receiving other intravenous solutions Butterfly* or scalp vein type 
needles are preferred for this type of infusion. However, during infusion of the 
solution containing CLAFORAN, it is advisable to discontinue temporarily the ad­
ministration of other solutions at the same site.
Reg’d TM of Abbott Laboratories.
Reconstitution
For Intramuscular U se : CLAFORAN should be reconstituted with Sterile Water 
for Injection or Bacteriostatic Water for Injection in accordance with the volumes 
recommended in the following table.
Reconstitution Table
Intramuscular
Volume to be 
Added to 
Vial (m L)'
Approximate 
Available 
Vol. (mL)
Approx. Average 
Concentration 
(mg/mL)
500 mg vial 2 2.2 230
1 g vial 3 3.4 300
2 g vial 5 6.0 330
'shake to dissolve.
For direct intravenous injection (bolus) and / or continuous intravenous 
in fu s io n ; 500 mg, 1 and 2 g vials should be reconstituted with at least 10 mL 
of Sterile Water for Injection. Reconstituted solution may be further diluted with 
50 to 1000 mL of the fluids recommended for IV infusion.
Reconstitution Table
Intravenous
Volume to be 
Added to 
Vial (mL)'
Approximate 
Available 
Vol. (mL)
Approx. Average 
Concentration 
(mg/mL)
500 mg vial10 1 0 .2 50
1 g vial 10 10.4 95
2 g vial 10 11.0 180
'shake to dissolve.
Solutions fo r IV In fu s io n : CLAFORAN is compatible with the following infu­
sion flu ids:
-  Sterile Water for Injection
-  0.9% NaCI injection
-  5% dextrose injection
-  0.9% NaCI and 5% dextrose injection
-  0.45% NaCI and 5% dextrose injection
-  0.2% NaCI and 5% dextrose injection
-  Sodium Lactate injection
- 5% dextrose and 0.15% KCI injection
- Plasma-Lyte 56 Electrolyte Solution in 5% dextrose injection
- Ringer's injection
- Lactated Ringer's solution
- Lactated Ringer’s with 5% dextrose injection 
CLAFORAN is also compatible with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 mL of Sterile Water for Injection is isotonic. 
Stability o f Solution
S to ra ge : Solutions of CLAFORAN range from light yellow to amber, depending 
on concentration and the diluent used. The solutions tend to darken depending 
on storage conditions and should be protected from elevated temperatures and 
excessive light.
"Reg'd TM of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original vial as described under Reconstitution 
maintains satisfactory potency for 24 hours at room temperature (25°C) and for 
48 hours under refrigeration (0-5°C). Only freshly prepared reconstituted solu­
tions may be further diluted with 50 to 1000 mL of the recommended infusion 
fluids in Viaflex" intravenous bags. Such solutions maintain satisfactory poten­
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration 
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine maintains satisfactory potency for 
up to 24 hours at room temperature and 48 hours under refrigeration (reference 
to lignocaine restrictions is advisable).
CLAFORAN solutions exhibit maximum stability in the pH 5-7 range.
Special In s tru c tio n s : Parenteral drug products should be inspected visually 
for particulate matter and discoloration prior to administration. Solutions of 
CLAFORAN range from light yellow to amber, depending on concentration and 
diluent used. The dry powder as well as solutions tend to darken, depending 
on storage conditions.
Incom patib ilities : Solutions of CLAFORAN must not be admixed with 
aminoglycoside solutions. If CLAFORAN and aminoglycosides are to be ad­
ministered to the same patient, they must be administered separately and not 
as a mixed injection.
Solutions of CLAFORAN should not be prepared with diluents having a pH above 
7.5 such as Sodium Bicarbonate Injection.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, 
in vials containing 500 mg, 1.0 and 2.0 g of cefotaxime sodium (expressed as 
acid on a dry basis).
S to ra ge : CLAFORAN in the dry state should be stored at room temperature, 
protected from light and heat.
Product monograph available on request 
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Treatment of Experimental Peritonitis With Intraperitoneal
Povidone-Iodine Solution
Intraperitoneal lavage with povidone- 
iodine solution has been reported by 
some to be beneficial in the treatment 
of peritonitis and by others to cause 
local and toxic side effects. In this 
study, 200 white mice, divided into 
four groups of 50, were subjected to 
bacterial peritonitis. The first group 
had no treatment; peritoneal lavage 
was carried out using povidone-iodine 
solution in the second group and a 
0.9% sodium chloride solution in the 
third. In the fourth group, antibiotics 
(clindamycin and gentamicin) were in­
stilled intraperitoneally without perito­
neal lavage. The povidone-iodine solu­
tion had no beneficial effect, the death 
rate after 1 week (76%) being similar 
to that in the control group (78%) and 
much higher than that in mice treated 
with sodium chloride lavage (38%) and 
antibiotics without lavage (1 6%). A 
second series of experiments was, 
therefore, carried out to investigate 
the toxic effect of povidone-iodine so­
lution intraperitoneally on mice with­
out peritonitis; the solution was found 
to be toxic.
II a ete rapporte par certains que le lav­
age intraperitoneal a la povidone-iode 
pouvait etre utile dans le traitement de 
la peritonite alors que d'autres ont 
signale des reactions locales et des 
reactions indesirables toxiques.
Dans cette etude, on a provoque une 
peritonite bacterienne chez 200 souris 
blanches reparties en quatre groupes 
de 50. Le premier groupe n'a recu 
aucun traitement; le second groupe a 
ete soumis a un lavage de plevre a la 
povidone-iode, alors que le troisieme
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groupe recevait un lavage au chlorure 
de sodium a 0.9%. Chez le quatrieme 
groupe, des antibiotiques (clindamy- 
cine et gentamicine) ont ete instilles 
dans la cavite peritoneale, mais il n'y a 
pas eu de lavage de plevre. La solution 
de povidone-iode n'a exerce aucun 
effet benefique, la mortalite apres 1 
semaine (76%) etant similaire a cede 
du groupe temoin (78%) et beaucoup 
plus elevee que chez les souris ayant 
recu un lavage au chlorure de sodium 
(38%) ou des antibiotiques sans lavage 
(16%). Une deuxieme serie d'experi- 
ences a done ete demarree pour 
etudier la toxicite de la povidone-iode 
en lavage intraperitoneal chez des 
souris qui n'avaient pas de peritonite. 
La solution s'est averee toxique.
Peritonitis is responsible for approxi­mately 50% of the deaths from septic shock. As a treatment for peritonitis, lavage of the peritoneal cavity with antiseptic and antibacterial solutions gives good results.1'2 No clear benefit has been documented from lavage with povidone-iodine solution.1-11 Re­cently, this solution has been used preoperatively in elective colonic sur­gery,35 in the treatment of fungal12 and other infections of the skin13 and in the treatment of burns,14 and has been found useful.We carried out a two-stage experi­ment, first to find out if povidone- iodine solution was of benefit as a lavage fluid in the treatment of perito­nitis and second to study its toxicity in this context.
Materials and Methods
Stage 1
Two hundred white mice of both sexes (mean weight 35 g) were injec­ted intraperitoneally with 0.2 ml of Escherichia coli solution.They were divided into four groups of 50 each: group 1 control, group 2 povidone-iodine lavage, group 3 sodi­um chloride lavage, group 4 antibiot­
ics but no lavage.
With the exception of group 4, each animal was anesthetized with ether and subjected to laparotomy 6 hours after bacterial injection.Group 1. —  Only peritoneal biop­sies and cultures were performed.Group 2. —- In addition to biopsies and cultures the peritoneal cavities were lavaged with povidone-iodine di­luted to 1 in 20 with Ringer’s lactate solution. After lavage, fluid was again taken from the peritoneal cavity for 
culture.Group 3. —  The same procedures as in group 2 were followed using sodi­um chloride (0.9%) as the lavage solu­
tion.Group 4. —  No laparotomy was performed on these 50 mice. They were treated with 40 mg/kg clin­damycin and 8 mg/kg gentamicin di­vided into two equal doses over 24 
hours.The mice were followed up for 2 weeks. When one died, its peritoneal cavity was cultured and biopsies were taken from the liver, mesentery and small intestine. All biopsies were ex­amined under the light microscope.
Stage 2
Twenty healthy mice were subject­ed to laparotomy and their peritoneal cavities lavaged with the povidone- iodine solution. As a control group, another 20 mice were subjected to laparotomy but not lavaged. Iodide concentrations in the blood, liver and peritoneum were measured on post­
operative days 1 and 2 with a potenti­ometer.
Statistical Analysis
The x2 test was used to calculate statistical differences; p values less than 0.05 were considered significant.
Findings
Stage 1
In the mice subjected to laparotomy E. coli was identified in all cultures
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FIG. 1 — Mortality in mice with perito­
nitis after 2 weeks. N S = sodium chloride, 
PVI = povidone-iodine.
taken and in addition to reactionary 
ascites the viscera and peritoneum 
were hyperemic.
Necrosis and inflammation (rich in 
neutrophils, poor in lymphocytes) 
were seen in peritoneal biopsies (Fig. 
1).
At the end of 1 week, the death 
rates in groups 1 to 4 were 78%, 76%, 
38% and 16% respectively. Similar 
results were noted at the end of week 
2 (Fig. 2). The povidone-iodine solu­
tion had no positive effect whereas 
sodium chloride solution and antibi­
otics did. Also, the death rate for 
group 2 mice was higher than that of 
the group 1 control. The difference 
between these two groups was not 
significant, but the difference between 
group 1 and other groups was.
Cultures from the peritoneal cavi­
ties of mice that died grew E. coli and 
the liver, small bowel and mesenteric 
biopsies showed inflammatory cells 
(Figs. 3 to 5).
Stage 2
The death rates in the lavage group 
were 40% on day 1 and 45% on day 2 
compared with only 10% for both 
days in the control group (p < 0.05) 
and did not change during a 1-week 
observation period.
At the end of day 1 iodine values 
had increased twofold in blood and 
approximately sevenfold in the liver 
and peritoneum of mice lavaged with 
the povidone-iodine solution. These 
values returned to normal by the end 
of day 2 (Fig. 6).
Discussion
Identification of the source and
FIG. 3 —  Inflammatory cell infiltration in liver (hematoxylin and eosin, X 100).
type of bacterial and chemical con­
tamination is of prime importance 
in the treatment of peritonitis.1 The 
systemic administration of antibiot­
ics, fluid and electrolytes, decompres­
sion of the gastrointestinal system and 
peritoneal lavage with antibiotics and 
antibacterial agents are also recom­
mended.1'26'11
The use of the povidone-iodine so­
lution as a peritoneal lavage fluid is 
still debatable; some recommend it, 
others condemn its use because of its 
local and toxic side effects.1 7'15-18
Gilmore and colleagues2’5 6 reported 
that povidone-iodine solution yielded 
good results with no toxicity in both 
their clinical and experimental 
studies. Other reports noted that la­
vage with povidone-iodine decreased 
the number of deaths, reduced wound 
infection and had no side effects, 
especially in the treatment of fecal 
and purulent peritonitis.7 9'12 It is still 
used in the treatment of burn pa­
tients.14
McAvinchey and colleagues19 in
their study using peritoneal irrigation 
in the treatment of peritonitis in rats 
found the death rates were 90%, 60% 
and 0% in the povidone-iodine, con­
trol and metronidazole plus amikacin 
sulfate groups respectively. In the first 
stage of our study, at the end of week 
1 the death rates were 78% in the 
povidone-iodine group, 76% in the 
control group, 38% in the sodium 
chloride and 16% in the antibiotic 
groups. One week later these rates 
were 82%, 76%, 48% and 30% respec­
tively. Consequently, it can be said 
that the povidone-iodine solution had 
no beneficial effect in our study.
Ahrenholz1 found that povidone- 
iodine lavage caused chemical burns 
in the peritoneal cavity and had a 
toxic effect not only on bacteria but 
also on peritoneal cells.
Lineaweaver and colleagues20 inves­
tigated the effects of 1% povidone- 
iodine, 0.25% acetic acid, 3% hydro­
gen peroxide and 9.5% sodium hypo­
chlorite on wound healing. They 
found that all these solutions exerted
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FIG. 4 — Inflammatory cells in intestine (hematoxylin and eosin, X 40).
FIG. 6 — Iodide concentrations (ng/ml)in blood (-----------), peritoneum (—•—•—)and liver ( ° — ° — °).
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FIG. 5 — Inflammatory cell infiltration in mesentery (hematoxylin and eosin, X 100).
toxic effects on fibroblasts (povidone- iodine caused a 25% to 30% cell death).
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Multiorgan Failure in Critically III Patients
Of 1136 patients admitted consecu­
tively to two medical-surgical inten­
sive care units, 100 were found to 
have multiorgan failure, defined as fail­
ure of more than two organ systems. 
The average duration of stay in the 
intensive care units was 13.4 days. 
The overall death rate was 78% com­
pared with 12.8% for patients without 
multiorgan failure. The most common 
initiating illnesses or insults were sep­
sis, surgery, accidental trauma and 
cardiogenic shock. Of potential risk 
factors studied, shock, sepsis, surgery, 
pre-existing organ disease and age 
over 65 years were the most common. 
Although sepsis occurred before or 
during the course of multiorgan failure 
in 78 patients, in only 34 was sepsis 
judged to be the prime insult leading 
to muitiorgan failure. Surgery during 
the course of multiorgan failure had 
neither an adverse nor beneficial effect 
on outcome. The mean number of 
organ systems failing was 4.36 for 
survivors and 5.03 for nonsurvivors. 
The most common systems to fail 
were central nervous, cardiovascular 
and respiratory.
Sur 1136 hospitalisations consecuti- 
ves a deux unites de soins intensifs 
medico-chirurgicaux, 100 patients 
souffraient d'une defaillance plurifonc- 
tionneile definie comme I'insuffisance 
de plus de deux organes. La duree 
moyenne du sejour aux soins intensifs 
a ete de 13.4 jours. La mortalite glo- 
bale fut de 78% comparativement a 
1 2.8% pour les patients qui n'etaient 
pas atteints de defaillance plurifonc- 
tionnelle. Les maladies ou lesions cau- 
sales les plus frequentes etaient la 
sepsie, la chirurgie, les traumatismes 
et le choc cardiogenique. Parmi les
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facteurs de risque etudies, le choc, la 
sepsie, la chirurgie, une maladie orga- 
nique preexistante et un age superieur 
a 65 ans ont ete le plus souvent re- 
trouves. Meme si une sepsie est sur- 
venue avant ou durant une defaillance 
plurifonctionnelle chez 78 patients, on 
juge qu'elle fut la principale cause de 
cette defaillance dans seulement 34  
cas. La chirurgie pendant une periode 
de defaillance plurifonctionnelle paraft 
n'avoir eu ni influence benefique, ni 
effet indesirable sur I'issue. Le nombre 
moyen d'organes defaillants fut de 
4.36 pour les survivants et de 5.03 
pour ceux qui sont decedes. Les sys- 
temes les plus souvent touches ont ete 
les systemes nerveux central, cardio- 
vasculaire et respiratoire.
Many patients with serious illnesses, 
previously the cause of death, are now 
cured by modern intensive care tech­
niques. The course of critical illness is 
frequently dictated by the multiorgan 
failure syndrome (MOFS), which may 
be defined as dysfunction of more 
than two organ systems.1 It is associ­
ated with a high death rate, indicating 
that current methods of treatment are 
inadequate.
Previous studies2^6 have identified 
risk factors that influence the devel­
opment and outcome of MOFS after a 
common insult, such as sepsis. This 
report examines a group of patients 
with multiorgan failure after a variety 
of insults, to determine its prevalence, 
initiating factors and prognostic sig­
nificance in critically ill patients in 
medical-surgical intensive care units, 
whether there are causative factors, 
such as sepsis, that are common to all 
patients with multiorgan failure and 
whether appropriate surgical interven­
tion affected survival.
Patients and Methods
The charts of all patients admitted 
over a 1-year period to the combined 
medical-surgical intensive care units 
at University and Victoria hospitals,
London Ont., were reviewed. Those 
with failure oi more than two organ 
systems are the subject of this study.
The patients were divided into 
“surgery” and “no surgery” groups. 
All patients in the surgery group had a 
surgical procedure under general anes­
thesia either immediately before or 
during MOFS. The “no surgery” 
group had no operative procedure 
either before or during MOFS.
The criteria for organ failure are in 
agreement with those used in other 
studies.1-5’7
Pulmonary failure was defined by: 
a fall in arterial oxygen tension to less 
than 50 mm Hg on room air, the need 
for mechanical ventilation for longer 
than 48 hours because of hypoxemia 
or hypoventilation, or radiologic evi­
dence of pulmonary edema with a 
pulmonary capillary wedge pressure 
of less than 18 mm Hg.
Cardiovascular failure was defined 
by a cardiac index of less than 2.5 
L/min-m-2 with normal or elevated 
filling pressures, or dependence on 
inotropic drugs to maintain adequate 
tissue perfusion as assessed by clinical 
criteria.
Renal failure was indicated by a 
serum creatinine level of more than 
176.8 /imol/L, or double the previous 
level if pre-existing renal impairment 
was present, or a creatinine clearance 
of less than 0.5 ml/s or urine output 
less than 30 ml/h over 24 hours, 
despite adequate hydration.
Liver failure was defined as a rise 
in the serum bilirubin level of more 
than 68.4 ^mol/L or the aspartate 
aminotransferase to more than twice 
the normal level in the absence of 
duct obstruction, hemolysis or hepati­
tis of viral or toxic etiology.
The criteria for failure of the hemo­
poietic system were a platelet count of 
less than 50 X 109/L in the absence of 
previously documented autoimmune 
thrombocytopenia, disseminated in­
travascular coagulation documented 
by fibrinogen levels of less than 2.0 
g/L, fibrin-fibrinogen degradation 
products greater than 10 /ug/ml or 
positive protamine sulfate test, or a
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clinical bleeding diathesis as indicated 
by spontaneous bleeding from mu­
cous membranes or bleeding from 
puncture sites.
Gastrointestinal failure was defined 
by a patient’s inability to tolerate 
enteral feeding in the absence of me­
chanical obstruction and excluding an 
initial 5-day period after abdominal 
surgery, acalculous cholecystitis, pan­
creatitis in the absence of gallstones, 
trauma or alcohol abuse, or gastroin­
testinal bleeding requiring transfusion 
of more than two units of packed cells 
in 24 hours.
Central nervous system failure was 
a decreased level of consciousness 
ranging from confusion to coma in 
the absence of CNS infection or struc­
tural abnormalities.
The initiating illness or insult is 
defined as the single most important 
life-threatening illness from which the 
patient did not recover before the 
onset of MOFS.
In our study, risk factors are classed 
as those that might influence survival 
of MOFS patients; they differ from 
initiating factors. Some could not by 
themselves cause MOFS (e.g., smok­
ing, low serum albumin level) but 
would have been present before its 
onset; others occurred after the onset 
of MOFS. For each patient the follow­
ing potential risk factors were record­
ed: age greater than 65 years, obesity, 
malnutrition, diabetes mellitus, malig­
nant disease, alcohol abuse, smoking, 
immune suppression, shock, sepsis, 
surgery, gastrointestinal bleeding and 
pre-existing organ dysfunction.
We defined malnutrition as a 
serum albumin level less than 25 g/L, 
weight loss of more than 10% within 
30 days or more than 20% within 6 
months, weight more than 20% below 
the ideal body weight or energy intake 
of less than 4184 kJ/d for 7 days or 
more.3
Criteria for immune suppression 
included: continuous steroid therapy 
for longer than 30 days, high-dose 
steroid therapy of more than 15 
mg/kg of methylprednisolone or its
equivalent for 5 days or longer, che­
motherapy within 1 year, radiothera­
py within 1 year, lymphoma or im­
mune deficiency syndrome.3
Shock was defined by a systolic 
blood pressure of less than 80 mm Hg 
for longer than 30 minutes.
Sepsis was indicated by: the pres­
ence of appropriate organisms on cul­
ture supported by clinical signs of 
fever, leukocytosis and physical or 
radiologic findings, including findings 
at laparotomy (abscess, necrotic bow­
el, perforation of a hollow viscus and 
peritonitis). Pre-existing organ dys­
function was indicated by angina pec­
toris, previous myocardial infarction, 
congestive heart failure, chronic ob­
structive lung disease, chronic renal 
failure or biopsy proven cirrhosis.
Mean values of variables were com­
pared by unpaired /-tests. Differences 
were considered significant at a p 
value of < 0.05.
Findings
Incidence
Of 1136 critically ill patients admit­
ted consecutively to the two medical- 
surgical intensive care units, 100 
(8.8%) had MOFS. There were 67 
males and 33 females ranging in age 
from 6 to 84 years (mean 61.4 years). 
There was no significant difference in 
age between survivors and nonsurvi­
vors. The average duration of stay in 
the intensive care units was 13.4 days 
(range from 1 to 78 days). Survivors 
spent a mean of 20 days in the inten­
sive care unit and nonsurvivors a 
mean of 12 days (p < 0.0005). The 
death rate, when there was failure of 
three or more organ systems, was 78% 
versus 12.8% in patients without 
MOFS.
Initiating Illness or Insult
The primary insult or initiating 
event for the MOFS was most com­
monly sepsis, followed by surgery, 
accidental injury and cardiogenic
shock (Table I). When serious sepsis 
occurred with another insult it was 
arbitrarily considered to be the initi­
ating illness.
Time Sequences
There was no significant difference 
in the time interval between the pri­
mary insult and the onset of MOFS 
between the survivors and nonsurvi­
vors (4.4 ± 5.4 days versus 6.6 ± 9.9 
days respectively) (p = 7.05). Patients 
who died within 24 hours of the 
primary insult were excluded from the 
study.
The interval between primary in­
sult and death was 26.5 ± 25.8 days 
and 8.5 ± 6.3 days for the surgical 
and nonsurgical groups respectively (p 
<  0 . 001) .
In 45%, MOFS began within 24 
hours of the initial insult; in 11% of 
patients MOFS developed more than 
2 weeks after the initial insult.
The interval between the primary 
insult and death in both groups mani­
fested a distinct trend. In thte nonsur­
gical group, 38% died within 5 days 
after which there was a gradual de­
crease in the number of deaths. In the 
surgical group there were two peaks: 
early, within 5 days of the initial 
insult, and late, after 2 weeks. This 
includes 30% who died more than 4 
weeks after their initial insult.
The majority of patients died with­
in 5 days of the development of 
MOFS. In the nonsurgical group there 
were no deaths after 2 weeks.
Risk Factors
The frequency of potential risk fac­
tors is shown in Table II. Shock, 
sepsis, surgery, pre-existing organ dis­
ease and age greater than 65 years 
were most common, in decreasing 
order of frequency. Comparison of 
survivors and nonsurvivors using x2 
analysis showed that malnutrition and 
malignant disease were more common 
in nonsurvivors (p < 0.05).
Episodes of hypotension were doc-
T a b le  1— P rim a ry  Insu lt
Insu lt
Surgery, n o . (%) N o su rge ry , n o . (% )
T o ta ls
N o n su rv ivo rs  
(n =  4 3 )
S u rv ivo rs  
(n  =  17)
N o n s u rv iv o rs  
(n =  3 5)
S u rv iv o rs  
(n  =  5 )
Sepsis 11 (2 6 ) 5  (2 9 ) 17  (4 9 ) 1 (2 0 ) 3 4
Surgery 18 (4 2 ) 5  (2 9 ) 0 0 2 3
Traum a 4  (9) 7 (4 1 ) 1 (3) 0 12
M yo card ia l in fa rc tio n  o r h e a rt fa ilu re 2  (5) 0 9  (2 6 ) 1 (2 0 ) 12
G a stro in te s tin a l b le e d ing 3  (7) 0 4  (1 1 ) 1 (2 0 ) 8
H ypo vo le m ic  shock 3 (7) 0 0 1 (2 0 ) 4
R esp ira tory  fa ilu re 0 0 1 (3) 1 (2 0 ) 2
P a n crea titis 1 (2) 0 0 0 1
M a lig n a n t d isease 0 0 1 (3) 0 1
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umented in 90% of patients, making it 
the most common risk factor for mul­
tiorgan failure. Septic and cardiogenic 
shock were the most frequent causes 
of hypotension, but hypotensive peri­
ods occurred before the development 
of MOFS in only 76% of patients.
Pre-existing Organ Dysfunction
Pre-existing organ dysfunction was 
present in 60 of the 100 patients and 
the affected organ system was first to 
fail in the course of MOFS in 47% of 
these cases.
Sepsis
Although sepsis has been widely 
implicated as the major cause of 
MOFS,2'5-7 we found that in only 34 
patients was it the initiating event or 
cause of multiorgan failure. To be 
considered as the cause of MOFS, 
sepsis had to occur before the onset of 
any organ failure. In 78% of patients, 
sepsis occurred before or during the 
course of multiorgan failure, its fre­
quency being similar in both surgical 
and nonsurgical groups.
Of 44 surgical patients who had 
sepsis, only 22 had the complication 
before the onset of MOFS. Thus, even 
in the surgery group sepsis cannot be 
implicated as a cause in more than
50%. The two most common locations 
of the septic process were bronchopul­
monary and intra-abdominal (Table 
III). Many patients had more than 
one focus or more than one episode of 
sepsis.
Intra-abdominal Sepsis With MOFS
When intra-abdominal sepsis was 
combined with MOFS the death rate 
was 84%, and it was 78% (p > 0.05) in 
patients who did not have intra­
abdominal sepsis. Twenty-five pa­
tients with MOFS had intra-abdomi­
nal abscesses; all were drained, 22 
operatively and 3 percutaneously. De­
spite adequate surgical intervention 
only four of these patients survived.
Blood Cultures and MOFS
Twenty-two of 35 nonsurvivors in 
the nonsurgical group had positive 
blood cultures; none of the survivors 
had positive blood cultures (p < 
0.0005 [x2 analysis]). However, in the 
surgical group, positive blood cultures 
were not necessarily associated with 
poor survival.
Surgery in MOFS
The role of surgery in treatment of 
MOFS was examined. Of 44 patients
who had surgery during the course of 
MOFS, it was for “cure” (e.g., drain­
age of abscess) in 26 and for other 
indications in 18. Comparing the sur­
gical and nonsurgical groups by x2 
analysis, we found that surgery during 
the course of MOFS either for “cure” 
or other indications had neither an 
adverse nor beneficial effect on out­
come. We could not determine the 
effect of surgery on outcome in the 
patients for whom surgery was indi­
cated, because surgical treatment was 
never withheld; thus, there was no 
control group. Our impressions were 
that in surviving patients who had 
surgery for “cure”, the intervention 
tended to be early in the course of the 
syndrome.
Number o f Organ Systems Failing
By entrance criteria, all patients 
had failure of more than two organ 
systems. Most patients had failure of 
four to six organ systems (mean 4.36 
for survivors and 5.03 for nonsurvi­
vors) (p < 0.05) (Table IV). Cardio­
vascular and renal failure were more 
common in nonsurvivors than in sur­
vivors (p < 0.05).
The most common systems to fail 
were the central nervous, cardiovascu­
lar and respiratory systems (Table 
IV). The respiratory system was most
Table  II— P o te n tia l Risk F a c to rs  fo r  M u ltio rg a n  Failure S yn d ro m e  (M OFS)
Risk fa c to r
S u rge ry , no. (%) N o s u rg e ry , no. (%)
N on su rv ivo rs , 
no. (%)
(n =  7 8 )
S u rv ivo rs , 
no. (%) 
(n =  2 2 ) T o ta ls
N o n s u rv iv o rs  
(n =  4 3 )
S u rv ivo rs  
(n =  17)
N o n s u rv iv o rs  
(n =  3 5 )
S urv ivors  
(n =  5)
A ge 2 2 8 2 0 4 4 2  (5 4 ) 1 2 (5 5 ) 5 4
O b e s ity 9 3 6 1 1 5 (1 9 ) 4 ( 1 8 ) 19
M a ln u tr it io n 19 4 17 1 3 6  (4 6 ) 5 ( 2 3 ) 4 1 *
D ia b e tes  m e llitu s 9 1 4 0 1 3 (1 7 ) 1 (5) 14
M a lig n a n t d isease 12 1 8 0 2 2  (2 8 ) 1 (5) 2 3 *
A lc o h o l abu se 11 3 13 2 2 4 ( 3 1 ) 5 ( 2 3 ) 2 9
S m o kin g 16 4 12 1 2 8  (36) 5 ( 2 3 ) 3 3
Im m u n e  su p p re ss io n 6 0 4 0 1 0 (1 3 ) 0  (0) 10
Shock 3 8 15 3 4 3 7 2 ( 9 2 ) 1 8 (8 2 ) 9 0
Sepsis 3 3 14 2 6 5 5 9  (7 6 ) 1 9 (8 6 ) 7 8
S urgery 4 3 17 0 0 4 3  (5 5 ) 1 7 ( 7 7 ) 6 0
P re -e x is tin g  o rgan
disease 2 4 8 2 3 5 4 7  (6 0 ) 1 3 (5 9 ) 6 0
G a s tro in te s tin a l
b lee d ing 3 1 4 1 7 (9) 2  (9) 9
*p  <  0 .0 5  s u rv iv o rs  v e rs u s  n o n su rv ivo rs .
T a b le  III— Foci o f  S epsis
Surgery, no. (%) N o su rge ry , no. (%)
'lo n s u rv iv o rs S u rv ivo rs N on surv ivo rs S u rv ivo rs
Focus (n =  4 3 ) (n =  17) (n =  3 5) (n = 5) T o ta ls
P u lm o n ary 1 0  (2 3 ) 4  (2 4 ) 11 (31) 3 (6 0 ) 2 8
A b d o m in a l 18 (4 2 ) 4  (2 4 ) 3 (9) 0 2 5
B lood  s tre a m 5 (1 2 ) 1 (6) 10 (29) 0 14
C entra l lines 3 (7) 3 (1 8 ) 3 (9) 0 9
S o ft tis s u e /w o u n d s 3  (7) 2  (1 2 ) 4  (11) 0 9
G e n ito u rin a ry 0 3  (18) 1 (3) 4  (8 0 ) 8
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frequently the first to fail but was 
followed closely by the other two.
The overall death rate associated 
with MOFS in patients with more 
than two organ system failures was 
78.0% (Table V), compared with 
12.8% for patients in the intensive 
care unit without MOFS.
Discussion
One would not expect multiorgan 
failure to be a feature of untreated 
injury or infection, and it was not 
described in the past when available 
treatment for sepsis and injury was 
minimal. Modern treatment prolongs 
critical illness and is likely a permis­
sive factor that allows time for multi­
organ failure to occur. However, in­
terventions such as operation, anes­
thetics and analgesics, intubations, re­
straints and invasive monitoring, may 
have a causative role.
Tilney and colleagues8 first de­
scribed multiple organ failure follow­
ing treatment of patients who had 
ruptured abdominal aortic aneurysms. 
Since then, MOFS has been associat­
ed with intra-abdominal infections, 
accidental trauma and surgical proce­
dures.25 Most authors have described 
multiorgan failure occurring second­
ary to one of these initiating factors. 
To achieve a broader view, we studied 
multiorgan failure in all admissions to 
two medical-surgical intensive care 
units. In this setting, the initiating 
factors are multiple and include sep­
sis, accidental trauma, surgical trau­
ma, myocardial infarction, hypovo­
lemic shock, primary respiratory fail­
ure, pancreatitis and malignant dis­
ease. We did not find a single cause or 
abnormal state that was common to 
all patients with multiorgan failure; 
hypotension came closest as it preced­
ed the syndrome in 78% of cases. It 
seems clear that multiorgan failure 
may be initiated by a wide range of 
illnesses or injuries.
Sepsis
Whereas Fry and colleagues5 found 
that 95% of patients with MOFS after 
emergency laparotomy had sepsis, 
Faist and colleagues4 found only 56%. 
In our series, sepsis was identified in 
78 patients but was the initiating 
event in only 34. None the less, clini­
cal observation suggests that sepsis 
occurring during MOFS contributes 
to its progression.
Intra-abdominal sepsis is particu­
larly devastating. It was associated 
with a death rate of 84% in patients 
with MOFS, despite appropriate sur­
gical intervention. This high rate has 
been noted by others.9*10 Indeed, Fry 
and colleagues11 found that organ fail­
ure was one of the determinants of 
death in patients with intra-abdomi­
nal abscess.
Sepsis and Surgical Intervention
Some6*7*10 have suggested that unex­
plained development or worsening of 
organ failure is due to intra-abdomi­
nal sepsis, which may or may not be 
evident from clinical signs and local­
ization studies. These authors suggest 
that “blind” or non-directed laparoto­
my in such patients may uncover pus 
and therefore improve survival. In the
series of Ferraris,9 laparotomy in pa­
tients with MOFS was associated with 
a 52% death rate. Other studies report 
much higher death rates. When non- 
directed laparotomy was performed as 
a potentially curative procedure, 
death rates were as high as 80% and 
100%.10*12 The mortality is also high if 
no intra-abdominal cause for MOFS 
is found. Death rates of this magni­
tude make it difficult to justify blind 
laparotomy in MOFS. In our series, 
even when surgery was clearly indicat­
ed (laparotomy in this group), direct­
ed and positive, the death rate was 
84%. We concluded therefore that al­
though laparotomy is reasonable as a 
directed procedure, it is hard to justi­
fy as a non-directed procedure. Oth­
ers13 have reached the same conclu­
sion.
Pre-existing Organ Disease
Pre-existing organ disease may be a 
risk factor for multiorgan failure. 
Eiseman and associates14 found that 
23 of 42 MOFS patients had pre­
existing organ disease and that the 
diseased organ subsequently failed 
during the course of multiorgan fail­
ure. In our series, 60 patients had 
pre-existing organ disease and in 28 
the diseased organ was the first to fail. 
However, in 10% of the patients, the 
diseased organ was not involved in 
subsequent organ failure.
Etiology of MOFS
There has been much speculation 
about the underlying etiology of mul­
tiorgan failure. Some considered that 
sepsis was the predominant factor 
while others have implicated shock. 
Certainly both are associated with the 
syndrome. In our series, all patients 
had either sepsis or shock before the 
onset of organ failure. Goris and col­
leagues15 have suggested that the basic 
feature common to all patients with 
MOFS is severe inflammation. They 
suggest that toxic oxygen radicals re­
leased by phagocytes which have been
Table IV— Number of Organ Systems Failing and Associated Death Rates
No. of systems 
failing
Nonsurvivors 
(n =  78)
Survivors 
(n =  22) Total no.
Death 
rate, %
3 5 6 11 45
4 24 5 29 83
5 19 9 28 68
6 24 1 25 96
7 6 1 7 86
Mean 5.03 4.36
Table V-— Organ Systems That Failed
Organ system
Surgery, no. (%) No surgery, no. (%)
Nonsurvivors, 
no. (%)
(n =  78)
Survivors, 
no. (%) 
(n =  22) Totals
Nonsurvivors 
(n =  43)
Survivors 
(n =  17)
Nonsurvivors 
(n =  35)
Survivors 
(n =  5)
Cardiovascular 39 10 31 4 70 (90) 14(64) 84*
Pulmonary 39 13 29 4 68 (87) 17(77) 85
Renal 35 8 28 3 63 (81) 11 (50) 74*
Hepatic 27 13 23 1 50 (64) 14(64) 64
Blood 23 10 22 1 45 (58) 11 (50) 56
Central nervous 35 14 34 3 69 (88) 17(77) 86
Gastrointestinal 20 12 7 0 27 (35) 12(55) 39
*p < 0.05 survivors versus nonsurvivors.
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stimulated as a result of tissue trau­
ma, burns, endotoxin and other 
agents are responsible for the picture 
of generalized severe inflammation 
and remote organ failure. Richards 
and colleagues16 have suggested that 
fibronectin deficiency is associated 
with multiorgan failure.
Conclusions
Multiorgan failure is common 
(8.8% incidence) in medical-surgical 
intensive care units. Its etiology is 
multifactorial. Sepsis and shock are 
the most prominent features but are 
not always present. The death rate in 
patients with failure of three or more 
organ systems is 78% compared with 
12.8% in critically ill patients without 
multiorgan failure. Current methods 
of treatment are inadequate. Surgical 
intervention is associated with a very 
high mortality even when pus is found 
and drained. It is difficult to justify 
use of blind or non-directed laparoto­
my.
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Lipomas of the Colon: a Clinicopathologic Review
The authors review their experience 
with lipomas of the colon at St. Boni­
face General Hospital in Winnipeg, 
Man., during the period 1974 to 1985, 
and compare their clinicopathologic 
evaluation with that reported in the 
literature.
Among 1 5 patients (average age 
66.7 years), the majority of whom 
were women, 17 lipomas were found; 
all were submucosal. One-third of the 
lesions were symptomatic. The most 
frequent symptoms were abdominal 
pain, rectal bleeding and a change in 
bowel habit. Only one patient had mul­
tiple lesions. The right colon was most 
frequently affected.
Five patients underwent major co­
lonic resection either because the di­
agnosis was confused with carcinoma 
or because of intussusception. Only 
one patient was treated by colotomy 
and polypectomy.
Although most lipomas are small 
and asymptomatic, tumours larger 
than 2 cm tend to produce complica­
tions or be confused with carcinoma.
Les auteurs font etat de leur pratique 
dans le traitement des lipomes du 
colon a I'Hopital general de St-Boni- 
face, a Winnipeg, Manitoba, entre 
1974 et 1 985. Ms comparent leur eval­
uation clinico-pathologique avec celle 
qui est decrite dans la presse medicate.
Dix-sept lipomes, tous sousmu- 
queux, ont ete retrouves chez 15 pa­
tients (age moyen 66.7 ans), de sexe 
feminin surtout. Le tiers des lesions 
etait symptomatique. Douleur abdomi- 
nale, saignement rectal et modification 
du transit intestinal representaient les
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symptomes les plus frequents. Un seul 
patient avait des lesions multiples. Le 
colon droit etait le plus frequemment 
affecte.
Cinq patients ont subi une resection 
colique importante, soit parce que le 
diagnostic laissait croire a un carcino- 
me, soit a cause d'une intussuscep­
tion. Un seul patient fut traite par 
colotomie et polypectomie.
Meme si la plupart des lipomes sont 
petits et asymptomatiques, les tu- 
meurs de plus de 2 cm tendent a 
causer des complications ou a etre 
confondues avec un carcinome.
Lipomas of the colon are uncommon. Their clinical importance arises from the difficulty in differentiating them from carcinoma and a tendency for them to produce complications when they are large enough to be symptom­atic. As a result, patients have under­gone major surgical procedures for a benign condition. This paper reviews our experience at St. Boniface Gener­al Hospital in Winnipeg with lipomas of the colon encountered during the period 1974 to 1985 and compares our clinicopathologic evaluation with that found in the literature.
Patients
The study involved all patients with a pathological diagnosis of lipoma of the colon whether symptomatic or found incidentally in surgical speci­mens or at autopsy.
Findings
We found 17 lipomas in 15 patients (9 women and 6 men) aged from 43 to 81 years (mean 66.7 years). Ten pa­tients were over 60 years of age. Five patients were symptomatic; the most frequent symptoms were abdominal pain, rectal bleeding and change in bowel habit. Of those with symptoms, 40% presented with intussusception. In one case a lipoma obstructed the
appendiceal lumen causing appendici­tis.
The diameter of 14 lipomas mea­sured ranged from 0.8 cm to 5.5 cm 
(mean 2.2 cm). Four of the five caus­ing symptoms were larger than 2 cm; 
the fifth, whose size was not reported, was the lesion causing appendiceal obstruction. In the two cases of intus­susception, the lipomas were larger than 4 cm.
All tumours reported in this series were submucosal and composed of adult-type fatty tissue with no sarco­matous change. Multiple lesions (three in the cecum) were found in only one patient. Lipomas occurred more frequently in the right colon, with the cecum and ascending colon each accounting for 29.4% of the to­
tal. There were associated colonic car­cinomas in six patients, pancreatic carcinoma in one and ovarian cancer in another.
Five of the lesions were seen on barium enema study as filling defects. All were larger than 2 cm and none was diagnosed as a lipoma. The two causing intussusception were diag­nosed correctly on barium enema ex­amination.
Two patients underwent colono­scopy; the lesion was noted but not recognized as a lipoma. Biopsy speci­mens appeared normal. In one patient with a rectosigmoid carcinoma an as­sociated lipoma (2 X 1.5 cm) was not mentioned on the sigmoidoscopy re­port.In this series, only one patient un­derwent colotomy and excision of a lesion in the ascending colon, diag­nosed as a lipoma by palpation at laparotomy. Three patients had either sigmoid resection or right hemicolec­tomy because the barium enema study showed a filling defect presumed to be carcinoma. The two with intussuscep­tion required bowel resection.
Discussion
Lipomas of the colon, although in­frequent, are second only to adenoma-
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tous polyps as the most frequent be­
nign bowel tumours.1'2 The true inci­
dence has not been established but is 
reported in autopsy series to vary 
between 0.035% and 4.4% (Table 
I ) .  1,3,4 Most reported cases are associ­
ated with complications requiring sur­
gery.4 The etiology and pathogenesis 
are not known.5 Approximately 65% 
of lipomas of the gastrointestinal tract 
are in the colon.5-7
As in this series, many authors12'5'6'8
have reported a 1.5 to 2-fold increase 
in occurrence in women, but this 
preponderance is less marked on re­
view of all available series. Women 
are affected in 53.6% and men in 
46.4% of cases (Table I). Most lipo­
mas occur in the fifth to seventh 
decades, the average age being 63.3 
years (Table I), a time when differen­
tiation from carcinoma is critical.
Colonic lipomas occur most often 
in the right colon (40% to 68%)1'5'7'9'10
(Table II). This distribution is the 
reverse of both carcinoma and adeno­
matous polyps.11-13 It has been stated 
that 90% of these lesions are sub­
mucosal and 10% subserosal.4'7'14 
Available data indicate, however, that 
submucosal lesions are found in 
95.6% of cases (Table III). The aver­
age size is 3.25 cm (Table III). Multi­
ple lesions, which are found mostly in 
the right colon and are submucosal, 
occur in 15% of cases (Table III).
Tab le  I— Inc id e n ce  o f C o lon ic  L ip o m as a n d  D is tr ib u t io n  b y  A g e  a n d  Sex
Series N o. cases In c idence, %
A g e , y r 
R ange M ean
Sex, %
F M
Long  and co lleagues, 1 9 4 9 14 3 3 0 .5  a u to p sy — 5 4 5 4 .5 4 5 .4
W e in b e rg  and F e ldm an, 1 9 5 5 4 5 8  a u to p sy  
7 8  co lle c ted  
series
4 .4  a u to p s y  
0 .2  co lle c ted  
series
D 'J a v id , 1 9 6 0 s 2 7 8 — 10  m o  -  8 7  yr 5 5 6 2 .6 3 7 .4
H aller and R ob e rts , 1 9 6 4 ’ 2 0 0 .3 2  a u to psy  
2 .1  surg ica l
— 7 0 .7 7 5 2 5
W y c h u lis  and co lleagues, 1 9 6 4 2 6 7 — 4 0 - 8 5 6 2 .5 4 3 .3 5 6 .7
C astro  and S tearns, 1 9 7 2 s 4 5 — 4 1  -  8 4 6 2 .6 6 0 4 0
De Beer and Sh inya , 1 9 7 5 26 2 2 0 .8 3  c o lo n o sco p ic  
exam
4 9 - 8 0 6 6 5 4 .5 4 5 .4
J a w o rs k i, 1 9 8 0 '° 6 — — 7 2 0 1 0 0
M ic h o w itz  and co lleagues, 1 9 8 5 18 2 2 — 4 1  -  7 4 6 0 7 2 .7 2 7 .3
Presen t s tu d y 15 — 4 3 - 8 1 6 6 .7 6 0 4 0
Average 1 .7 4  au to psy 6 3 .3 5 3 .6 4 6 .4
T a b le  II-— L oca tio n  o f C olonic  L ip o m a s
Series No. A p p e n d ix
Ileocecal
valve Cecum
A s c e n d in g  T ra n sverse  D esce n d in g  
c o lo n  c o lo n  co lo n S ig m o id R e c tu m
W e in b e rg  and F e ldm an, 1 9 5 5 4 5 8  (autopsy) 
lipom as, 4  n o t 
localized
— — 39 6 5 2 1 1
7 8  lipom as 
co lle c ted  series, 
9 n o t loca lized
18 10 19 16 4 2
D 'J a v id , 1 9 6 0 s 2 7 8  cases, 4  n o t 
localized
1 16 68 3 7 5 6 3 9 41 16
H aller and R ob e rts , 1 9 6 4 1 2 9  lipom as 0 0 12 9 7 0 1 0
W ych u lis  and co lleagues, 1 9 6 4 2 7 6  lipom as 0 Excluded 21 11 17 12 12 3
C astro  and S te a rn s , 1 9 7 2 s 4 5  cases, p lu s  4  
m u ltip le  
lo ca tion s
0 3 9 p lus 3 
cecum  and 
a scend ing  
colon
6 6 2 7 5
De Beer and Sh inya, 1 9 7 5 2S 2 3  lipom as 0 0 13 5 3 1 1 0
M ic h o w itz  and co lleagues, 
1 9 8 5 18
2 2  cases 0 0 10 5 4 2 1 re c to s ig m o id
Presen t s tu d y 17 lipom as 1 2 5 5 2 0 2 0
T a b le  III-— G ross P a th o lo g ic  Features o f  C o lo n ic  L ip o m as
Series
Size, cm
Range A ve rag e
M u ltip le ,
%
S u b m u co sa l,
%
S u b se ro sa l,
%
Long and co lleagues, 1 9 4 9 14 — — — 9 4 6
W e in b e rg  and F e ldm an, 1 9 5 5 4 — 4 .0 — — —
H aller and R ob e rts , 1 9 6 4 1 0 .6  -  5 .0 — 3 5 — —
W y c h u lis  and co lleagues, 1 9 6 4 2 0 . 3 -  10 2 .7 2 1 3 .4 — —
C astro  and S tearns, 1 9 7 2 s 0 .5  -  8 .0 3 .0 2 4 .4 9 7 .8 2 .2
De Beer and Sh inya , 1 9 7 5 2S 1 - 3 2 .3 4 .5 — —
J a w o rs k i, 1 9 8 0 ’ ° 2 . 2 - 6 . 0 3 .5 0 1 0 0 0
M ic h o w itz  and co lleagues, S y m p t. 0 . 4 - 2 . 1 1 .2 5 18 8 6 .3 1 3 .6
1 9 8 5 18 
P resen t s tu d y
A s y m p t. 1 .7 -  1 2 .4  
0 . 8 - 5 . 5
7 .0 5
2 .2 6 .7 1 0 0 0
Average 3 .2 5 1 4 .6 9 5 .6 4 .4
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Typically, lipomas are localized en­
capsulated lesions, either sessile or
FIG. 1 — Submucosal lipoma of ileocecal 
valve, measuring 5.5 X 5.0 X 3.5 cm caused 
cecocolic intussusception with rectal bleed­
ing and large-bowel obstruction.
FIG. 2 — Cross-section of lesion in Fig.
FIG. 3 — Submucosal lipoma of sigmoid 
colon (3 cm in diameter) caused altered 
bowel habits.
pedunculated, composed of adult-type 
fat cells414 (Figs. 1 to 3). Although 
they frequently undergo ulceration, 
necrosis, inflammation or cystic de­
generation, there is little tendency to 
become malignant. Castro and 
Stearns5 knew of one unreported case 
of liposarcoma complicating a lipoma. 
Snover15 reported two cases of pseu- 
dosarcomatous atypia secondary to 
ulceration and stressed the impor­
tance of recognizing such changes as 
reactive.
Reported series indicate that 47% 
of patients with lipomas are symp­
tomatic and 53% asymptomatic (Ta­
ble IV). Symptoms are directly related 
to size712 and caused by tumours mea­
suring 2 cm or more in diame- 
ter.3-5-6-12-16 The most frequent symp­
toms are abdominal pain 68%, change 
in bowel habit 64% and rectal bleed­
ing 44% (Table IV); they can be attri­
buted to protrusion of the mass into 
the bowel lumen, due to colonic 
motor activity and contraction of the 
muscularis mucosae, causing luminal 
obstruction or forming the leading
FIG. 4 — Submucosal lipoma of colon 
causing intussusception with large- and 
small-bowel obstruction (arrows).
point for an intussusception. Second­
ary traumatic inflammatory changes 
result in necrosis, ulceration and he­
morrhage. Robertson and colleagues17 
reported a case of spontaneous expul­
sion of a tumour presumably follow­
ing this sequence of events.
Rectal bleeding secondary to lipo­
ma is usually slow, leading to chronic 
iron deficiency anemia, and may 
occur even when the mucosa appears 
intact.6 D’Javid8 reported that the in­
cidence of bleeding increased distally 
in the bowel as stools became hard, 
dry and abrasive. Several cases of 
life-threatening hemorrhage have 
been reported.5-8-19
Lipomas are the most frequent 
cause of intussusception in adults.7-12-20 
Mayo and colleagues16 estimated that 
50% of clinical lipomas present as an 
intussusception. However, we found 
lower values of 0% to 40% with an 
average of 17.7% (Table IV). Most 
palpable masses are produced by an 
intussusception.4-8 Figure 4 shows the 
appearance at barium enema exam­
ination of a lipoma of the colon caus­
ing intussusception and subsequent 
bowel obstruction.
Less frequent complications of lipo­
mas include protrusion from the 
anus,21 rectal prolapse and appen­
diceal obstruction.4
Barium enema is the most frequent 
examination performed (Table V). 
Here the lesion may be seen as a 
smooth, sharply demarcated in­
traluminal filling defect. The adjacent 
bowel wall is normally distensible and 
contractile with intact mucosa.22 The 
most characteristic diagnostic finding 
is that, unlike other tumours, the 
shape of the filling defect is not cons­
tant.11-23 It is round or ovoid during 
the filling phase but assumes a dis­
tinctly elongated configuration during 
evacuation (squeeze sign).13-22 Barium 
enema studies may not always be 
diagnostic of lipoma but are necessary 
to rule out carcinoma. Loludice and 
Lang24 reported a case of a colonic
Table IV— Symptoms and Signs of Colonic Lipomas and Correlation With Size
Symptoms, % Size of symptomatic
r , lesions, no./total no.
,, Asymptomatic, % cnange --------------------------------
Symptomatic, ------_ ----------------- Abdominal Rectal Intus- in bowel Not
Series % Autopsy Incidental pain bleeding ijusception habit > 2 cm < 2 cm specified
Long and colleagues, 194914 75.8 24.2 80.6 35.5 32.2 83.9
D'Javid, I9 6 0 8 — — — 75.5 49.6 33.0 50.3
Haller and Roberts, 1964’ 15 55 30 100 33.3 0 100 3/3 0/3 0/3
Wychulis and colleagues, 19642 56.7 43.3 55.3 44.7 7.9 63.1
Castro and Stearns, 19726 26.6 20 53.3 66.7 33.3 25.0 33.3 9/12 2/12 1/12
De Beer and Shinya, 197525 32 68 71.4 42.8 0 57.1
Jaworski, 1980'° 100 0 50.0 50.0 16.7 83.3 6/6
Michowitz and colleagues, 198518 36.4 63.6 50 62.5 4.5 62.5
Present study 33.3 6.7 60.0 60 40 40 40 4/5 0/5 1/5
Average 47 53.0 67.7 43.5 17.7 63.7
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Table V - Radiologic Diagnosis by Barium Enema
Series
No. of 
lesions seen
Diagnosis 
of lipoma
Size if 
seen, cm
Long and colleagues, 19491'1 28 1 positive 
2 likely
—
Haller and Roberts, 19641 18 4 suspicious 
of lipoma
All > 2
Wychulis and colleagues, 19642 34 4 —
Castro and Stearns, 19726 15 None —
De Beer and Shinya, 197526 7 — —
Jaworski, 1980’° 4 None —
Michowitz and colleagues, 198518 8 5 /8  positive —
Present study 5 None All > 2
lipoma producing an apple-core de­
fect on barium x-ray study and simu­
lating carcinoma. Lesions less than 2 
cm in diameter are not usually visi­
ble.1 Since the fatty lucency of a 
lipoma cannot be appreciated on bari­
um studies, a water enema using low 
kilovoltage x-rays was advocated but 
has fallen out of favour due to the 
difficulty of the technique.
Endoscopy has proven to be of 
some value in the diagnosis when the 
typical appearance is that of a smooth 
wide-based polyp, orange red at the 
tip due to blood vessels coursing over 
the surface, progressing to a yellow 
colour at the base. Several techniques 
may aid in the diagnosis: the pillow or 
cushion sign,25 the tenting sign25 and 
the naked fat sign pathognomonic of 
lipoma.20
Computed tomography is consid­
ered highly successful in the diagnosis 
of lipomas. Megibow and colleagues26 
and Heiken and colleagues27 reported 
six cases in which a diagnosis of 
lipoma by enhanced computed to­
mography was made by demonstrat­
ing a filling defect with negative atten­
uation numbers indicating fat. Four 
of these cases were confirmed at en­
doscopy or surgery. In addition, Ho 
and associates28 reported on a patient 
who had simultaneous lipoma and 
adenomatous polyps; computed to­
mography permitted their differentia­
tion by appearance and attenuation 
number.
The management o f colonic lipo­
mas is primarily surgical but those 
discovered at endoscopy may be re­
moved by electrocautery snare.12 22 Al­
though some12-23 advocate conserva­
tive treatment, most2-5'6'19'29 agree that 
surgical intervention is indicated in 
suspected or proven lipoma, not only 
to provide absolute differentiation 
from carcinoma but to prevent com­
plications that may necessitate more 
extensive surgical procedures later. 
D efin itive ly  diagnosed lipom as 
should be treated by colotomy and 
excision; large tumours, multiple tu­
mours or intussusception need seg­
mental resection and end-to-end anas­
tomosis.
We thank Drs. G.P. Sharma and A. 
Molgat and Mr. P. Shoenut for their assis­
tance in the preparation of this manu­
script.
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D a v id  E. W e s s o n , m d , fr c sc
Early Results With the J-Pouch Procedure in Children
Mucosal proctectomy with J-pouch 
construction and ileostomy were per­
formed on eight patients (age range 
from 4 to 18 years), five with ulcer­
ative colitis and three with familial 
polyposis coli.
Complications of the first stage in­
cluded transient neuropraxia of the lat­
eral popliteal nerves, partial dehis­
cence of the ileoanal anastomosis and 
prolapse of the loop ileostomy.
The ileostomy was closed 2 to 7 
months after initial surgery and was 
associated with four further complica­
tions: enterocutaneous fistula at the 
ileostomy site, early and late bowel 
obstruction and pouchitis. Stool fre­
quency decreased as the length of 
follow-up increased: 3 to 4  stools daily 
for three children at 2 years postopera- 
tively compared with 4 to 10 stools 
daily in all children 1 month after sur­
gery.
Functional results were satisfactory 
and all patients preferred the J pouch 
to an ileostomy.
Une proctectomie muqueuse avec 
construction d'un sac en J et ileosto- 
mie ont ete pratiquees chez huit pa­
tients (ages de 4 a 18 ans), dont cinq 
malades souffrant de colite ulcereuse 
et trois de polypose colique.
Les complications de la premiere 
etape operatoire comprennent une 
neuropraxie transitoire des nerfs popli- 
tes lateraux, une dehiscence partiel de 
I'anastomose ileo-anale et un prolap­
sus de I'anse de l'ileostomie.
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L'ileostomie fut refermee de 2 a 7 
mois apres la chirurgie initiate et cette 
intervention fut rattachee a quatre 
nouvelles complications: une fistule 
entero-cutanee au point d'ileostomie, 
des obstructions intestinales immedia­
te et retardee et une infection de la 
poche d'ileostomie. La frequence des 
selles a diminue avec la duree de la 
periode de surveillance: 3 a 4  selles 
quotidiennes chez trois enfants 2 ans 
apres I'operation, comparativement a 
4 a 10 selles quotidiennes chez tous 
les enfants apres 1 mois.
Les resultats fonctionnels ont ete 
satisfaisants. Tous les patients ont 
prefere le sac en J a l'ileostomie.
Recently there has been renewed in­
terest in restorative proctocolectomy 
with ileoanal anastomosis to treat ul­
cerative colitis and familial polyposis 
coli. In theory, this procedure can 
eliminate all the diseased colonic mu­
cosa, preserve normal anorectal func­
tion and avoid the need for a perma­
nent ileostomy. The operation may be 
performed with a straight ileoanal 
anastomosis without an internal reser­
voir pouch12 or with a reservoir con­
structed from terminal ileum. The 
pouch may be in the shape of a J as 
described by Utsunomiya and col­
leagues,3 an S as described by Parks 
and associates4 or two, separate, par­
allel limbs of ileum as described by 
Ferrari and Fonkalsrud.5 This report 
describes the use of the J pouch in 
children. I chose the J pouch because 
it was simple to construct, seemed to 
result in less diarrhea than the straight 
ileoanal anastomosis and allowed 
spontaneous evacuation of stool, 
which is not always possible with the 
S pouch.4
Patients and Methods
Eight consecutive children (five 
boys and three girls) were operated on 
over a 2-year period, beginning in 
June 1983. Five had ulcerative colitis 
and three had familial polyposis coli.
The J pouch was constructed at a 
mean age of 11 years (range from 4 to 
18 years) and in all cases was done in 
two stages. The first stage consisted of 
mucosal proctectomy, construction of 
the J pouch, endorectal pull-through, 
ileoanal anastomosis and proximal di­
verting ileostomy. The ileostomy was 
closed at a second procedure a few 
months later. All patients with ulcer­
ative colitis had undergone a previous 
subtotal colectomy and Brooke ileos­
tomy. Patients with familial polyposis 
coli underwent abdominal colectomy 
at the time of the restorative proc­
tocolectomy and had not had a previ­
ous ileostomy.
Operative Procedure
For the first stage, broad-spectrum 
antibiotics (usually ampicillin, clin­
damycin and gentamicin) were pre­
scribed, beginning 1 hour before sur­
gery and continuing for 5 to 7 days. 
No attempt was made to reduce the 
rectal inflammation in patients with 
ulcerative colitis.
In the first two cases, the children 
were placed in Lloyd-Davies stirrups 
on the operating table from the onset 
whereas the last six were left supine 
until the mucosal dissection and con­
struction of the J pouch were com­
pleted. They were then placed in the 
lithotomy position, in Lloyd-Davies 
stirrups, for the pull-through and 
ileoanal anastomosis.
The abdomen was opened through 
a long midline incision and the rec­
tosigmoid mobilized down to the level 
of the peritoneal reflection. From the 
abdominal approach, the outer layers 
of the rectum were then divided cir­
cumferentially down to the mucosa 
with a scalpel, and the mucosa was 
stripped from the muscle cuff to the 
dentate line. No other dissection was 
necessary within the pelvis. The rectal 
muscle cuff was left intact from the 
peritoneal reflection to the level of the 
internal anal sphincter.
The ileostomy was taken down and 
a point 10 to 20 cm from the terminal
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ileum chosen for the apex of the 
pouch. The small-bowel mesentery 
was mobilized to allow this point to 
come at least 2 or 3 cm below the 
symphysis pubis. The J pouch was 
constructed according to the method 
of Utsunomiya and colleagues,3 the 
two limbs being 10 to 20 cm in length, 
depending on the size of the patient. 
A quarter-inch Penrose drain was 
placed through the mesentery and 
around the apex of the J and pulled 
through the anus to position the 
pouch for ileoanal anastomosis. In the 
first two patients a GIA stapler was 
used to construct the pouch; in the 
last six it was constructed by hand, 
using two layers (outer interrupted, 
inner continuous) of 3-0 Vicryl su­
tures. The latter method is almost as 
fast as the stapler, eliminates the po­
tential for leaks between the staple 
lines and allows more accurate appo­
sition of the antimesenteric borders of 
the two limbs of the J.
The patient was then placed in the 
Lloyd-Davies stirrups and the rectal 
mucosa everted and excised at the 
dentate line from below, as in a Soave 
procedure for Hirschsprung’s disease.6 
Special care was taken to remove all 
of the rectal mucosa. The J pouch was 
then pulled through the rectal muscle 
cuff making sure that there was no 
rotation. The apex of the pouch was 
opened and the ileoanal anastomosis 
made at the dentate line with a single 
layer of interrupted 3-0 Vicryl su­
tures, taking fairly large tissue bites 
on both sides. Three stitches were 
placed in each quadrant of the anasto­
mosis.
The muscle cuff was divided by 
electrocautery in the posterior midline 
to the level of the coccyx and allowed 
to slip down to the floor of the pelvis 
to prevent the cuff from limiting J- 
pouch distension. No attempt was 
made to stitch the muscle cuff around 
the pouch. Two flat Jackson-Pratt 
drains were placed deep in the pelvis 
beside the pouch and brought out 
through a separate stab incision in the 
left lower quadrant; none were 
brought through the perineum. All 
drains were removed in 2 to 4 days or 
when they had stopped draining.
A proximal loop ileostomy was 
brought out in the right lower quad­
rant and anchored to the skin with 
interrupted 3-0 Vicryl sutures. A strut 
left through the mesentery to prevent 
retraction of the stoma was removed 
5 to 7 days later.
The first rectal examination was 
performed 3 to 4 weeks after opera­
tion at which time the ileoanal anasto­
mosis was inspected and palpated. If 
healing was satisfactory, a contrast
roentgenogram of the pouch was ob­
tained to detect any leaks.
No attempt was made to dilate the 
pouch with either a balloon or instilla­
tions through the ileostomy. No 
sphincter exercises were used.
The patients were readmitted for 
closure of the ileostomy an average of 
4 months (range 2 to 7 months) after 
proctocolectomy, when both clinical 
examination of the anastomosis and 
radiologic examination of the pouch 
indicated complete healing. At opera­
tion, the pouch was inspected endo- 
scopically using a flexible sigmoido­
scope. If the pouch was intact and the 
mucosa was healthy, the ileostomy 
was closed in a standard fashion.
No special diets or dietary restric­
tions were applied. No antidiarrheal 
medications were given for the first 
10 to 14 days. Thereafter, loperamide 
and bulk-forming agents were used as 
required. The patients were reassessed 
clinically 1, 3, 6 and 12 months after 
ileostomy closure. Their functional 
status was determined by number of 
stools, fecal incontinence, need to use 
perineal pads or diapers, ability to 
distinguish feces from gas and need 
for medications. After the first year, 
the patients were reassessed every 12 
months by flexible sigmoidoscopy and 
by evaluation of function.
Results
All patients underwent closure of 
their ileostomies, were satisfied with 
the results of the procedure and were 
functioning normally (Table I). One 
works full-time as a bricklayer’s help­
er and seven are in school.
Complications
There were no intrapelvic leaks, 
abscesses or other septic complica­
tions; however, major problems were 
common. The first two patients, who 
were in the lithotomy position 
throughout the operation, suffered 
transient neuropraxias involving the
lateral popliteal nerves of both legs. 
They have  since fully recovered. Al­
though the  legs were well padded, this 
complication was probably due to the 
unusually long time (about 6 hours) 
spent in the stirrups. None of the 
remaining six had any neurologic 
problems.
One child had partial dehiscence of 
the ileoanal anastomosis which was 
visible on perineal inspection. This 
healed slowly by secondary intention, 
and the ileostomy was successfully 
closed 4 months later.
The ileostomy was too proximal in 
one child, who needed several admis­
sions because of dehydration due to 
high ileostomy losses. The problem 
resolved after closure of the ileosto­
my. In one patient the loop ileostomy 
prolapsed, necessitating reoperation. 
In another, an enterocutaneous fistula 
developed at the site of the ileostomy 
closure, b u t it healed spontaneously.
After closure of the ileostomy one 
child suffered a partial obstruction in 
the afferent loop to the pouch necessi­
tating reoperation. The bowel was di­
vided longitudinally where the affer­
ent loop entered the pouch and was 
closed transversely in the manner of a 
Heineke-Mikulicz pyloroplasty. This 
closure was protected by reconstruct­
ing the loop ileostomy. Nine months 
later, the ileostomy was reclosed and 
the child now has good function.
There were two major late compli­
cations. One child had an adhesive 
small-bowel obstruction, which neces­
sitated enterolysis, the other had mild 
weight loss and minor rectal bleeding 
due to pouchitis. In the latter there 
was marked friability and redness of 
the pouch mucosa on endoscopy. Bi­
opsy of the mucosa showed a nonspe­
cific inflammation, but cultures of the 
stool grew normal fecal flora. The 
patient responded well to a course of 
metronidazole taken orally.
Function
In general, the functional results
Table 1— Patient Summary
J pouch to
Colectomy ileostomy
Patient Age, to J pouch closure
no. yr Sex Indications for colectomy interval, mo interval, mo
1 15 M Chronic ulcerative colitis 10 2
2 18 M Familial polyposis coli — 7
3 12 F Familial polyposis coli — 2
4 4 M Chronic ulcerative colitis 18 6
5 10 F Chronic ulcerative colitis 18 4
6 12 M Chronic ulcerative colitis 9 3
7 11 M Familial polyposis coli — 2
8 7 F Chronic ulcerative colitis 8 4
Mean 11 ±  2 13 ±  2 4 ±  1
±  SEM
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were excellent. After the first-stage 
operation most patients experienced 
discharge of mucus through the anus, 
which was difficult to control. One 
passed stool per rectum before closure 
of the ileostomy, presumably because 
of spillover past the loop.
All patients were able to defecate 
spontaneously and distinguish feces 
from gas. None required rectal intu­
bations or irrigations. Stool frequency 
and continence are summarized in 
Tables II and III. The two patients 
who required diapers at night were 
the youngest in the series. One had 
ulcerative colitis at 1 year of age and 
underwent colectomy a year later, be­
fore being toilet trained. He is now 
continent during the day but still 
wears a diaper at night. The second, 
who also had ulcerative colitis, was 
aged 7 years at the time of her pull- 
through. She is continent during the 
day but wears a diaper at night be­
cause of occasional gross fecal incon­
tinence.
Discussion
Although these initial results are 
satisfactory, there are several obvious 
drawbacks to widespread adoption of 
the J-pouch procedure. The morbidity 
is high, the functional results are less 
than perfect and the long-term results 
unknown.
One technical point is of interest. 
Others7 have preferred to remove the 
entire rectal wall down to the level of 
the levator ani muscles and to remove 
the distal rectal mucosa using the 
perineal approach. This is quicker 
and may allow the pouch to distend 
more easily in the pelvis. However, 
the extracolonic dissection carries 
with it the risk of injuring the pelvic 
autonomic nerves, as described by 
Neal and colleagues.8 Most pediatric
surgeons experienced in performing 
the Soave procedure for Hirsch­
sprung’s disease will likely find it 
easier to do the endorectal dissection 
from above.
The morbidity was high in this 
series, but most of the complications 
were either self-limiting or easily cor­
rected. Pouchitis may be the most 
serious complication of all. Its true 
incidence, cause and natural history 
are unknown; it can be insidious. The 
one patient who had this complica­
tion was only mildly symptomatic 
with slight weight loss and rectal 
bleeding. He did not have diarrhea, 
but the degree of inflammation of the 
pouch mucosa was extreme. Pouchitis 
may go undetected unless routine en­
doscopic examination is performed.
Most reports on restorative proc­
tocolectomy have indicated that stool 
frequency decreases markedly with 
time. This was not obvious in our 
series. In fact, the initial daily stool 
frequency 1 month after closure of the 
ileostomy averaged only 6 (range from 
4 to 10). However, with time there 
was a gradual improvement in the 
rectal urgency and less need for an- 
tidiarrheal medication. These patients 
pass stools about as frequently as 
patients with ileostomy empty their 
appliance. In a follow-up study of 675 
patients who had undergone proc­
tocolectomy and Brooke ileostomy at 
the Mayo Clinic, Pemberton and col­
leagues9 found that most patients 
emptied their appliances four to eight 
times daily (median six times).
The children and their parents pre­
ferred the functional results of the 
J-pouch procedure to the previous 
ileostomy although the results appear 
to be a little disappointing since most 
patients had some night-time soiling 
and two wore pads or diapers at night 
after 6 months. However, the soiling
Table II— Mean Stool Frequency During Follow-up Period
Months after 
ileostomy closure 
(no. of patients)
Mean no. of stools per patient
Day Night Total Range
1 (8) 5 1 6 4 - 1 0
6(7) 5 1 6 4 -  9
12(5) 5 0 5 3 - 1 0
24 (3) 3 0 3 3 -  4
Table III— Functional Status During Follow-up Period
Months after 
ileostomy closure 
(no. o f patients)
No. of patients with functional status
Soiling Pad/diaper
On
medicationDay Night Day Night
1 (8) 2 6 0 2 6
6(7) 2 4 0 2 3
12(5) 1 2 0 1 2
24(3) 0 0 0 0 0
was minor except in the two youngest 
patients, already mentioned, who re­
quired toilet training after ileostomy 
closure.
The initial choice of the J pouch 
was supported by the fact that stool 
frequency did seem to be lower than 
reported for the straight ileoanal anas­
tomosis without an internal pouch.2 
This was also noted by the Mayo 
Clinic group.10 They concluded that 
this was because there is decreased 
peristalsis and greater degree of com­
pliance to distension with the pouch 
than with the straight ileoanal anasto­
mosis.11
All patients in the present series 
were able to empty their pouch spon­
taneously and none required intuba­
tion for evacuation, as has been re­
ported with the S pouch.4
This paper was prepared with the assis­
tance of the Medical Publications Depart­
ment, The Hospital for Sick Children, 
Toronto, Ont.
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Announcing a  
transform ation 
of parenteral antibiotic 
therapy
PRIMAXINi
(imipencm and cilastatin sodium for injection)
the first carbapenem antibiotic
FMMAXINlv
(imipenem and cilastatin sodium for injection)
A carbapenem, representing a totally new class of antibiotics
A .  .
The broadest spectrum  
single-agent antibiotic
possessing bactericidal activity against a great 
m ajority of clinically significant pathogens
A
*•
PRIM AXIN* offers the activity of < ,
the penicillins against gram-positive aerobes -  
including coverage of Streptococcus faecalis
plus
»*• i*-
the aminoglycosides and 3rd generation cephalosporins 
against gram-negative aerobes -  v ,
including coverage of Pseudomonas aeruginosa
plus
the antianaerobic agents -  1
including coverage of Bacteroidesfragilis
PRIMAXIN* is not active against Corynebacterium group JK, Fusobacterium varium, Mycobacterium spp, 
Chlamydia spp., Streptococcus faecium, Pseudomonas maltophilia, and some strains of: P. cepacia,
P. pseudomallei, methicillin-resistant staphylococci, and Flavobacterium spp.
Single-agent antibiotic for 
documented and empiric 
therapy in many im portant *
□ infections usually treated with combination 
therapy
□ infections complicated by underlying 
disease
□ nosocomial infections
Imipenem and cilastatin sodium are present in a 1:1 ratio in PRIMAXIN* I.V. 
Imipenem is the sole antibacterial component. The role of cilastatin sodium is to 
prevent the inactivation of imipenem in the kidney and obtain antibacterial 
concentrations of imipenem in the urine.
+Caused by organisms susceptible to PRIMAXIN* I.V.
infections i
Clinical efficacy in many 
important infections
EFFICACY IN INTRA-ABDOMINAL INFECTIONS1
91% cure or 
improvement
in  164 evaluable patients
1. Kager, L., Nord, C.E.: Imipenem/ 
cilastatin in the treatment of intra­
abdominal infections: A review of 
worldwide experience, Rev Infect Dis 
7 (Suppl 3): S518-S521, July-August 
1985.
EFFICACY IN LOWER RESPIRATORY TRACT 
INFECTIONS'
85%  cure or 
improvement
in  2 0 4  evaluable 
patients
2. Acar, J.E: Therapy for lower 
respiratory tract infections with 
imipenem/cilastatin: A review of 
worldwide experience, Rev Infect Dis 
7 (Suppl 3): S513-S517, July-August 
1985.
+Caused by organisms susceptible to PRIMAXIN* I.V.
EFFICACY IN BACTERIAF SEPTICEMIA3
90%  cure or 
improvement
in D 5 evaluable 
patients
3. Eron, L.J.:
Imipenem/ cilastatin 
therapy of bacteremia,
Am J Med 78 (Suppl 6A):
95-99, June 7, 1985.
EFFICACY IN GYNECOLOGICAF
INFECTIONS4
97%  cure or 
improvement
in 72  evaluable 
patients
4. Sweet, R.L.: Imipenem/ 
cilastatin in the treatment 
of obstetric and gynecologic 
infections: A review of 
worldwide experience,
Rev Infect Dis 7 (Suppl 3):
S522-S527, July-August 1985.
PRIMAXIN
(imipenem and cilastatin sodium for injection)
IV
PRIMAXIN* I.V. offers management 
advantages over combination therapy 
that includes an aminoglycoside
Generally well tolerated -  
safety profile 
sim ilar to cefazolin’
□ 1723 patients, including the severely ill, have received therapy in clinical trials. 
The incidence of the most common adverse experience (nausea) was no greater 
than 2%.
0  Avoids the potential nephrotoxicity or ototoxicity experienced with 
aminoglycosides.
□ Avoids the potential hypoprothrombinemia and clinical bleeding experienced 
with cephalosporins with MTTf side chain.
□ Avoids the potential disulfiram-like effect experienced with metronidazole and 
cephalosporins with MTT side chain.
Convenience of a single agent
The broadest spectrum single­
agent antibiotic representing 
a transformation of parenteral 
antibiotic therapy
5. Calandra G.B., Ricci F.M., Wang C., Brown K.R.: Safety and 
tolerance comparison of imipenem/cilastatin to cephalothin and 
cefazolin, J  Antimicrob Chemother 12 (suppl D): 125-131,1983.
+ Certain antibiotics which possess, as part of their molecular structure, the l-methyl-5-thiotetrazole (MTT) 
group have been associated with hypoprothrombinemia (and in some cases, clinical bleeding) and with 
a disulfiram-like effect.
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PRIMAXIN*
(imipenem and cilastatin sodium 
for injection)
Antibiotic
-r CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have 
been reported with PRIMAXIN' especially when 
recommended dosages based on renal function 
and body weight were exceeded. These exper­
iences have occurred most commonly in patients 
with CNS disorders (e.g., brain lesions or 
history of seizures) and/or who have compro­
mised renal function. However, there were rare 
reports In which there was no recognized or 
documented underlying CNS disorder. Close 
adherence to recommended dosage schedules 
is urged, especially in patients with known factors 
that predispose to seizures.
4 ACTION
Imipenem exerts a bactericidal action by inhibiting 
-v cell wall synthesis in aerobic and anaerobic gram­
positive and gram-negative bacteria.
•* PRIMAXIN* consists o f tw o com ponents: 
(1) im ipenem, a derivative of thienamycin, a 
carbapenem antibiotic; and (2) cilastatin sodium, a 
specific inhibitor of dehydropeptidase-l a renal 
enzyme w hich metabolizes and inactivates 
imipenem. Cilastatin blocks the metabolism of 
imipenem in the kidney, so that concomitant 
administration of imipenem and cilastatin allows 
antibacterial levels of imipenem to be attained in the 
urine.
’  Inhibition of cell-wall synthesis is achieved in gram­
negative bacteria by the binding of imipenem to 
penicillin binding proteins (PBPs). In the case of 
E s c h e r ic h ia  c o li and se lec ted  s tra in s  o f 
Pseudomonas aeruginosa, imipenem has been 
shown to have highest affinity for PBP-2, PBP-1a 
and PBP-1b, with lower activity against PBP-3. The 
preferential binding of imipenem on PBP-2 and 
PBP-1 b leads to direct conversion of the individual 
cell to a spheroplast resulting in rapid lysis and cell 
♦ death without filament formation. When imipenem 
is removed prior to complete killing of gram- 
t  negative species, the remaining viable cells show a 
measurable lag, termed a “ post-antibiotic effect” 
(PAE), prior to resumption of new growth.
INDICATIONS AND CLINICAL USE
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) may be indicated in the treatment of 
serious infections when caused by sensitive strains 
4 of bacteria. Where considered necessary, therapy 
may be initiated on the basis of clinical judgment 
before results of sensitivity testings are available. 
"" Continuation of therapy should be reevaluated on 
the basis of bacteriological findings and of the 
patient's clinical condition.
Imipenem is active in vitro against a wide range of 
gram-positive and gram-negative aerobic and 
anaerobic bacteria, including most strains which 
„  are beta-lactamase producing. Patients have 
y  responded while under treatment with PRIMAXIN* 
for single or mixed infections of the following body 
■ systems, when they were associated with a number 
of pathogenic species and strains of the genera 
listed:
1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
3. Intra-Abdominal Infections
4. Gynecological Infections
-< 5. Septicemia
6. Endocarditis caused by Staphylococcus 
, aureus
■ 7. Bone and Joint Infections
8. Skin Structure Infections
Gram-positive Aerobes
•  Listeria monocytogenes
• Nocardia asteroides
•  Staphylococcus (excluding many strains
•*- which are methicillin resistant)
•  Streptococcus (excluding S. faecium)
*• Gram-negative Aerobes
•  Acinetobacter
•  Citrobacter
•  Enterobacter
• Escherichia coli
•  Haemophilus influenzae
•  Haemophilus parainftuenzae
•  Klebsiella
•  Morganella morganii
•  Neisseria
•  Proteus (indole positive and indole negative 
strains)
•  Providencia
•  Pseudomonas aeruginosa
•  Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. diflicile)
•  Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
WARNINGS
PRIMAXIN* (imipenem and cilastatin sodium for 
in jec tion ) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN* OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
S EN S IT IV ITY  REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN*. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may 
respond to drug discontinuance alone. In more 
seve re  cases, m anagem ent may in c lu d e  
s igm oidoscopy, appropria te  bacte rio log ica l 
studies, fluid, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN* (imipenem and 
cilastatin  sodium for injection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient’s condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusionarstates, or seizures have been 
reported with PRIMAXIN* especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherenceto recommended dosage 
schedules is urged especially in patients w ith 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS TR A TIO N ). A n t i­
convulsant therapy should be continued in patients 
with a known seizure disorder. If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on an ti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN* 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pa irm en t (see DOSAGE AND A D M IN IS ­
TRATION - Dosage in Patients with Renal 
Insufficiency).
Use in Pregnancy
The use of PRIMAXIN* in pregnant women has not 
been studied, therefore, PRIMAXIN* should be used 
during pregnancy only if clearly needed. Use of this 
drug in women of childbearing potential requires 
that the anticipated benefits be weighed against 
possible hazards.
Reproduction studies with bolus I.V. doses suggest 
an apparent intolerance to PRIMAXIN* (including 
emesis, inappetence, body weight loss, diarrhea
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
these or other species. Inotherstudies, PRIMAXIN* 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
under TOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN* is excreted in 
milk. If the use of PRIMAXIN* is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN* is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN* and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN*.
PRIMAXIN* should not be mixed with or physically 
added to other antibiotics. PRIMAXIN* has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN* with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials. Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it d ifficu lt to 
determ ine causal re lationship of adverse ex­
periences to therapy with PRIMAXIN*.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN* were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as 
possib ly , p robab ly , or d e fin ite ly  re la ted  to 
PRIMAXIN* were:
Incidence (%)
Gastrointestinal
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 0.2
pseudomembranous colitis
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <0.1
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures 0.2
(see PRECAUTIONS)
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia <0.1
Special Senses
transient hearing loss in
patients with impaired hearing <0.1 
tinnitus <0.1
Respiratory TABLE 1 Dosage in Infants and Children
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia <0.1
Renal
oliguria/anuria <0.1
polyuria <0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema <0.1
flushing <0.1
cyanosis <0.1
hyperhidrosis <0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
Hepatic: Increased SGPT.SGOT, alkaline phospha­
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, increased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN* 
(im ipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I.V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN* should be determined by 
the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN* 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
Dosage in Elderly Patients
The recommended dosageof PRIMAXIN* in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status of elderly 
pa tients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
ADULT DOSAGE OF PRIMAXIN*
I.V . Administration
Severity  
of infection
Dose
(m g of im ipenem )
Dosage
Interval
D aily
Dose
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fully 
susceptible)
500 mg 6 h 2.0 g
Severe* infections
due to less
susceptible
organisms
or life threatening
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
x Primarily some strains of Ps. aeruginosa.
The recommended total daily dosage of PRIMAXIN* 
in children and infants 3 months of age and older is 
60 to 100 mg/kg of body weight divided into 4 equal 
doses given at six hour intervals. The higher 
dosages should be used for infants and young “  
children. The total daily dosage should not exceed 
2 gram s. C lin ica l data are in s u ff ic ie n t to 
recommend an optimum dose for infants and 
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
Each reconstituted 250 mg or 500 mg dose should A 
be given by intravenous infusion over twenty to 
th irty  minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less.
Contents of the 13 mL vials must be suspended and 
transferred to 100 mL of an appropriate infusion 
solution.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a t in in e  c le a ra n c e s  o f 
<5 mL/min/1.73m2 (<0.08 mL/s/1.73m2) should 
not receive PRIMAXIN* unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
hem odia lys is . The pa tien t should rece ive 
PRIMAXIN* after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefully 
m o n ito re d ; fo r pa tien ts  on hem od ia lys is , 
PRIMAXIN* is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN* in 
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN*
IN RELATION TO RENAL FUNCTION
RENAL
FUNCTION
CREATININE 
CLEARANCE 
mL/min/1.73 m2 
(mL/»/1.73 m2)
DOSE
(g)
DOSAGE
INTERVAL
(h)
M AXIMUM
TOTAL
DAILY
DOSAGE
(9)
Mild
impairment 3 1 -7 0
(0.52-1.17 )
0.5 6 - 8 1 .5 -2
Moderate
impairment 2 1 -3 0  
(0.35 -  0.50)
0.5 8 -1 2 1 -1 .5
Severe*
impairment 0 - 2 0
(0 -0 .3 3 )
0.25 -  0.5 12 0 .5 -1 .0 * *
Patients w ith crea tin ine  clearance of 6 to 
20 mL/min/1.73 m* (0.1 -0.3 mL/s/1.73 irp) should 
be treated with 250 mg (or 3.5 mg/kg whichever is 
lower) every 12 hours for most pathogens. When 
the 500 mg dose is used in these patients, there may 
be an increased risk of seizures.
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to 
ensure complete transfer of the contents of the vial 
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection 
5% or 10% Dextrose Injection 
5% Dextrose Injection with 0.02% sodium 
bicarbonate solution
5% Dextrose and 0.9% Sodium Chloride 
Injection *
5% Dextrose Injection with 0.225% or 0.45% 
saline solution 
NORMOSOL-M in D5-W 
5% Dextrose Injection with 0.15% potassium 
chloride solution 
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN* range from colourless to 
yellow. Variations of colour within this range do not t> 
affect the potency of the product.
PRIMAXIN*, as supplied in vials and reconstituted 
as above maintains satisfactory potency for four 
hours at room temperature and for 24 hours under 
refrigeration (4°C). PRIMAXIN* has been found to 
be stable in 0.9% Sodium Chloride Injection for 
10 hours at room temperature and 48 hours under 
refrigeration.
DOSAGE FORMS
xx The highest dose is only recommended fo r 
infections due to less susceptible organisms 
primarily some strains of Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
AVAILABILITY
PRIMAXIN* is supplied as a sterile powder mixture 
in vials containing imipenem anhydrous and 
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg 
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg 
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature 
below 30° C.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736 
(72) x (serum creatinine concentration, pmol/L)
FULL PRODUCT MONOGRAPH 
AVAILABLE ON REQUEST
(318-a,7,87)
*®Trademark
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526 
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN" is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
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Effects of Immobilization and Continuous Passive Motion 
on Postoperative Muscle Atrophy in Mature Rabbits
The effects of continuous passive mo­
tion and cast immobilization on muscle 
atrophy were compared 3 weeks after 
bilateral arthrotomies on 10 mature 
New Zealand rabbits. The gastrocne­
mius, rectus femoris and tibialis ante­
rior muscles were excised and 
weighed, and the dry weights of the 
gastrocnemius were also determined. 
The protein concentration and cross- 
sectional areas of types I and II muscle 
fibres in the rectus femoris and tibialis 
anterior muscles were measured. 
Compared with the results in rabbits 
treated by cast immobilization, contin­
uous passive motion significantly (p < 
0.05) reduced muscle atrophy as de­
termined from the wet and dry 
weights of the gastrocnemius mus­
cles, the protein content in the tibialis 
anterior muscles and the cross-sec­
tional areas of the type II fibres in the 
rectus femoris muscles.
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On a compare chez 10 lapins de Nou- 
velle Zelande adultes, les effets de la 
mobilite articulaire passive continue et 
ceux de I'immobilisation par platrage 
sur I'atrophie musculaire, 3 semaines 
apres une arthrotomie bilaterale. Les 
gastrocnemiens, le muscle droit an- 
terieur de la cuisse et le muscle jam- 
bier anterieur furent excises et peses; 
on a aussi determine le poids sec des 
gastrocnemiens. Lateneuren proteine 
et les aires transversales occupees par 
les fibres musculaires de type I et II 
des muscles droits anterieurs de la 
cuisse et jambiers anterieurs ont aussi 
ete mesurees. Comparativement a 
I'immobilisation par un platre, la mobi­
lite articulaire passive continue a dimi- 
nue significativement (p < 0.05) I'atro- 
phie musculaire du lapin, tel que le 
demontrent les poids frais et secs des 
gastrocnemiens, la teneur en proteine 
des muscles jambiers anterieurs et les 
aires transversales des fibres de type II 
dans les muscles droits anterieurs de 
la cuisse.
The time-honoured practice of immo­
bilizing limbs after injuries and opera­
tions leads to joint stiffness and atro­
phy of the muscles,1-6 with the result 
that extended periods of rehabilita­
tion are often necessary for the limb 
to regain normal function. Altered 
function of a muscle (due to immobi­
lization) affects not only its size and 
strength, but also its histologic and 
biochemical characteristics.37-10 Atro­
phy of a muscle is characterized by an 
immediate and exponential decrease 
in its wet weight, total protein con­
tent7 and the cross-sectional area of 
its fibres.3*511’12 The reduction in wet 
weight is paralleled by a proportion­
ate reduction in dry weight6 and pro­
tein content.6*13 The beneficial effects 
of continuous passive motion (CPM) 
on articular cartilage and periarticular 
tissues, and on the regeneration of 
articular cartilage have recently been
demonstrated in animals.14-26 As a 
result of these experimental investiga­
tions, the concept of CPM has been 
applied to the care of humans with a 
variety of disorders and injuries of 
synovial joints.25*27*28
We designed a study to compare 
the effects of CPM and cast immobili­
zation on muscle atrophy postopera- 
tively.
Materials and Methods
Under general inhalation anesthesia 
(halothane, nitrous oxide and oxy­
gen), medial arthrotomies were per­
formed on both knee joints of 10 
adult male New Zealand rabbits, each 
weighing between 3.3 and 3.7 kg. 
After dislocation, then reduction of 
the patellae, the capsular incisions 
were closed with continuous 4-0 Vic­
ryl sutures and the skin with continu­
ous subcuticular 4-0 stainless steel 
sutures.
One of the two limbs was randomly 
selected to be immobilized in a long- 
leg plaster cast with the knee held in 
80° of flexion and the ankle in 50° of 
plantar flexion. The rabbit was then 
placed in the CPM apparatus so that 
the other limb could be moved pas­
sively and continuously for the dura­
tion of the experiment, as described 
previously.20*29 After 3 weeks of such 
treatment the animals were sedated, 
then killed by an intravenous over­
dose of sodium pentobarbital.
The animals were weighed and the 
ranges of motion of the ankle and 
knee joints measured, at least twice, 
using a goniometer (the median value 
was used). The tibialis anterior and 
rectus femoris muscles were dissected 
free. Anticipating that the cross-sec­
tional areas of the muscle fibres 
would vary with the degree of short­
ening or lengthening of each muscle, 
we controlled this variation by hold­
ing the knee and hip joints in 90° of 
flexion and the ankle joints in 30° of
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plantar flexion before we took muscle 
samples. Furthermore, the length of 
muscle to be excised was kept cons­
tant by fixing the ends of each sample 
in a specially designed clamp (Fig. 1) 
before excision. One sample was ob­
tained from the anterior region of the 
rectus femoris muscle and one from 
the medial region of the tibialis ante­
rior. While still held in the clamps, 
each sample was immersed in a bath 
of isopentane, “snap frozen” in liquid 
nitrogen, then weighed.
In a cryostate at -25°C, transverse 
sections, 10 pm thick, were cut from 
the muscle samples then stained for 
myofibrillar adenosine triphosphatase 
activity (preincubation pH 9.4) ac­
cording to the methods of Padykula 
and Herman30 as modified by Guth 
and Samaha.31 Using a Bausch and 
Lomb digital image analyser (System 
Omnicon 3000; Bausch and Lx>mb, 
Rochester, NY) connected to a micro­
scope, we measured the cross-section­
al areas of the type I and type II 
muscle fibres in a randomly selected 
group of 50 fibres for each type. The 
remaining parts of the rectus femoris 
and tibialis anterior and the whole 
gastrocnemius muscles were carefully 
excised and blotted dry, and the fat 
and connective tissue were removed. 
The wet weight of each specimen was 
obtained and the samples were then 
stored on dry ice. For dry weights, the 
gastrocnemius muscles were diced 
and dried in an oven at 72°C for 120 
hours before weighing.
The protein concentration in a 25- 
to 30-mg sample taken from the prox­
imal aspects of each of the tibialis 
anterior and rectus femoris muscles 
was determined according to the 
method of Lowry and colleagues,32 
using bovine serum albumin as a stan­
dard. Protein levels were measured 
within 12 hours after the animals had 
been killed. Since it is necessary to 
dessicate the whole muscle to obtain 
its dry weight, this procedure or the 
combination of protein concentration 
and muscle fibre size, but not both, 
could be determined in any one mus­
cle.
The data were analysed using the 
paired /-test, with differences being 
accepted as significant at a probability 
level of p < 0.05.
Results
Gross Findings
One animal with a dislocated patel­
la was excluded from the analysis. 
Each animal lost an average of 16% of 
its original body weight during the 
experiment.
Range of motion in both the ankle 
and knee joints was significantly re­
duced in the limbs treated by cast 
immobilization, compared with those 
receiving CPM (Fig. 2).
Wet and Dry Weights
The mean wet weights (± one stan­
dard deviation) of the gastrocnemius 
muscles were 7.58 =t 1.37 g in the cast 
limbs compared with 9.61 ± 1.97 g in 
the CPM limbs (p < 0.05) (Fig. 3). 
The wet weights of rectus femoris 
muscles in the cast limbs (8.02 ± 
0.028 g) were lower than those in the 
CPM limbs (8.30 ± 1.07 g), but this 
difference was not statistically signifi­
cant. The wet weights of the tibialis 
anterior muscles were equal in the 
cast (4.28 ± 0.76 g) and CPM (4.28 ± 
0.96 g) groups. The dry weights of the 
gastrocnemius muscles were signifi­
cantly (p < 0.05) lower in the cast 
limbs than in the CPM limbs (1.85 ± 
0.34 g versus 2.33 ± 0.50 g) (Fig. 4).
Protein Concentration
The protein concentration, ex­
pressed as a percentage of the wet 
weight of the muscle (grams of protein 
per gram of muscle), in the tibialis 
anterior was significantly (p < 0.05) 
lower in the cast group (17.95% ± 
1.69%) than in the CPM group 
(19.64% ± 2.41%). There was no sig­
nificant difference between the pro-
FIG. 1 — Specially designed muscle 
clamp consisting of two straight hemostats 
held fixed distance apart by clamp consist­
ing of two metal plates. Ends of muscle 
sample to be excised were fixed in clamps 
before excision and held in position during 
histochemical fixation.
tein concentration in the rectus femo­
ris of the cast (19.47% ± 1.24%) and 
the CPM (20.21% ± 1.49%) groups.
FIG. 2 — Range of motion of ankle and 
knee joints 3 weeks postoperatively for nine 
rabbits. Values are mean ± one standard 
deviation. * = significantly different (p < 
0.05).
FIG. 3 — Wet weights of gastrocnemius 
muscles 3 weeks postoperatively (nine rab­
bits). Values are mean ± one SD. * =  
significantly different (p < 0.05).
FIG. 4 — Dry weights of gastrocnemius 
muscles 3 weeks postoperatively (nine rab­
bits). Values are mean ± one SD. * = 
significantly different (p < 0.05).
Table I— Cross-Sectional Areas of Muscle Fibres in Nine Rabbits*
Rectus femoris Tibialis anterior
Group Type 1 Type Ilf Type 1 Type II
Cast 3593 ±  1280 2910 ±  555 4237 ±  862 3253 ± 608
CPM 3966 ±  1348 3795 ±  629 3460 ±  450 2750 ± 526
•Values are expressed as the mean ±  one SD (in pm2), 
tp  < 0.05.
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Histochemical Findings
The cross-sectional areas of the 
muscle fibres are listed in Table I. 
The average cross-sectional areas of 
both type I and type II fibres in the 
rectus femoris muscles of the casted 
limbs were lower than those in the 
CPM-treated limbs, although the dif­
ference was only statistically signifi­
cant for the type II fibres. Interesting­
ly, this pattern appeared to be re­
versed in the tibialis anterior muscles 
although these differences were not 
statistically significant (Table I).
Discussion
Our experiment demonstrated that 
gastrocnemius muscles undergo a sig­
nificantly greater loss of wet and dry 
weight in limbs that are immobilized 
postoperatively than do those treated 
by CPM. Moreover, the cross-section­
al areas of the type II fibres in the 
rectus femoris muscles in the cast 
group were significantly smaller than 
those in the CPM group.
Normally, the protein concentra­
tion in a muscle is not affected by 
moderate systemic weight loss.613 
However, the protein concentrations 
in the tibialis anterior muscles were 
significantly lower in the cast group 
than in the CPM group, even though 
the wet weights of these muscles were 
equal in both groups. Consequently, 
the total protein content (protein con­
centration X wet weight of the mus­
cle) was significantly lower in the 
tibialis anterior muscles from the 
limbs treated by cast immobilization 
than in those from the limbs treated 
by CPM. This could be interpreted to 
mean that the muscles were edema­
tous, but this would conflict with the 
observation that the cross-sectional 
areas of both the type I and type II 
fibres were slightly, but not signifi­
cantly, greater in the immobilized ti­
bialis anterior muscles than in the 
CPM-treated muscles. The latter ob­
servation is consistent with the phe­
nomenon of transient hypertrophy, 
described in muscles that have been 
immobilized in a position of light 
stretch.7'33
A factor that might have affected 
the results for the tibialis anterior 
muscles was that during immobiliza­
tion these muscles were held under 
tension. The length of a muscle during 
immobilization, relative to its resting 
length, influences the amount of atro­
phy that will occur. When a muscle is 
immobilized in a state of relaxation, 
atrophy will occur in a matter of 
days.7-33 However, when a muscle is 
immobilized in a state of tension, the
atrophic changes are preceded by a 
period of transient hypertrophy.7*33 
This was illustrated in 1957 by Fergu­
son and colleagues,4 who demonstrat­
ed marked hypertrophy of the tibialis 
anterior muscle after 3 weeks of cast 
immobilization with the muscle under 
tension.
Many authors5'81213 have related 
the histochemical changes in cross- 
sectional areas (or diameters) of the 
muscle fibres to the other parameters 
of muscle atrophy, but apparently 
they gave no consideration to the 
dependence of these measurements on 
the length of the muscle at the time of 
excision and histochemical fixation. 
We believe that the cross-sectional 
area or diameter of a muscle fibre 
should increase if a muscle is allowed 
to shorten before, or after, excision of 
the specimen. Therefore, in our study, 
the joints were held in a similar posi­
tion in all animals and a specially 
designed clamp was used to standard­
ize the length of each muscle sample 
before excision and to maintain this 
length during histochemical fixation.
A relatively greater degree of atro­
phy was observed in the type II than 
the type I fibres of the rectus femoris 
muscles. Although the explanation for 
this observation is not clear, oth­
e r s , 12,13 have shown that changes in 
size with atrophy or hypertrophy de­
pend on many factors and may differ 
for the two fibre types.
Conclusions
Our investigation has demonstrated 
that, with respect to wet and dry 
muscle weight, protein content and 
histochemical muscle fibre size, 
atrophic changes in muscles from 
three major compartments of rabbits’ 
limbs subjected to an operative proce­
dure can be substantially reduced by 
using continuous passive motion rath­
er than cast immobilization.
Although we cannot extrapolate 
these findings directly to other clinical 
situations in which a joint has been 
injured or inflamed, this conclusion 
might also be valid for nonoperative 
abnormalities of synovial joints. For 
example, CPM has been shown to 
have a protective effect on articular 
cartilage in septic arthritis,22 and to 
enhance the clearance of synovial ef­
fusions and hemarthroses14-15 and the 
healing of articular cartilage de­
fects.19'20'22 These are conditions fre­
quently treated by rheumatologists 
and orthopedic surgeons, and for 
which the prescribed treatment tradi­
tionally has included resting or splint­
ing the affected joints. The prevention 
of muscle atrophy is a goal to be
considered not only in patients post­
operatively, but also in those suffering 
from acute inflammatory conditions 
that limit active motion of joints.
We thank Mr. Ajai Kumar for technical 
assistance.
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Colonoscopy in the Follow-up of Patients With Colorectal
Carcinoma
In an effort to determine the value 
of colonoscopy in the follow-up of 
patients who have undergone resec­
tion for colorectal carcinoma, the au­
thors evaluated prospectively 100 con­
secutive patients who, during follow­
up after resection for colorectal can­
cer, had normal findings on barium 
enema examination and also under­
went colonoscopy. The follow-up from 
operation to colonoscopy ranged from 
8 months to 1 5 years (average 2.6 
years). Two recurrent and two meta­
chronous carcinomas were detected.
In addition, 25 polyps (3 benign) were 
removed from 22 patients. Twelve of 
the malignant polyps were less than 1 
cm in dimension, the other 10 were
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larger. Colonoscopy is considered valu­
able in this setting for earlier detection 
and removal of recurrent and meta­
chronous carcinomas and potentially 
premalignant lesions.
En vue de determiner I'interet de la 
colonoscopie dans I'examen de con- 
trole des patients qui ont subi la resec­
tion d'un carcinome colorectal, on 
a evalue de facon prospective 100 
patients qui, en cours de surveillance 
de post-cure, presentaient des resul- 
tats normaux au lavement baryte et 
qui ont aussi subi une colonoscopie. La 
periode ecoulee entre I'operation et la 
colonoscopie a varie entre 8 mois et 
15 ans (moyenne 2.6 ans). Deux reci- 
dives et deux carcinomes metachrones 
ont ete deceles. De plus, 25 polypes (3 
benins) ont ete reseques chez 22 
patients. Douze des polypes malins 
avaient une taille inferieure a 1 cm; les 
10 autres etaient plus gros. Dans un 
tel contexte, la colonoscopie fut utile 
puisqu'elle permit la detection de reci- 
dives et de carcinomes metachrones, 
et que plusieurs lesions premalignes 
ont ete decelees et resequees.
It is an established fact that patients 
who have undergone resection of a 
colorectal carcinoma run an increased 
risk of development of a metachro­
nous carcinoma, polyp or anastomotic 
recurrence.1-3 The degree of follow-up 
after resection is controversial. Propo­
nents of intensive follow-up state4-5 
that should a recurrent or metachro­
nous lesion be detected when a pa­
tient is asymptomatic, the probability 
of cure by repeat resection will be 
increased, since the newly detected 
lesion will be at a more favourable 
stage6 than if  the patient were symp­
tomatic. Opponents710 argue that in­
tensive follow-up is not worth the 
effort and expense, since up to 62%'1 
of new lesions will be detected when 
the patient presents with symptoms 
between scheduled follow-up sessions.
Among those favouring intensive 
scrutiny, the method by which it is 
carried out is under discussion. Some 
suggest colonoscopy in all cases, with 
or without barium enema examina­
tion because it enables the detection 
of anastomotic recurrences, metachro­
nous carcinomas or new polyps, 
which can be removed. Colonoscopy 
permits the detection of lesions that 
may have been missed on barium 
enema study and can more accurately 
evaluate the nature of suspicious nar­
rowings in the bowel.
The purpose of this prospective 
study was to determine if colonoscopy 
was of value in the follow-up of pa­
tients who had undergone resection 
for colorectal carcinoma.
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Patients and Methods
The study comprised 100 consecu­
tive asymptomatic patients (57 men, 
43 women) who had undergone resec­
tion for colorectal carcinoma. They 
ranged in age from 35 to 82 years 
(average 63 years). The locations of 
the primary carcinomas are listed in 
Table I and the Dukes’ staging in 
Table II.
Scheduled follow-up examinations 
carried out were as follows: proctosig­
moidoscopy, presence of carcinoemb- 
ryonic antigen, liver function tests 
and complete blood counts every 3 
months for the first 2 years postopera- 
tively, then every 6 months for anoth­
er 3 years and annually thereafter; 
chest x-ray every 6 months for 5 years 
and single-contrast barium enema an­
nually. Subsequently, at varying times 
postoperatively the patients under­
went colonoscopy. Patients with posi­
tive findings on barium enema were 
excluded from the study, since it was 
our intent to see if by colonoscopy we 
were able to pick up lesions that were 
missed on barium enema examina­
tion.
A metachronous carcinoma was de­
fined as that occurring more than 1 
year after the initial resection.
Results
The colonoscopy was performed
Table 1— Location of Primary Carcinomas
Location No. of patients
Rectum 44
Sigmoid colon 30
Descending colon 6
Transverse colon 5
Ascending colon 10
Cecum 5
Table II-— Dukes' Staging of Primary
Carcinoma
Stage No. of patients
A 36
B 37
C 27
Table III— Histologic Type of Polyps Found at 
Colonoscopy
Histologic type
Size, cm
< 1 cm > 1 cm
Tubular adenoma 8 2
Tubulovillous adenoma 4 5*
Villous adenoma —  3
Hyperplastic 3
*1 polyp with carcinoma in situ.
from 8 months to 15 years after initial 
resection (mean 2.6 years). The exam­
ination was completed to the cecum 
in 94% of cases; in the remaining 6% 
it was considered incomplete because 
of technical difficulties, patient intol­
erance or poor bowel preparation.
Colonoscopic findings included two 
anastomotic recurrences, both of 
which occurred 1 year after right he­
micolectomy. Metachronous car­
cinomas were detected in two pa­
tients, in the ascending colon and 
cecum, 1 year after sigmoid and low 
anterior resections respectively. 
Twenty-five polyps were found in 22 
patients; 3 polyps were benign. 
Twelve of the malignant polyps were 
found to be less than 1 cm in dimen­
sion and 10 were larger than 1 cm. 
The histologic variety of each polyp is 
listed in Table III and the location in 
Fig. 1.
Discussion
After “curative” resection for colo­
rectal carcinoma the goal of follow­
up should be the detection of anas­
tomotic recurrences or metachronous 
lesions at a time when further treat­
ment for cure may be possible.
Whereas it was generally believed 
that 75% of colorectal carcinomas 
could be detected with rigid or flexi­
ble sigmoidoscopy,12 a recent shift in 
the distribution of large-bowel cancer 
has been observed.1314 In our study, 
nearly 75% of primary carcinomas 
were in the left colon and malignant 
lesions that developed after resection 
were predominantly right sided. Thus, 
had the traditional methods of follow­
up been used, 86% of neoplastic le­
sions, two metachronous carcinomas
FIG. 1 — Location of polyps found at 
colonoscopy. Circles = less than I cm in 
dimension, squares = more than 1 cm, 
triangles = benign polyps. FFS = extent of 
flexible sigmoidoscopy.
and two anastomotic recurrences 
would have gone undetected until, 
presumably, symptoms developed.
Buhler and colleagues4 noted that 
repeat resections for cure were possi­
ble in 66% of patients who were 
asymptomatic at the time the recur­
rent lesion was detected, but in symp­
tomatic patients the lesion was usual­
ly unresectable. Since many reports 
have documented that most recur­
rences occur within the first 2 years 
after resection of the primary le­
sion,1015 it seems reasonable to con­
centrate follow-up efforts during this 
period. Those opposed to intensive 
follow-up71115 state that the poor 
reoperation rate for cure, ranging 
from 7% to 20%, negates the cost and 
effort applied.
Although follow-up aimed at de­
tecting recurrent disease has met with 
little success, it has been suggested 
that intensive scrutiny would be more 
productively directed toward the de­
tection of metachronous polyps and 
carcinomas. There is considerable evi­
dence that patients who have had a 
previous colorectal carcinoma are at 
risk for metachronous neoplasms 
since their entire colorectal mucosa 
seems to be unstable and potentially 
malignant,16 the so-called “terrain 
preparee” . It is also accepted that 
many, if not most, colorectal car­
cinomas develop from an adenoma­
tous polyp.1718
Although a metachronous lesion is 
defined as one occurring after resec­
tion of the primary carcinoma, some 
authorities6 require a 2-year interval 
before a lesion would be classified as 
such. Thus, the metachronous neo­
plasms in our series would be consid­
ered as missed synchronous lesions, 
present at the time of the original 
resection, and one would be com­
pelled to conclude that barium enema 
examination failed to detect these le­
sions, since all patients had the exam­
ination before resection. A similar 
point has been expressed by oth­
ers.6'19'20 This would justify colonos­
copy preoperatively to clear the colon 
of all other neoplastic elements. In 
one report21 preoperative colonoscopy 
identified 55% of synchronous neo­
plasms that were undetected on bari­
um enema examination. Indeed, it 
may alter the extent of resection in 
some patients.21 24
That the entire colon must be eval­
uated is not in dispute, rather it is the 
method by which evaluation is ac­
complished that is controversial. Two 
methods are currently available: bari­
um enema and colonoscopy. Both 
have their limitations.
Although some may take issue with
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our use of single-contrast barium 
enema examination, there is evidence 
that both single- and double-contrast 
examinations have almost identical 
sensitivities for detecting polyps larg­
er than 1 cm in diameter.25 Double­
contrast barium enema is, however, 
superior in detecting smaller neo­
plasms (less than 1 cm) and polyps in 
general, regardless of size.25 Single­
contrast barium enema examination 
allows diagnosis of most malignant 
lesions.25 It is the examination most 
commonly performed, being less cost­
ly, less time-consuming and better 
tolerated in elderly patients than the 
double-contrast technique.25
The prevalence of carcinoma in 
small adenomatous polyps is negligi­
ble as illustrated by Ott and col­
leagues26 in a review of 2344 adeno­
mas; they recorded a rate of invasive 
malignant disease of 0.09%. The ques­
tion then arises whether it is necessary 
to detect polyps less than 1 cm in size. 
The general consensus appears to be 
that detection of diminutive adeno­
mas in patients over 70 years old is 
less crucial because of a limited life 
span. However, a recent study27 re­
vealed a 15% incidence of invasive 
carcinoma in polyps less than 1 cm in 
size; thus, miniature polyps may be of 
importance in younger patients. It 
must be pointed out that this high 
incidence of carcinoma in small pol­
yps has not been reported by others, 
and the reason for the discrepancy is 
unclear.
Colonoscopy, although hailed as 
the best diagnostic tool available to 
evaluate the entire colon,28 is not 
infallible. It, too, has several “blind 
spots” where lesions may be over­
looked. For polypoid lesions it is asso­
ciated with a false-negative rate of 
12%,29 similar to that of double-con­
trast barium enema examination.30 It 
may also fail to detect carcinoma in 
10% of cases.29 The procedure is not 
without complications. Perforation 
rates of 0.1% to 0.6% and bleeding 
rates of 2.2% to 4.7% have been re­
ported.29 Inability to reach the cecum 
ranges from 9% to 37%,2-3'22'31'32 a 
serious limitation in view o f the re­
cently observed right-sided shift of 
neoplasia. It is also more costly, seda­
tion is often necessary and the com­
plication rate is higher than for the 
barium enema study.25 However, it is 
superior in enabling direct inspection 
o f the mucosa, thus having a false­
positive rate of zero.30 It can detect 
the so-called diminutive polyp, biopsy 
and destroy it using the cautery biop­
sy forceps. Although it can confirm 
the suspicion of anastomotic recur­
rence, the problem is now believed to
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begin extraluminally, before reaching 
the mucosa, a fact that is better appre­
ciated on barium enema examina­
tion.33 Taken together, barium enema 
and colonoscopy have a combined 
sensitivity approaching 100%.30
Although many studies have com­
pared the efficacy of both procedures, 
they are not directly comparable; 
some have been conducted prospec­
tively, others are retrospective. Peri­
ods of follow-up vary, and generally 
the conclusions reached are biased, 
depending on whether the author is 
an endoscopist or radiologist.
We believe that colonoscopy plays 
a valuable role in the follow-up of 
patients after resection for colorectal 
carcinoma, but we share the view of 
others34-35 that the two examinations 
are complementary and that one 
should not be done to the exclusion of 
the other.
Another point needing clarification 
is the timing and frequency o f colono­
scopy. An apparent consensus is that 
it should be performed preoperatively 
since it enables synchronous polyps to 
be removed, neoplasms to be identi­
fied and modification of the planned 
operative procedure in 5% to 16% of 
cases.22-24 Should obstruction, perfora­
tion or other mitigating circumstances 
prevent its performance preoperative­
ly, then it should be done within the 
first 3 to 6 months after resection. 
Postoperative follow-up should be 
most intense in the first 2 years; the 
frequency of colonoscopy in this peri­
od is debatable. Despite the many 
suggestions on the subject in the liter­
ature, there is little conclusive evi­
dence justifying the cost and risk of 
performing colonoscopy more often 
than annually during the initial 2 
years after colorectal resection. This 
question can only be answered defini­
tively by a long-term prospective 
study.
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The frequency of head injury is sub­stantial and the problem is associated with a correspondingly high cost to 
society. Approximately 50 000 pa­tients are discharged from Canadian hospitals annually with a diagnosis of either skull fracture or intracranial injury.1 It has been estimated that there are between 20 000 and 30 000 serious head injuries in Canada each year.2 In 1983, over 3400 deaths were attributed to such injuries.3Although the exact economic costs of head injury to Canadian society are not known, statistics from the United States give some idea of their poten­tial magnitude. In 1974, the total direct and indirect economic costs of head injury in the US were estimated at over $2.3 billion.4 If that figure is adjusted to reflect population differ­ences between the two countries, then the equivalent costs to Canadian soci­ety at that time would have been approximately $230 million. Recent­ly, Ivan2 has estimated that the cur­
rent cost to Canada of head trauma is $4 billion a year. Although these two figures differ substantially, even the lower figure represents substantial 
economic costs to Canada.In spite of its importance as a health care problem, relatively few studies have investigated adult head injuries in Canadian settings. Klonoff and Thompson5 reviewed the inci­dence of head injuries in individuals over the age of 16 years who were either seen in the emergency depart­ment of Vancouver General Hospital or admitted to that hospital in 1967. Their data indicated a preponderance of injuries for men and a higher inci­dence among younger adults. Twice as many men as women were admitted to hospital. The single greatest cause of head injury was motor vehicle acci­dents (39.6%) with falls being the next most frequent cause (19.3%).
Nelson and colleagues6 studied the
epidemiology of head injuries among patients admitted to the Trauma Unit at Sunnybrook Medical Centre from Apr. 1, 1981 to Dec. 31, 1982. Over two-thirds of the patients admitted were classified as head injured. Over 80% of these injuries were the result of motor vehicle accidents or pede­strian-motor vehicle accidents. In this study also there were more than twice as many men as women. Nelson’s patients were younger than those in Klonoffs study, with over 70% being less than 41 years old. The death rate was greatest in those over the age of 60 years; in that group one of every four patients admitted with head inju­
ries died.Parkinson and associates7 studied 3000 consecutive patients with head injury admitted to the Health Sci­ences Centre in Winnipeg. Unlike the previous studies, children were in­cluded. Again there was a predomi­nance of males and younger patients. Their sample also showed almost as 
many falls (873) as traffic-related in­juries (988), a finding that is probably attributable to the inclusion of chil­dren. In their setting, 35% of the head injuries were sustained in fights or assaults compared with 12.9% in the study of Klonoff and Thompson5 and 1.5% in that of Nelson and col­leagues.6One striking aspect of the existing epidemiologic literature has been the lack of a consistent definition of head injury across the studies. Klonoff and Thompson5 did not specifically define their criteria for head injury but did include patients with injuries to the scalp alone, while both Nelson and colleagues6 and Parkinson and associ­ates7 excluded these injuries. Parkin­son’s group also did not define clearly their criteria for calling patients head injured. These two studies included only patients who were hospitalized, but Klonoff and Thompson5 also in-
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eluded patients seen only in the emer­
gency department. Nelson’s group in­
cluded only those patients who had 
either computed tomographic evi­
dence of brain lesion, loss of con­
sciousness or post-traumatic amnesia, 
and their sample included only pa­
tients who were admitted to the Trau­
ma Unit; other head-injury admis­
sions to Sunnybrook Medical Centre 
were not included.
The absence of common diagnostic 
criteria makes it difficult to compare 
the results from these different 
studies. One possible way to assure 
greater diagnostic consistency across 
settings would be to use the Interna­
tional Classification of Diseases 
(ICD-9).8 While there are some prob­
lems classifying head injuries by this 
system,910 it at least provides some 
basis for consistency of definition 
across settings.
A second problem with previous 
Canadian studies has been a lack of 
information about the severity of the 
injury. Different criteria have been 
used and, in some cases, scant atten­
tion has been paid to the issue of 
severity. The Glasgow Coma Scale 
(GCS)9 has gained increasing accep­
tance as a quantitative index of the 
severity of head injury. Providing 
GCS scores would permit researchers
Table I— ICD-9 Diagnoses of Patients 
Included in Present Study
Fractures
800 Fracture skull -  vault
801 Fracture skull -  base
803 Fracture skull -  not specified 
Intracranial injury (excluding those with skull 
fracture)
850 Concussion
851 Cerebral laceration and contusion
852 Hemorrhage -  subarachnoid, subdu­
ral, extradural
853 Hemorrhage -  other and unspecified,
intracranial
854 Head injury -  not specified
to compare severity of injuries across 
samples.
Bearing in mind the limitations of 
the existing literature, we designed a 
study to provide data on a sample of 
head-injured individuals whose diag­
noses were based on ICD-9 criteria, 
with severity documented (where pos­
sible) by GCS scores.
Method
We reviewed the charts of patients 
who had been discharged (or died) 
with a diagnosis of closed head injury 
in either 1978 or 1982 at Sunnybrook 
Medical Centre in Toronto. Time of 
discharge was used because medical 
charts at this institution are coded 
and filed on the basis of date of 
discharge. Two different years were 
chosen in the hope that this approach 
would provide some estimate of the 
stability of the findings over time.
Between 1978 and 1982, two major 
changes occurred in the evaluation of 
head-injured patients treated at our 
hospital. First, the hospital did not 
acquire its first computed tomography 
scanner until September 1978. Before 
then, computed tomograms were ob­
tained at other hospitals, so fewer 
computed tomograms were available 
for 1978. Second, GCS scores were 
not routinely obtained on patients 
admitted in 1978, but this practice 
had changed by 1982.
Table III— Type of Accident
Type 1978 1982
Motor vehicle 76 120
Pedestrian 15 21
Bicycle 4 4
Sports 16 17
Interpersonal violence 15 10
Fall 84 85
Hit by falling object 7 10
Unknown 2 1
Table II— Distribution of Patients by Age, Sex and Year of Discharge
1978* 1982
Age, yr Males Females Males Females
1 1 -1 9 40 11 37 11
20 -  29 36 7 53 21
3 0 - 3 9 18 9 19 15
4 0 - 4 9 12 9 27 8
50 -  59 14 13 22 8
60 -  69 14 6 12 9
7 0 - 7 9 3 9 9 8
80 -  89 7 7 3 4
90 + 3 0 1 1
Totals 147 71 183 85
Mean age 36.7 47.7 36.6 42.4
SD 21.7 21.9 18.6 22.1
*1 patient missing because his age was not recorded.
Patients
Patients were included in the study 
only if their discharge diagnoses in­
cluded one of the ICD diagnoses list­
ed in Table I. Patients with fractures 
of the facial bones and those with 
superficial facial and scalp lacerations 
were excluded because they would not 
likely have brain dysfunction and our 
primary interest was in patients with 
potential brain injury. Using the 
ICD-9 criteria shown in Table I, we 
identified 219 cases for 1978 and 268 
for 1982. There were an additional 19 
charts for the 2 years that either could 
not be located or had a questionable 
diagnosis of head injury.
Findings
Data on patient age and sex by year 
of discharge are presented in Table II. 
The head-injured patients were rela­
tively young, with a tendency for 
males to be younger than females. 
The mean age of the patients for 1978 
and 1982 was 40.3 and 38.4 years 
respectively.
With respect to the type of acci­
dent, approximately 43% of the cases 
involved some form of motor vehicle 
accident (including bicycles) in 1978 
(Table III). In 1982, this figure was 
54%. In both years, the second most 
frequent cause of accident was a fall. 
Almost all the head injuries were of 
the closed type, 96.3% in 1978 and 
98.1% in 1982. The death rate was 
13% in 1978 and 15% in 1982.
Data on length of stay are present­
ed in Table IV. In both years, over 
half of the patients were discharged 
within 2 weeks of admission.
The frequency of associated extra­
cranial complications was high (Table 
V). Over 90% of the patients sus­
tained multiple injuries. The number 
of patients who were admitted 
through the Trauma Unit increased 
from 63 (28.7% of the 1978 sample) 
to 122 (45.5% of the 1982 sample) 
between the study years.
Table IV - -Length of Hospital Stay
Stay, d 1978 1982
1 62 38
2 19 20
3 6 10
4 7 8
5 12 14
6 5 6
7 6 8
8 - 1 4 38 50
1 5 - 2 8 24 49
2 9 - 5 6 24 37
57 -  84 8 17
> 84 8 11
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Glasgow Coma Scale scores for 
1982 are presented in Table VI. Using 
a cut-off score of 13 and above, we 
could classify approximately 50% of 
these injuries as mild. However, there 
was a large number (71) for whom 
complete scores could not be ob-
Table V— System Involved for Extracranial
Complications
System 1978 1982
Musculoskeletal 76 111
Respiratory 33 87
Cardiovascular 12 19
Central nervous 143 220
Gastrointestinal 15 36
Genitourinary 13 30
Integumentary 154 187
Table VI— Glasgow Coma Scale (GCS) at
Admission*
GCS 1982
3 6
4 3
5 2
6 7
7 1
8 2
9 7
10 5
11 6
12 17
13 33
14 100
‘ Glasgow Coma Scale scores were only
infrequently recorded in 1978 and are there-
fore not reported here. In 71 patients a
medical condition (e.g., intubation) precluded
scoring. In 8 the score was not recorded.
Table VII—Type of X-ray Procedure
Procedure 1978 1982
Skull x-ray 192 131
Brain scanning 22 2
Tomography 7 10
Computed tomography (at
Sunnybrook Medical
Centre) 21 206
Echoencephalography 9 0
Angiography 31 6
Cerebrospinal fluid flow study 0 4
Isotope cisternography 2 0
Fluoroscopy 2 0
Table VIII— Discharge Placement*
Placement 1978 1982
Home 159 156
Convalescent care 8 12
General hospital 6 6
Rehabilitation centre 10 47
Chronic care 8 5
Extended care 2 2
*ln 1978 there were 26 deaths and in 1982, 
40.
tained. Since 73% of this group were 
intubated, they were probably among 
the more severely injured.
Table VII addresses changes in the 
radiologic investigation of these pa­
tients over the 2 years in question. 
The impact of computed tomography 
is particularly noteworthy. Only 21 
scans were done in 1978 at our insti­
tution, but by 1982 the number had 
reached 206. Although the number of 
patients increased between the 2 
years, the only diagnostic procedures 
that showed an increase were comput­
ed tomography, tomography and 
studies of cerebrospinal fluid flow. 
Other data indicate that a higher per­
centage of the patients underwent 
monitoring of intracranial pressure in 
1982 (18.6%) than in 1978 (1.4%).
An attempt was also made to deter­
mine the percentage of head injuries 
that might have been the result of 
suicide attempts. Patients were classi­
fied as such if the discharge summary 
and some correlative piece of infor­
mation, such as the social worker’s 
notes, made- reference to this as a 
factor. With these criteria, the inci­
dence was 2.7% in 1978 and 1.1% in 
1982. However, since this was not a 
prospective study and since incidence 
figures for suicide are often underesti­
mated,11 our rates may be low.
Estimates were also made of the 
use of alcohol at the time of the 
accident. Patients were classified as 
using alcohol if this was reported in 
either the admission notes or dis­
charge summary. If there was no such 
reference, the patient was classified as 
not using alcohol, even if there was a 
documented history of alcohol abuse. 
By these criteria, 24.6% of the 1978 
patients and 17.5% of the 1982 pa­
tients showed signs of alcohol use at 
the time of their injury.
Table VIII presents information 
about the discharge placement of pa­
tients. In both years, the majority of 
patients were discharged home, but 
from 1978 to 1982, there was an 
increase in the percentage of patients 
admitted to rehabilitation institu­
tions.
Discussion
Previous studies of the demograph­
ic characteristics of head-injured pa­
tients have found that victims are 
predominantly young males. Our 
study replicated these findings. In 
both years, there were approximately 
twice as many males as females and 
approximately two-thirds of the pa­
tients were under the age of 50 years. 
Head injury was most commonly 
caused by motor vehicle accidents.
with the next most frequent cause 
being falls. In contrast to findings 
from some American studies, few in­
juries resulted from violence.
The severity of injuries seen in the 
present study is also similar to that 
reported in other investigations. For 
example, in one cooperative study of 
Glasgow Coma Scale scores in hospi­
tals in Galveston and Houston,12 it 
was found that 53% of such injuries 
fell in the mild range (that is, greater 
than 12). In the present study, 49.6% 
of the patients admitted in 1982 had 
GCS scores in this range.
It is apparent that there are some 
differences in the findings obtained 
between the 2 years surveyed in this 
study. There were more admissions to 
hospital in 1982 and a higher percent­
age of these admissions came through 
the Trauma Unit. Lacking GCS scores 
from 1978, one cannot conclude that 
the injuries in 1978 were less severe 
than those seen in 1982, but given the 
increase in percentage (and number) 
of Trauma Unit admissions, it is pos­
sible that there has been some change 
in the types of injuries sustained by 
those admitted.
One of the clearest changes between 
1978 and 1982 was the increase in 
intracranial pressure monitoring. The 
impact that computed tomography has 
had on the use of other radiologic pro­
cedures is also clearly demonstrated.
The death rates noted here indicate 
that many of the patients were severe­
ly injured. The percentage of deaths is 
similar to that reported by Nelson and 
colleagues6 (16%) and Klonoff and 
Thompson5 (13.6%). Parkinson and 
associates7 reported a rate of 4.4%, 
but their sample contained a high 
incidence of interpersonal violence 
and may, therefore, not have com­
prised injuries as severe as in other 
settings.
This study also suggests that the 
average person admitted to our hospi­
tal with cerebral injury is likely to 
have involvement of some other body 
system. In both years about 70% of 
the patients had at least one body 
system other than the central nervous 
system involved. While some of these 
injuries may have been minor (such 
as skin abrasions and lacerations), 
others were not. Recently, there has 
been substantial research on the psy­
chosocial problems associated with 
head injury. While the effects of head 
injury should not be underestimated, 
these problems may be a function not 
just of the head injury but also of all 
the other injuries sustained. Indeed, 
there is some evidence that the psy­
chosocial sequelae in trauma patients 
with and without head injury do not
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differ,13 suggesting that head injury does not have a unique psychosocial impact.
This study also provides a basis for estimating some of the economic im­pact of head injury. In 1978, the estimated average cost of a day’s stay in our hospital (exclusive of physi­cian’s fees and direct bills to the provincial health plan) was $215. (This represents the average cost to the hospital of a day’s stay by the average patient. The average cost of care for head-injured patients may be higher.) By 1982 this figure had risen 
to $320/d. Thus, the direct costs of hospitalization for head-injured pa­
tients in this hospital were approxi­mately $767 000 for the year 1978. The estimated costs for 1982 had risen to $2.1 million or, alternatively, approximately $7836 per patient. Sta­
tistics Canada figures for 1980-19811 give an average length of hospital stay of approximately 8.3 days (versus 24.5 days in our setting) for the aver­age patient over the age of 15 years with either a skull fracture or a head injury. If the annual Canadian inci­dence of 50 000 patients a year is multiplied by 8.3 days, and the result­ing figure is multiplied by a cost of $320/d, then the hospital cost of head injury would be $132.8 million. This figure, of course, excludes physician’s and surgeon’s fees, post-hospital care and income loss.
While the current study gives some idea of various demographic charac­teristics as well as of the medical and surgical treatment of head-injured pa­tients, there is clearly a need for further research on this topic. For example, there is a need for replica­tion in other Canadian settings to determine more precisely how much variation there is across settings in the type and severity of such injuries. This is one area in which the use of standardized diagnostic criteria (such as the ICD-9) and standardized crit­eria for severity (such as the GCS) can be useful. Our study also suggests that there have been some changes, even over the relatively brief period of the present study, in the ways in which head injury is investigated and treat­ed. It is therefore important to have regular reviews of the care of head- 
injured people in Canada.
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SESAP V Critique
ITEM 112
Overwhelming postsplenectomy sepsis (OPSI), recognized since 1952, highlights the importance of preserving the spleen for prevention of OPSI. Progression from health to death frequently occurs in a matter of hours. Patients who have had splenectomy should be informed about the importance of reporting even minor respiratory and other infections promptly. Most fatal sepsis occurs in the first two years after splenectomy, but it has been reported many years later.
Pneumococci have been isolated in approximately 50% of the cases. Polyvalent pneumococcal vaccine gives some protection, but not all of the types of Pneumococci involved are included in the vaccine. Aggressive treatment of all infections in these patients is therefore still necessary. The incidence of OPSI among trauma victims who have had splenectomy is much lower than that among patients who have had the splenectomy for hematologic disease.Although accessory spleens or the development of splenosis (autoimplantation of fragments of spleen) might provide protection against OPSI, fatal sepsis has been reported after both.
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Preservation of the Spleen Using Human Fibrin Seal
Because of the sp leen 's  role in host 
defence and the recognition of over­
whelm ing post-splenectom y sepsis, 
the current aim of treatment for sple­
nic injuries is to preserve the spleen. A  
number of hemostatic agents have 
been used in an effort to control bleed­
ing but have not proved satisfactory. 
The authors report the resu lts of an 
experiment using a tw o-com ponent fi­
brin seal on injured rabbit spleens.
In female rabbits a longitudinal lac­
eration of the entire spleen w a s  made. 
After 2>/2 m inutes of continuous hem ­
orrhaging, the spleens were either not 
treated (5 rabbits) or treated by sple­
nectomy (5), suture repair (10) or fi­
brin-seal repair (10). Hemoglobin val­
ues were measured preoperatively and 
3  days postoperatively.
The greatest number of deaths 
within 14  days occurred in the un­
treated group. There w as no difference 
in death rate between the treated 
groups; similarly, there w a s  no differ­
ence in blood loss or fall in hemoglobin 
values. Fewer adhesions formed in the 
fibrin-seal group than in the others (p < 
0.02). Histopathological examination 
revealed a greater fibrinoblastic re­
sponse  in the spleens treated with 
fibrin seal than in the other groups.
The authors believe that fibrin seal
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is an effective and safe hem ostatic 
agent applicable to splenic parenchy­
mal injuries, and that it prom otes 
w ound healing and su pp re sse s adhe­
sion formation.
A  cause du role important de la rate 
dans les m ecanism es de defense im- 
munitaire et puisque Ton connaTt bien 
le risque de sepsie fulm inante post- 
splenectomie, le traitement actuel des 
lesions spleniques v ise  a conserver la 
rate. Quelques agents hem ostatiques 
ont ete utilises pour tenter de juguler 
I'hem orragie m ais aucun ne s 'e s t  
avere satisfaisant. Les auteurs decri- 
vent les resultats d 'une  experience au 
cours de la quelle un adhesif de fibrine 
a deux constituants fut utilise su r des 
rates lesees de lapin.
Chez des lapines, une laceration 
longitudinale fut pratiquee sur toute la 
longueur de la rate a I'a ide d 'un  scalpel 
no. 10. Ap res 2 1/2 m inutes d 'hem orra- 
gie continue, la rate fut soit la issee 
san s  traitement (5 lapines), traitee par 
splenectom ie (5), reparee par suture 
(10) ou reparee a I'a ide de l'adhesif de 
fibrine (10). L 'hem oglobinem ie fut me- 
suree en preoperatoire et 3 jours apres 
I'operation.
Le plus grand nom bre de deces a 
survenir au cours des 1 4  jours d 'obser- 
vation fut enregistre au sein du groupe 
non traite. On n 'a  observe aucune dif­
ference de taux de mortalite entre les 
groupes traites. De meme, il n 'y  a eu 
aucune difference entre les traite- 
m ents en ce qui concerne la perte 
sanguine et la chute de I'hem oglobi- 
nemie. L 'adhesif de fibrine a cause  
m oins d 'adhesions que les autres trai- 
tem ents (p < 0.02). L 'exam en histopa- 
thologique a revele une reponse fibri- 
noblastique plus importante dans les 
rates traites avec l'adhesif de fibrine 
que dans les autres groupes.
Les auteurs croient que l'adhesif de 
fibrine est un hemostatique su r et effi- 
cace qui se  prete au traitement du 
parenchyme splenique en favorisant la 
cicatrisation et en supprim ant la for­
mation d 'adhesions.
Historically, the treatment of choice 
for the ruptured spleen has been sple­
nectomy.1 However, with increasing 
knowledge of the spleen’s role in host 
defences and recognition of the entity 
of overwhelming post-splenectomy 
sepsis,2’3 enthusiasm for retaining 
splenic tissue has become wide­
spread.4-6
Procedures such as splenorrhaphy, 
once discarded, are now accepted 
methods for managing splenic trau­
ma. However, splenic preservation 
must be proven to be as safe as 
splenectomy and to minimize the risk 
of fulminant sepsis.
Attempts to salvage the spleen have 
included the use of partial splenecto­
my, splenic suture, splenic artery liga­
tion, the application of hemostatic 
agents and no treatment. In addition, 
splenic autotransplantation has been 
performed.
A variety of topical hemostatic 
agents have been used to control sple­
nic surface bleeding (e.g., Avitene, 
Gelfoam) but these agents have not 
been entirely satisfactory.7’8
This study examines the use of high­
ly concentrated human fibrinogen as a 
hemostatic agent in splenic injury.
Material and Methods
The two-component fibrin seal sim­
ulates the physiologic process of 
wound closure. Its mode of action is 
based on the central function of fibrin 
in blood coagulation, creating a he­
mostatic clot.
The major ingredients of this two- 
component adhesive are fibrinogen 
and thrombin solutions. The fibrino­
gen solution contains fibrinogen, Fac­
tor XIII, fibronectin, calcium plas­
minogen and aprotinin. The thrombin 
solution contains thrombin and calci­
um chloride. When the two solutions 
are mixed, fibrinogen is transformed 
to fibrin monomers which aggregate 
to form a gel. Concomitantly, throm­
bin acts upon Factor XIII and, in the 
presence of calcium, Factor Xllla is 
formed. This factor cross-links the
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fibrin monomers to form a high- 
molecular-weight polymer. Cross­
links between the fibrin polymer and 
the collagen of the tissue to which the 
sealant was applied are also formed.
In the course of wound healing, 
plasminogen activators convert plas­
minogen to plasmin. The cross-linked 
fibrin is lysed into fibrin degradation 
products. This process is retarded by 
the antifibrinolytic agent aprotinin.
Thirty female rabbits, each weigh­
ing between 2.2 and 2.6 kg and fed a 
water and pellet diet, were anesthe­
tized with intravenous sodium thio­
pental. Under sterile conditions, a 
midline laparotomy was performed 
on each rabbit and the spleen mobi­
lized. A no. 10 scalpel blade was used 
to create a longitudinal laceration 
down the entire length of the spleen. 
The spleen was then observed for 2V2 
minutes, during which time the 
wound did not stop hemorrhaging.
Animals were randomized into four 
groups: splenectomy (5 rabbits), su­
ture repair (10), fibrin-seal repair (10) 
and no repair (5).
In the suture and fibrin-seal repair 
groups, splenectomy was performed if 
the repair failed to control the he­
morrhage.
The abdominal incisions were 
closed in two layers with 2-0 silk 
sutures, and the animals were allowed 
to recover in warm surroundings.
All blood losses were carefully mea­
sured. Blood samples were obtained 
preoperatively and on postoperative 
day 3 for a complete blood count. The 
animals were then explored again on 
postoperative day 14 or within 24 
hours of death. Careful note was 
made of adhesion formation, and the 
spleens were removed for histopatho- 
logical examination.
Statistical analysis was performed 
with Student’s paired t-test, analysis 
of variance and Duncan’s multiple 
range test.
1001-
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FIG. 1 — Mortality by group. Hatched 
bars = alive, black bars = dead.
Results
Of the animals that had no repair, 
two (40%) died. None of the animals 
that underwent splenectomy alone 
died, but one that had suture repair 
did. In the fibrin-seal group none 
died, although one animal required 
splenectomy because of a hilar vessel 
injury (Fig. 1).
Blood loss for the animals that 
underwent splenectomy or splenorr­
haphy did not differ significantly (Fig. 
2). Those that underwent splenectomy 
lost an average of 6.8 ml compared 
with 6.2 ml and 7.0 ml for those that 
underwent suture repair and fibrin- 
seal repair, respectively.
The decrease in hemoglobin con­
centration did not differ significantly 
between groups (Fig. 3); however, the 
decrease within each group was sig­
nificant (p < 0.05).
The platelet counts were also evalu­
ated pre- and postoperatively. There 
was no significant difference between 
the splenectomy and the suture-repair 
group, but between these two and the 
fibrin-seal-repair groups, the change 
was significant (p < 0.05) (Fig. 4).
At autopsy the rabbits that did not 
undergo splenectomy or splenorrha­
phy and survived 14 days all had 
extensive adhesions. The animals that 
died had blood within the peritoneal 
cavity.
Adhesions formed in 60% of the 
animals that had splenectomy and in 
50% of those with suture repair but in 
only 20% of those with fibrin-seal 
repair (p = 0.02 compared with no 
repair, splenectomy and suture repair) 
(Fig. 5).
Histopathological examination of
10 —
8 -
FIG. 2 — Blood loss by group.
the spleens repaired with the fibrin 
seal showed an intense inflammatory
FIG. 3 — Change in hemoglobin level by- 
group. ■ =  splenectomy, O =  suture, A  =  
fibrin seal.
FIG. 4 — Change in platelet count by 
group. ■ = splenectomy, O = suture, A =  
fibrin seal.
100 r
FIG. 5 — Adhesion formation by group. 
Hatched bars = yes, black bars = no.
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reaction at the spleen-fibrin seal in­
terface. A great number of fibroblasts 
were present, indicating an effective 
wound healing process. In spleens 
without fibrin seal, wound healing 
was also seen, but the reaction was 
less intense with fewer fibroblasts.
Discussion
Because of increasing recognition of 
the spleen’s role in immunologic func­
tion, the principle of preservation is 
now firmly implanted in surgical 
practice. The risks and benefits of 
attempting splenic preservation, how­
ever, must be weighed against those of 
splenectomy.
In children, the incidence of sepsis 
after a normal spleen has been re­
moved because of injury ranges up to 
6% and the death rate up to 73%.9 
There is little question that the bene­
fits of splenic preservation outweigh 
the risks.
In adults, though, the overall mor­
tality of an isolated splenic injury 
requiring splenectomy is less than 
0.5%, and the incidence of post­
splenectomy sepsis is significantly less 
than that in children.10
Any attempt to preserve the spleen 
must yield results superior to the risks 
involved with splenectomy and de­
layed post-splenectomy sepsis.
Approaches to preservation of a 
damaged spleen include observation 
without operation, reimplantation of 
splenic tissue and splenic repair. The 
nonoperative approach has been used 
successfully in children, but the safety 
of this method in adults is controver­
sial. In one series,11 73% of patients 
initially managed nonoperatively later 
required surgery.
When the spleen cannot be repaired 
because it is too badly injured, splenic 
reimplantation has been performed to 
preserve splenic tissue. It has been 
shown experimentally and clinically 
that reimplanted splenic fragments 
will restore a number of functional 
parameters lost after splenectomy. 
However, there is no proof that return 
of these areas of function correlates 
with a reduced risk of overwhelming 
post-splenectomy sepsis. In addition, 
uptake of radionuclides does not cor­
relate with immunologic function. 
Splenic mass and blood flow seem to 
be the crucial factors. This method of 
splenic autotransplantation, therefore, 
remains investigational.1213
A direct attack on the bleeding site 
appears to be the best approach for 
splenic salvage. This includes splenic 
artery ligation, splenic suture, partial 
splenectomy, application of hemostat­
ic agents or combinations of them.
The fibrin seal can be used as the 
primary hemostatic agent, or as an 
adjuvant in managing the traumatized 
spleen, without increasing the periop­
erative morbidity or mortality and 
without increasing the incidence of 
delayed hemorrhage.
Injuries to the hilar vessels of the 
spleen are not amenable to conserva­
tive management and should be treat­
ed by splenectomy. However, for sple­
nic parenchymal injuries, fibrin seal 
gives rapid and adequately hemostatic 
repair. For these injuries, sutures may 
not be required, thereby reducing fur­
ther trauma and maximizing the 
amount of viable tissue remaining. 
Fibrin seal also has the theoretical 
advantage of being effective for a 
pre-existing coagulopathy, because of 
the direct application of components 
of the coagulation system to the 
wound.
Fibrin seal seems to evoke less 
peritoneal inflammatory response 
than other agents, as evidenced by the 
lack of adhesion formation. Histologi­
cally, however, there is an intensive 
inflammatory response with respect to 
tissue reactivity. Fibrin seal evokes an 
increased fibroblastic response in the 
tissue-fibrin seal interface. There is 
some evidence to suggest that fibrin 
and Factor XIII stimulate fibroblast 
growth within the injured organ, pro­
moting wound healing.14
The use of the fibrin seal, therefore, 
appears to be a safe and effective 
method for repairing splenic paren­
chymal injuries. Maximum preserva­
tion of splenic tissue is achieved with 
no increased risk of delayed hemorrh­
age. Further studies of splenic func­
tion require evaluation.
We acknowledge the financial assis­
tance of Immuno Canada for this project.
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tinued only with close observation. Significant diarrhea occuring up to several weeks post-therapy 
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes 
may respondtosimpledrugdiscontinuance.Moderatetoseverecases.includingthoseshowingulcera- 
tion or pseudomembrane formation, should be managed with fluid, electrolyte, and protein 
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help in 
persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Otbercauses 
of colitis should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal 
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this 
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco­
mycin were administered orally four times a day for 5 - 10 or more days, there was a rapid ob­
served disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
It should be noted that serious relapses have occurred up to one month after apparently successful 
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with 
caution in atopic individuals. Dalacin C Phosphate must be diluted for intravenous administration. 
(See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly 
yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the 
clinical situation.
As with all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy.
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic 
liver function tests should be performed during prolonged therapy. Blood counts should also be 
monitored,during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in 
patients with impaired hepatic function is greater than that found in normal patients, the dose of 
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not 
effective means of removing the compound from the blood. Periodic serum levels should be deter­
mined in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local
(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin 
phosphate) intramuscularly (with a solution containing 150 mg/ml), six (1.5%) demonstrated local 
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at 
the injection site and two developed sterile absesses.
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion, 
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and 
one patient developed both superficial and deep thrombophlebitis. The majority of these cases 
developed in conjuctionwiththe useofindwelling I.V.cathetersand itisdifficulttoknowhowmuchthe 
drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at 
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin 
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as follows:
Number o f Patients
Rash......................................................................................................................................................... 7
Urticaria................................................................................................................................................... 1
Pruritus....................................................................................................................................................  1
Fever, Leucocytosis...............................................................................................................................  1
Nausea, with or without vomiting..........................................................................................................  1
Diarrhea (See also under 'Warnings")....................................................................................................  4
Hypotension............................................................................................................................................. 1
Hypertension...........................................................................................................................................  1
Shortness of Breath................................................................................................................................ t
Superinfection' ....................................................................................................................................... 4
Cardiac a r re s t" .....................................................................................................................................  1
Bad or bitter taste in mouth....................................................................................................................  5
DOSAGE AND ADMINISTRATION
Adults ^
Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2,3 or 4 equal doses. Intramuscular injections of more than ^ 
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to"* '
I V. administration to a dilution of 300 mg in 50 mL of diluent (6mg/mL) or more, and infused in not less 
than 10 minutes. Administration of morethan 1200mg inasingle 1 hourinfusion isnot recommended, y- 
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each -4 
infused over 20 minutes or longer.
Severe Infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused ovei- 
20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by continuous drip or "  
in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:
Dose Diluent Time __
300 mg 50 mL 10 min.
600 mg 100 mL 20 min.
900 mg 150 mL 30 min. *■
1200 mg 200 mL 45 min.
Alternatively, drug may be administered 
by continuous I.V. infusion as follows:
in the form of asingle rapid infusion of the first dose followed
To maintain serum Rapid Maintenance
clindamycin levels infusion rate infusion rate *  <*■
Above 4 mcg/mL 10mg/min. for 30 min. 0.75 mg/min.
Above 5 mcg/mL 15mg/min. for 30 min. 1.00mg/min. N '
Above 6 mcg/mL 20mg/min.for30min. 1.25 mg/min.
Children: (Over one month of age) 4.
Intramuscular injection: 10 to 15 mg/kg/day in 2,3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses. +>
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration: ,
Moderately severe infections: 15 to 25 mg/kg/day by continuous drip or in 3 or 4 equal doses, each 
infused over 20 minutes or longer.
Severe infections: It is recommended that children be given no less than 300 mg/day regardless of body *  
weight. (Dilute Dalacin C Phosphate Sterile Solution in the same manner as for adults.)
Dilution and Compatibility:
4 mL (600 mg) Dalacin C Phosphate when diluted with 1000 mL of the following commonly used in­
fusion solutions was found to be physically compatible and demonstrated no significant change in pH r  
or antimicrobial potency over a period of 24 hours:
Sodium chloride injection k
Dextrose 5% in water
Dextrose 5% in saline M
Dextrose 5% in Ringer's Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride u
Dextrose 2V2% in Lactated Ringer's Solution (Hartmann's Solution)
Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is 
not recommended that Dalacin C Phosphate be mixed with any infusion solution containing B vitamins.
Supplied: .
Dalacin C Phosphate contains the following per mL of sterile solution: '
Clindamycin phosphate equivalentto clindamycin base 150 mg 
Benzyl alcohol 5 mg 
Disodium edetate 0.5 mg 
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a pH 
range of 5.5 to 7.0. t -
Dalacin C Phosphate is available in 2 mL and 4 mL ampoules.
NOTE: Do not store below 15°C. -4
Product Monograph available upon request. 4
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A Review of Intra-articular Knee Injuries in Racquet Sports
Diagnosed by Arthroscopy
Because of the recent rapid increase in 
the number of knee injuries related to 
racquet sports, the authors undertook 
a retrospective study of such injuries 
seen over a 5-year period at the Toron­
to Western Hospital Sports Medicine 
Institute. The 121 patients who pre­
sented over the study period with a 
racquet-sports-related knee injury re­
quiring arthroscopy represented 30% 
of all racquet-sports related injuries 
seen during that period. The mean age 
at presentation was 32.8 years and 
two-thirds of the patients were men. 
All the major racquet sports were rep­
resented. In all, 213 lesions (7 bilater­
al) were seen at 128 arthroscopies, 
and 165 arthroscopic procedures were 
performed. The most common lesion 
was meniscal followed by chon­
dromalacia patellae, anterior cruciate 
ligament tears, chondral lesions and 
pathologic plicae. Over 90% of the 
patients returned to their chosen rac­
quet sport within 3 months of the 
arthroscopy and most were playing at 
a similar performance level to that 
before the initial injury.
Devant I'augmentation rapide et 
recente du nombre de blessures du 
genou reliees aux sports de raquettes, 
les auteurs ont entrepris une etude 
retrospective des blessures de ce type 
qui ont ete vues au cours d'une perio- 
de de 5 ans au Toronto Western 
Sports Medicine Institute. Les 121 pa­
tients qui ont ete recus au cours de 
cette periode souffrant d'une blessure 
du genou reliee aux sports de raquet­
tes et necessitant une arthroscopie 
representaient 30% de toutes les bles-
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sures dues aux sports de raquettes 
vues durant la meme periode. L'age 
moyen etait de 32.8 ans et deux-tiers 
des patients etaient des hommes.
Tous les principaux sports de raquet­
tes etaient representes. Au total, 21 3 
blessures (dont 7 bilaterales) ont ete 
observees au cours de 128 arthrosco­
pies, alors que 165 interventions ar- 
throscopiques etaient pratiquees. Les 
blessures les plus frequentes affec- 
taient les menisques, suivies des 
chondromalacies rotuliennes, des 
dechirures du ligament croise antero- 
externe du genou, des lesions du carti­
lage et des replis pathologiques. Plus 
de 90% des patients sont retournes a 
leur sport de raquette prefere moins de 
3 mois apres I'arthroscopie et la plu- 
part jouait au meme niveau de com­
petition qu'avant leur blessure.
Participation in racquet sports has 
escalated rapidly over the past 10 
years. The United States Squash Asso­
ciation estimates that there are more 
than 500 000 people playing squash in 
that country, with the number in­
creasing at a rate of more than 20% 
annually.1 Racquetball is the fastest 
growing racquet sport in North Amer­
ica with more than 10 million people 
now playing,2 and tennis is as popular 
as ever. Despite this increase in par­
ticipation and a concomitant increase 
in the number of associated injuries, 
there is little information in the litera­
ture on the injury profile seen in 
racquet sports.3 5 The literature that 
does exist addresses the problems of 
facial and upper extremity injuries 
but virtually ignores the lower extrem­
ity. Over the past year we have seen a 
lot of injuries to the lower extremity, 
especially to the knee, related to rac­
quet sports. This prompted us to un­
dertake a retrospective analysis of rac­
quet-sports related injuries, with par­
ticular attention to knee injuries re­
quiring arthroscopy, seen over a 
5-year period (1982 to 1987) at the 
Toronto Western Hospital Sports 
Medicine Institute.
Patients and Methods
Of 404 racquet-sports related inju­
ries seen, 222 (55%) involved a knee 
joint and 121 (30%) knees required 
arthroscopic evaluation based on the 
history of the injury and the physical 
findings. The injuries in these 121 
patients were analysed by review of 
the patient’s chart and by detailed 
questionnaire with telephone follow­
up to form an epidemiologic profile in 
addition to accurate operative data. 
All patients were contacted. Although 
a formal follow-up might have provid­
ed more information, this was not 
possible for the majority of patients 
because many were from out of town.
Average follow-up was 27.2 months 
(range from 6 to 78 months). Several 
patients were followed up for less 
than 2 years, but since no strong 
conclusions are to be made based on 
the results of treatment, this should 
not be considered a major weakness 
of our study.
Findings
Two-thirds of the patients were 
male, ranging in age from 14 to 68 
years (mean 32.8 years). All patients 
suffered an acute knee injury during 
participation in a racquet sport. Al­
though several of these patients par­
ticipated in other sports and had pre­
vious injuries, they were only consid­
ered for this study if it was clear that 
the injury was caused while playing a 
racquet sport. Two-thirds were in­
jured playing squash or tennis, the 
remainder playing badminton or rac­
quetball (Table I). Competition level 
of the injured participants ranged 
from recreational beginner to profes­
sional, but over 90% of those injured 
were of an advanced amateur level of 
participation, playing at least twice a 
week.
Warm-up
Pre-game preparation and surface 
conditions were considered as possi-
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ble factors in the injuries and were 
therefore investigated in detail. In 
over 60% of the patients the warm-up 
procedure was inadequate; either 
there was no warm-up at all or inade­
quate time was given to stretching 
exercises or rallying. Of the remain­
der, 22 patients (18%) performed at 
least 5 minutes of rallying and 25 
(21%) engaged in a warm-up proce­
dure that included at least 10 minutes 
of slow, prolonged stretching followed 
by at least 5 minutes of rallying before 
competition. The surface played on 
varied depending on the sport. The 
condition of the playing surface was 
normal in the majority of cases. How­
ever, a small group of patients report­
ed playing on either hard, slippery or 
irregular surfaces.
Previous Injury
In response to questioning about 
previous injuries, most patients re­
ported none, but 22 had at least one 
prior knee injury, including 14 menis- 
cal tears, 9 medical collateral ligament 
sprains, 7 cases of patellar tendinitis 
and 2 anterior cruciate ligament tears. 
Seventeen of the patients had suffered 
ankle injuries in the past.
Mechanism of Injury
Over 85% of the patients injured 
their knee through a twisting mecha­
nism, either by a fast turn for a 
difficult shot, an improper landing 
after playing a high overhead shot, or 
as a result of fast stop or start (Table 
II). Twisting places rotatory forces on 
the knee joint and commonly leads to 
intra-articular injuries. In a small 
group of patients, direct contact with 
a wall, the racquet or, on one occa­
sion, a player, resulted in the injury to 
the knee joint.
Symptoms
Time from injury to presentation 
ranged from immediately to more 
than 6 months (Table III). Almost 
50% presented within 2 weeks and 
over 90% within 3 months. In all 
cases the patient’s symptoms at pre­
sentation were referable to the injury 
and were not simply exacerbations of 
previous injuries. The most common 
complaint upon presentation was of 
knee pain (over 90%). Other symp­
toms included intermittent swelling 
(62%), a feeling of instability (27%) 
and frank giving way (8%). These 
symptoms, combined with the find­
ings of joint line or patellofemoral 
tenderness, joint effusion or ligamen­
tous instability (demonstrated by an­
terior drawer, Lachman and pivot 
shift signs), led to the arthroscopic 
evaluation.
Arthroscopy
Of the 121 patients, 114 underwent 
a unilateral arthroscopy and 7 bilater­
al -  128 arthroscopic examinations in 
all. A total of 202 intra-articular le­
sions were found, indicating that in 
most cases more than one lesion was 
present (Table IV).
Five major categories of lesions 
were found at arthroscopy. The most 
common was meniscal lesions (76 
cases [60% of knees]). This preponder­
ance is likely related to the mecha­
nism of injury (i.e., twisting) reported 
by most patients. The other categories 
were chondromalacia patellae (32 
cases [25% of knees]), anterior cruci­
ate ligament injuries (28 cases [22% of 
knees]), chondral lesions (26 cases 
[20% of knees]) and pathologic pli­
cae (15 cases [12% of knees]). Other 
intra-articular lesions found included 
osteoarthritis, loose bodies, fat-pad 
contusions and traumatic synovitis. 
Eleven arthroscopies revealed no intra- 
articular lesions. Thus, in over 90% 
of knees subjected to arthroscopy, one 
or more lesions were found, and in all 
cases the condition correlated with 
the patient’s clinical presentation. 
Meniscal tears, the most common le­
sion, can be classified by type (Table 
V). Almost 50% of the meniscal tears 
were of the oblique or flap type. 
Vertical longitudinal tears, commonly 
known as bucket handle tears, and 
vertical transverse tears, commonly 
known as radial tears, made up the 
bulk of the rest. Medial meniscal tears 
far outnumbered lateral tears, and the 
posterior horn was the most common 
site of injury within the meniscus. 
These numbers correlate well with 
those reported in the literature.6
From the data presented one might 
consider the chronicity of the disease 
process seen arthroscopically. As al­
ready noted, most patients had more 
than one lesion or diagnosis. In all 
cases of potentially degenerative dis­
ease (i.e., osteoarthritis or late-stage 
chondromalacia), there was a more
acute problem as well (meniscal tear, 
chondral lesion or fat-pad contusion). 
It should also be remembered that the 
patients all had injuries referable to a 
racquet sport in the recent past to 
account for their acute condition.
A wide variety of arthroscopic sur­
gical procedures were performed to 
treat these intra-articular lesions (Ta­
ble VI). Of 165 procedures, there were
T a b le  1—-R a c q u e t  S p o rts  Participation
S p o rt N o. (% )
S q u a sh 4 3  (3 6 )
T e n n is 3 8 ( 3 1 )
B ad m in to n 2 5  (2 1 )
R acq u e tb a ll 1 5 (1 2 )
T a b le  II— M e ch an ism  of Injury
M ech an ism N o. {% )
T w is t in g 1 0 8  (8 9 )
Im p ro p e r lan d in g 4 0
F a s t  tu rn in g 61
F a s t  sto p 4
F a s t  start 3
D ire ct co n ta c t 6 (5)
O p p o n en t 1
W all 3
R a cq u e t 2
O ther 7 (6)
T a b le  I I I - -T im e  Fro m  Injury to  Presentation
T im e No. (% )
0  -  1 w k 3 8 ( 3 1 )
1 -  2  w k 1 9 (1 6 )
2 - 4  w k 2 9  (2 4 )
1 -  3  m o 2 3 ( 1 9 )
3  -  6  m o 8 (7)
>  6  m o 4  (3)
T a b le  IV — A rth ro s c o p ic  F in d in g s  (2 0 2  
Lesio n s)*
F in d in g s N o. (% )
M e n isca l le s io n s 7 6  (38)
C h o n d ro m a la c ia  pate llae 3 2 ( 1 6 )
A n te rio r cru c ia te  ligam e n t lesio ns 2 8 ( 1 4 )
C h o n d ra l le s io n s 2 6 ( 1 3 )
P a th o lo g ic  p lica 15 (7)
O ste o arth rit is 7 (3)
M isce llan eo u s
(in c lu d in g  lo o se  b o d ie s , fat-p ad
c o n tu s io n s , su b lu xa tin g  patella) 18 (9)
‘ N o th in g  fo u n d  in 11 knees.
T a b le  V — T y p e  o f M e n isca l L e s io n s (n =  7 6 )
T y p e  of lesion M edial Latera l T o ta l (%)
O bliqu e  (flap or "p a rro t b e a k ") 2 8 8 3 6  (4 7 )
V e rtica l lon gitu d ina l (b u cke t handle) 16 0 16 (21)
V e rtica l tra n sv e rse  (radial) 6 4 1 0 (1 3 )
M ultip le-p lane  (d egen erative/co m p lex) 6 2 8 ( 1 1 )
H orizontal 2 0 2 (3)
M isce llan eo u s
(d isco id , h yp e rm o b ile , m e n isca l cy st) 3 1 4  (5)
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61 soft-tissue resections, mainly to 
meniscal lesions, 40 shavings of the 
articular cartilage of the patella or the 
femoral condyle and 33 lavage proce­
dures. Trimming was considered to be 
the minimal resection in treating 
small meniscal tears. Debridement of 
articular cartilage of the femoral con­
dyle was performed on five occasions. 
Only 11 knees required open opera­
tive procedures, including reconstruc­
tive procedures for anterior cruciate 
ligament deficiency and open menis­
cectomies for difficult posterior horn 
tears to the lateral meniscus.
Other therapeutic modalities were 
used in the pre- and post-arthroscopic 
management period. Oral anti-inflam­
matory agents have been shown to 
reduce post-arthroscopy swelling and 
pain, allowing earlier, more-effective 
rehabilitation.7 Stretching exercises, 
ice, frictional massage and electro­
therapy were all used. In several pa­
tients with anterior cruciate ligament 
tears the knee was braced.
Return to Sport
Most patients (91%) returned to 
their sport within 3 months of their 
arthroscopy (range from 1 week to 6 
months) and achieved a performance 
level similar to that before injury 
(Table VII). Patients with meniscal 
lesions, chondral lesions or pathologic 
plicae tended to return more quickly, 
most within 3 months, whereas those
T a b le  V I— A rth ro s c o p ic  Surgica l P rocedures 
(n =  1 65 )
P rocedure No. (%)
R esection 61 (37)
M en isca l 51
Plica 10
A rtic u la r  ca rtila ge  shaving 4 0  (24)
Pate lla 19
M e d ia l fe m o ra l co ndyle 18
L ate ra l fe m o ra l condyle 3
Lavage 33 (20)
T rim m in g 10 (6)
M e n isca l 8
Fat pad 2
D e b rid e m e n t 8 (5)
C lo se d  la te ra l release 3 (2)
M isce lla ne o us
L a te ra l s u b s titu tio n  over th e
10 (6)
to p 6
O pen  m e n is c e c to m y 3
C h o n d ro p la s ty 1
Tab le  VII-— R eturn  to  S p o rt
T im e , m o No. (%)
0 -  1 3 0  (25)
1 - 3 55 (45)
3 - 6 2 0 (1 7 )
>  6 5 (4)
N o  re tu rn 11 (9)
with chondromalacia patellae or ante­
rior cruciate ligament injuries general­
ly had a more prolonged recovery. 
Eleven patients were unable to return 
to their sport as a result of their 
injury.
Discussion
In the past, emphasis has been 
placed on facial and upper extremity 
injuries in racquet sports. It is evident 
from this study that a substantial 
number of racquet sports injuries 
occur in the lower extremities, partic­
ularly knee joints. Over half the pa­
tients with knee injuries underwent 
arthroscopy and in 90% of those 121 
people, gross intra-articular lesions 
were found. The lesions seen were no 
different from those seen in other 
sports injuries, and the proportions of 
lesions were similar to those in other 
non-contact sports. Investigations 
into the causes of the injuries identi­
fied twisting as the major culprit, but 
no strong conclusions can be made 
with respect to causative or preven­
tive factors. It is our opinion that a 
proper warm-up, consisting of stretch­
ing and rallying for an adequate 
length of time, might reduce the num­
ber of injuries seen. Prospective, well- 
controlled studies into these and other 
potential preventive measures such as 
shoe type and condition are needed, 
so that appropriate recommendations 
can be made to the ever-growing num­
ber of racquet sports participants. The 
increasing use of protective equip­
ment to prevent eye injuries by 
squash and racquetball players is in­
dicative of the influence work such as 
this can exert. It was reassuring that 
over 90% of patients returned to their 
sport and that 80% returned within 3 
months and had regained their pre­
injury performance level. Just as other 
investigators have found in the past,8-9 
we believe that the use of operative 
arthroscopy, as opposed to more tra­
ditional open techniques, played a 
major role in the early and successful 
return of our patients to their desired 
activities.
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Trauma, Sepsis, and Shock. The Physiolog­
ical Basis of Therapy. Edited by George 
H.A. Clowes, Jr. 587 pp. Illust. Marcel 
Dekker, Inc., New York, 1988. $125.00 
(US). ISBN 0-8247-7502-3.
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BURNS AND THEIR TREATMENT. 3rd 
ed. I.F.K. Muir, T.L. Barclay and 
J.A.D. Settle. 177 pp. Illust. Butter- 
worth and Co. (Publishers) Ltd., Lon­
don; Butterworth Publishers, Stoneham, 
Mass., 1987. $65.00 (US). ISBN 
0-407-00333-9.
Muir and Barclay are joined by J.A.D. 
Settle to produce the third edition of Burns 
and Their Treatment. Comparison of this 
edition with the first reveals that all of the 
original chapter headings have been re­
tained and some of the original informa­
tion remains unchanged. Additions to the 
section on outpatient treatment include 
first aid and transport, and the last chapter 
on administrative aspects of burns in­
cludes design of a burn unit. Important 
material on the management of a large 
number of burns from a disaster is includ­
ed, based on first-hand experience with the 
Bradford football-stadium fire of 1985.
Burn shock and fluid resuscitation fills a 
quarter of this book. Plasma administra­
tion is advocated as the cornerstone of 
initial resuscitation. This practice is no 
longer common in North America but may 
be so in the United Kingdom. The estima­
ted volume requirement for the first 24 
hours is close to that calculated by the 
Brooke or Evan’s formula, with supple­
mentation orally by water or intravenously 
by 5% dextrose. The authors do not stress 
the overall importance of measuring hour­
ly urine output to regulate fluid replace­
ment but attach equal importance to rest­
lessness, colour, blood pressure, nausea 
and hematocrit value. (They mention crys­
talloid resuscitation methods and dismiss 
these as of no greater benefit because 
hematocrits in patients treated with crys­
talloid solutions are still high at the end of 
24 hours, a state one would expect in the 
presence of extensive burns.)
Although they recommend the use of 
plasma, the authors cite the cost and the 
dangers of transmitting hepatitis and 
AIDS. They advocate red blood cell ad­
ministration for burns to 10% or more of 
the body surface, although earlier they 
state that patients with burns of up to 15% 
of the body surface do not even require 
fluids intravenously. For burns of more 
than 25% of body surface area, they advo­
cate red blood cell administration 4 to 8 
hours and again 24 to 36 hours after 
injury. Today, unless escharotomies have 
been performed with excessive blood loss, 
red blood cells would not normally be 
administered until after 48 hours.
The book contains a curious mix of 
detail and lack of detail. For instance, 
morphine intravenously, 0.2 mg/kg body 
weight, is advocated but no time interval is 
given for repeat administration. There are 
three sentences on how to insert a subcla­
vian line for central venous pressure. Any­
one who needs such instruction would 
require much more detail. Use of Dextrane
202
in the first 24 hours is now of only 
historical interest but receives a full page, 
while crystalloid resuscitation, including 
hypertonic, advocated by Monafo and the 
Parkland formula of Baxter, both receive 
only brief mention.
Bums of the respiratory tract occupy 
two pages including a half-page description 
on how to do a tracheotomy, compared 
with three pages devoted to treatment of 
open wounds. No mention is made of the 
diagnostic criteria for smoke inhalation, 
including roles of patient history, broncho- 
scopic findings, blood gas levels, chest 
x-ray findings and results of zenon wash­
out, and no treatment principles are in­
cluded. It is evident that, although smoke 
inhalation is a major component in com­
prehensive burn care, these authors regard 
it as someone else’s problem.
The chapter on local treatment of the 
burn wound is a mix of old and new 
concepts and includes the only balanced 
evaluation of different treatment philoso­
phies such as early versus delayed excision. 
The role of topical antibacterials is 
touched on and the value of Sulfamylon in 
penetrating infected wounds is stressed. 
Today one would probably excise an in­
fected wound. Surprisingly, the important 
differentiation between bacterial coloniza­
tion and invasive infection is not ad­
dressed, and the value of a full-thickness 
biopsy for histologic examination and 
quantitative culture of the wound are miss­
ing. The open and closed methods of 
grafting are discussed, but practical infor­
mation on the use of sutures, staples, 
tie-over dressings and splints for grafting 
across joints is not given.
The usual methods of storage and refrig­
eration of grafts at 4°C is mentioned. 
Storage at — 4°C, providing 3 months of 
viable autografts, is advocated. This meth­
od has not become common and its inclu­
sion is, I think, misleading. The accepted 
pretreatment of skin with glycerol and 
rapid freezing to -70°C  is included. For 
limited donor sites, meshing nine to one is 
advocated. This technique has not really 
gained wide practical acceptance and other 
methods of circumventing limited donor 
sites are available. The text acknowledges 
the existence of AIDS and other blood and 
tissue-transmitted diseases but advocates 
the archaic and dangerous practice of har­
vesting extra skin from other burn patients 
for a patient requiring homograft, without 
first testing the donor burn patient for 
AIDS and hepatitis. This practice is to be 
condemned in 1987.
Escharotomy is buried in a section on 
management of limb burns but really be­
longs with initial management. No techni­
cal details are included.
The shortcoming of this third edition is 
its adherence to the original chapter head­
ings and format, which reflect burn prob­
lems at the time of initial publication in 
1962. Thus, emphasis on plasma for initial
fluid resuscitation, sparse mention of the 
complex problem of smoke inhalation in­
jury and opinions on the role of excisional 
surgery and topical antibacterial use, 
which do not reflect present practice, date 
this book. It would be interesting to know 
how many of the treatment methods de­
scribed are actually standard in British 
hospitals today.
CHARLES F.T. SNELLING, MD. FRCSC
Director,
Burn Unit,
Vancouver General Hospital,
855 West 12th Avenue,
Vancouver, BC 
V52 1M9
REOPERATIVE VASCULAR SU R ­
GERY. Edited by Hugh H. Trout, III, 
Joseph M. Giordano and Ralph G. De- 
Palma. 392 pp. Illust. Marcel Dekker, 
Inc., New York, 1987. $89.00 (US). 
ISBN 0-8247-7723-9.
This book is one of a series on the science 
and practice of surgery. Its editors are 
from The George Washington University 
Medical School in Washington, DC. The 
authors are experienced surgeons who 
present practical solutions to difficult 
problems.
Vascular surgery has developed rapidly 
in the past 35 years, so the number of 
reoperations has also increased. Second 
operations are more difficult due to scar­
ring and limited options. Few surgeons 
have extensive experience in this field.
Repeat operations on the vascular sys­
tem are required by progression of athero­
ma, myointimal hyperplasia, infection, re­
jection of transplants or development of 
false aneurysms. The management of prob­
lems such as false aneurysms, infected 
bifurcation grafts and occlusion of a bifur­
cation graft are discussed in the book. Less 
common problems such as failed in-situ 
vein grafts and reoperations for inferior 
vena caval obstruction or thoracic outlet 
compression are also included. There is a 
chapter on the role of myocardial revascu­
larization for patients with peripheral vas­
cular disease.
The book is attractively printed and has 
excellent illustrations. It will be valuable 
for vascular surgeons, for fellows in vascu­
lar surgery and any surgeons performing 
vascular procedures.
S.E. Ca r r o l l , m d , f r c s c
Professor of surgery,
University of Western Ontario,
St. Joseph’s Hospital,
268 Grosvenor St.,
London, Ont.
N6A 4V2
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Further Remembrances of That Revered Anatomist,
Dr. J.C. Boileau Grant
From access to  a detailed curricu lum  
vitae w ritte n  by Dr. Grant w h e n  he 
was about 75 years old, the  author has 
learned some little -kn o w n  fa c ts  of his 
background and life.
His ancestors came from  France 
and had been ennobled. One predeces­
sor was a m ayor of Paris. Several of 
his fam ily  decided to  em igra te  to  Great 
Britain w ith  the  Huguenot m ovem ent.
Grant graduated from  the  University 
of Edinburgh in 1908  in the  sam e class 
as his fu tu re  b ro ther-in -law , W illiam  
Boyd.
W hen W orld W ar I w as declared, he 
im m ediate ly volunteered fo r the  army. 
During service on the  W este rn  Front, 
he was m entioned in d ispatches in 
1916, won the  M ilita ry  Cross in 1917 
and a bar to  the  M ilita ry  Cross in 
1918.
A t the outbreak o f W orld  W ar II, 
Grant, w ho had been a professor of 
anatom y f irs t in W inn ipeg and then in 
Toronto fo r m any years, volunteered 
again for w a r service, but w a s  rejected 
as being too valuable a teacher to be 
allowed to  enlist.
Ayant pu consulter un curricu lum  vitae 
detaille ecrit par le Dr G rant alors qu 'il 
avait environ 75 ans, I'a u te u r a appris 
quelques fa its  peu connus sur ses an­
tecedents e t sa vie.
Ses ancetres, des gens qui avaient 
ete anoblis, venaient de France. Un 
d 'en tre-eux ava it e te m aire de Paris. 
Plusieurs m em bres de sa fam ille
*Emeritus Clinical Professor o f  Surgery, 
University o f British Columbia, Vancouver, 
BC
Accepted for publication Oct. I, 1987
Reprint requests to: Dr. C.L.N. Robinson, 
808 -  750 West Broadway, Vancouver, BC  
V5Z 1H7
avaient decide d 'em ig re r en Grande- 
Bretagne lors du deplacem ent des Hu­
guenots.
Grant ob tin t son d ip lom e en 1908 
de I'U nivers ite  d 'Edinbourg. II e ta it de 
la m em e prom otion que W illiam  Boyd, 
son fu tu r beau-frere.
A  la declaration de la Prem iere 
Grande Guerre, il s ’est im m ed ia tem ent 
porte volonta ire a I'A rm ee. Durant son 
service sur le fro n t occidenta l, son nom 
fu t m entionne dans les depeches m ili- 
ta ires en 191 6, il rem porta  la croix 
m ilita ire  en 1917  e t a jouta une ba rre t­
te  a sa croix en 1918 .
Au declenchem ent de la Seconde 
Guerre M ondiale, G rant, qui ava it ete 
professeur d 'ana tom ie  a W innipeg 
puis a Toronto pendant plusieurs an- 
nees, se porta de nouveau volontaire. II 
fu t  tou te fo is  re jete, ses m erites de 
professeur e ta n t juges trop  im portan ts  
pour lui pe rm ettre  de s 'enroler.
Dr. J.C.B. Grant (Fig. 1) died in 
August 1973 at the age of 87 years. 
Twelve years before he had written a 
detailed curriculum vitae, one copy of 
which was given to his brother-in-law, 
Dr. David Christie (Grant’s wife, Cat- 
riona, was a Christie, as was Enid, the 
wife of Dr. William Boyd). Because I 
had assisted in caring for him during 
his final illness and knowing that I 
had been an anatomy demonstrator 
for Dr. Grant, Dr. Christie be­
queathed the copy to me.
In an early paragraph of the curric­
ulum vitae, written when he was 75 
years of age, Grant states:
My mother was a direct descendant, 
20th generation, of Etienne Boileau, who 
was the first Mayor or Provost of Paris, in 
the year 1255. Being of the Reformed 
Church (Huguenots), some of the Boileaus 
left France for England and Ireland in the 
year 1685.
According to the Boileau family 
tree, a John Boileau (fourth genera­
tion after Etienne) was ennobled, by 
King Charles V, and the nobility con­
tinued for at least another nine gener­
ations, the last of the titled members 
of the family that remained in France 
was a Charles Boileau (Dr. Grant’s 
full Christian names were John 
Charles Boileau).
Grant graduated in medicine from 
the University of Edinburgh in 1908, 
in the same class as Dr. William 
Boyd. During the following year he 
was for a term resident medical offi­
cer at the Infirmary in Whitehaven, 
Cumberland. From 1909 to 1911, he 
was a fulltime demonstrator of anato­
my in the University of Edinburgh, 
under Professor Cunningham. He was 
also a demonstrator of anatomy from 
1911 to 1913 at the University of 
Durham, Newcastle-on-Tyne, under 
Professor R. Howden, who was the
FIG. I — Dr. J.C.B. Grant.
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editor of Gray’s Anatomy. He then 
served as resident medical officer in 
the ear, nose and throat department at 
the Infirmary in Bristol from 1913 to 
1914. In the meantime, he was locum 
tenens numerous times in general 
practice, to supplement his income.
In his curriculum vitae he titles war 
service as “Period of the First War”:
War was declared by Great Britain on 
Germany on 4 August, 1914. On the next 
morning, I wrote to the War Office apply­
ing for a commission in the R.A.M.C. and 
this I did not receive until 2nd November, 
1914. I was posted to a regiment of the 
Rifle Brigade, stationed on the Island of
Sheppey. In February 1915, as medical 
officer I helped to erect the first hospital, 
18th general hospital near Le Touquet, 
Paris Plage. On July 1915, I became medi­
cal officer to the 1st Battalion Grenadier 
Guards. On September 9th, 1917, I asked 
to be transferred to the 9th Division, for 
the reason that my remaining brother was 
adjutant to a Battalion in that Division. I 
was posted to the 8th Battalion Black 
Watch (R.H.). On 6th September 1918, I 
was transferred to 58th C.C.S. to do Ear, 
Nose, and Throat work. On 17th October 
1918, I was transferred to No. 10 Station­
ary Hospital to continue that work. On 
11th November 1918 came the Armistice.
Military Awards
The curriculum continues:
I was mentioned in Dispatches in Sep­
tember 1916, received a Military Cross 
(immediate award) in September 1917, 
and a bar to the Military Cross (immediate 
award) on August 19, 1918 (2nd army). In 
April 1919, I was demobilised and re­
turned to Anatomy and Newcastle-on- 
Tyne.
The exact deed of valour for the 
mention in dispatches has not been 
detailed, but was printed in The Lon­
don Gazette, Jan. 4, 1917, and signed 
by General Sir Douglas Haig, GCB, 
Commander, the British Armies in 
France, and dated Nov. 13, 1916 (Fig. 
2 ).
The Military Cross is dated July 31, 
1917, place of deed Boisinghe.
T./Capt. John Charles Boileau Grant, 
M.B., R.A.M.C. For conspicuous gallantry 
and devotion to duty during attack. Find­
FIG. 3 — Grant demonstrating anatomy of skull to one of his students.
ing that all his stretcher-bearers were occu­
pied, he went forward dressed the cases 
himself on the spot, sending them back as 
opportunity arose and stretchers turned 
up. By this gallant act of devotion he 
undoubtedly expedited the evacuation of 
the wounded from the shelled area.
This would have been awarded dur­
ing the Third Battle of Ypres, during 
an offensive under General Haig’s 5th 
Army.
The bar to the Military Cross is 
dated Apr. 19, 1918, place of deed 
Meteren. This action would have oc­
curred at the start of the last great 
German offensive, led by General Lu- 
dendorf. The offensive continued 
along the battle lines to the south as 
far as Chateau Thierry and Rheims 
for the remainder of the summer and 
autumn, and then Germany capitulat­
ed. It reads:
Bar to the Military Cross
T./Capt. John Charles Boileau Grant, 
M.C., M B.. R.A.M.C., 
attd 8th Bn., R. Highrs.
For conspicuous gallantry and devotion to 
duty. He attended to wounded men lying 
in the open under heavy fire, and subse­
quently for three days and nights, with 
little rest, he was constantly out with 
stretcher-bearers searching for and remov­
ing the wounded. He was undoubtedly the 
means of saving many lives, and his fine 
example was of the greatest value at a very 
trying time.
It has been stated that Dr. Grant, 
with characteristic modesty about his 
gallantry, did not collect his medals 
from Buckingham Palace (Mrs. Grant 
did it for him later).
When World War II was declared 
in 1939, Dr. Grant was 53 years of 
age and had been professor of anato­
my at the University of Toronto since 
1930. He went to enlist in the armed 
forces, but because of an inguinal 
hernia was rejected on medical 
grounds.
He immediately consulted Dr. Gor­
don Murray, who successfully operat­
ed on the hernia. When he again tried 
to enlist, he was told his contribution 
as an anatomy professor was much 
more important than as a garrison 
medical officer (Watters N: Personal 
communication, 1947).
Dr. Grant is remembered as a mag­
nificent teacher (Fig. 3), quick of 
thought and action. He could draw on 
the blackboard, using coloured chalks, 
with either hand or sometimes both 
hands simultaneously. Lectures were a 
demonstration of anatomical art, not 
to be forgotten. At the end of an hour, 
he would have filled four blackboards 
with coloured anatomical drawings, 
more an illustrator than an orator. ■
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HEAD OF DIVISION OF 
SURGICAL RESEARCH
The Research Institute of the Hospital for Sick 
Children, one of the largest and most active of its 
kind in the world, is seeking a Researcher with a 
Ph.D. and/or M.D. to head a surgical research 
group. Current research interests include: 
physiology of the microcirculation, transplantation, 
surgical oncology, and wound healing with 
emphasis on the musculoskeletal system. The 
present research group consists of 2.5 full time 
research scientists and eight part time 
clinician/scientists. The research activities are 
closely associated with well known surgical 
divisions covering all specialties of pediatric 
surgery. There is opportunity for modest growth of 
the research group in the near-term and further 
expansion in the future. Currently, approximately 
4,000 sq. ft. of space is available as well as access 
to experimental surgery animal facilities.
The successful applicant will be expected to 
obtain extramural funding to conduct his/her own 
research and encourage and develop the research 
activities of others.
Salary and level of appointment negotiable.
Please send replies, no later than June 1,1988, to: 
Dr. James D. Friesen, Director, Research 
Institute.
S88-24
jSS^^mversit^^venue^orontOj^Ontano^MSGJ^XS^
THE HOSPITAL 
FOR SICK CHILDREN
“CCAB provides direct 
assurance that consumer circulation 
claims are valid”
Lowell Lunden, Manager, Marketing Services 
The Quaker Oats Company of Canada Ltd.
“We make heavy use of consumer advertising as well 
as promotional techniques such as co-op coupon mail­
ings. As we handle direct mail campaigns ourselves, 
we were pleased when the Canadian Circulation Audit 
Board expanded its services to audit the distribution of 
direct mail coupons.”
Mr. Lunden is also enthusiastic about CCAB’s grow­
ing coverage of consumer magazines and community 
newspapers...“Just as many business-to-business 
advertisers insist on using only CCAB audited
publications, so do consumer mar­
keters gain from the high quality 
data presented through the CCAB 
Publisher’s Statement.” For 
further information call Patrick 
Sweeney at 416-487-2418.
Comprehensive Circulation Data 
for consumer, business 
and farm media
m m
RESEARCH ASSOCIATE 
ORTHOPEDIC SURGERY
The Division of Orthopedic Surgery of the University of 
Alberta is seeking a full time PhD researcher in mus­
culoskeletal surgery, immediately available with a 
background adaptable to either bio-materials, bio­
mechanics, exercise physiology, neurophysiology or 
functional electrical stimulation.
The appointment is for a minimum of three years. 
Deadline for application is May 31,1988. Appointment 
will be at the Associate Professor level. Salary com­
mensurate with rank. (Range -  $39,620 -$57,236).
Please send all correspondence to:
DR. M. MOREAU 
ROOM 4A37
EDMONTON GENERAL HOSPITAL 
111 STREET & JASPER AVENUE 
EDMONTON, ALBERTA, CANADA 
T5K0L4
The University of Alberta is an equal opportunity 
employer, but in accordance with Canada employment 
and immigration regulations, this advertisement is 
directed to Canadian citizens and permanent re­
sidents of Canada.
-S88-19
SURGEON-IN-CHIEF
TORONTO GENERAL AND TORONTO WESTERN 
HOSPITALS
The Toronto Hospital represents a merger of Toronto 
General Hospital and Toronto Western Hospital. The hospital 
is seeking a Surgeon-in-Chief to be responsible for the 
clinical and academic programs at both sites. The position is 
supported through the University of Toronto by an endowed 
chair which is located at the hospital.
The Surgeon-in-Chief will organize and lead strong clinical 
and academic programs in all sub-specialties of surgery. 
These programs are supported by over 800 beds, physician 
offices and ambulatory practice space, and hospital based 
research laboratories. The opportunity to creatively organize 
the surgical programs between the two hospitals to achieve a 
more productive clinical and academic environment is an im­
portant responsibility of this position.
The successful candidate must qualify as Professor or 
Associate Professor at the University of Toronto, must have a 
proven track record in academic surgery, and demonstrated 
leadership skills. Date of appointment open; closing date for 
receipt of applications May 31, 1988. Interested candidates 
should apply to:
Chairman
Surgeon-in-Chief Search Committee 
c/o President’s Office 
The Toronto Hospital 
585 University Avenue 
Toronto, Ontario 
M5G 2C4
-S88-17
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CLASSIFIED ADVERTISING
GENERAL 
SURGEON
The Red Deer Regional 
Hospital Centre hasa vacan­
cy fo r a General Surgeon. 
An interest in thoracic or 
vascular surgery is an asset, 
but not essential.
The Red Deer Regional 
Hospital Centre is a w ell- 
equ ipped, 400 bed ins ti­
tu tion , b u ilt in 1981, w ith  
seven operating rooms plus 
two others ‘shelled in ' fo r 
fu tu re  expansion. It serves 
Red Deer w ith a civic popu­
lation of 54,000 and a catch- 
mentarea o f approximately 
150,000.
Further inform ation can be 
obtained by contacting:
Chief of Staff Office 
Red Deer Regional 
Hospital Centre 
P.O. Bag 5030 
Red Deer, Alberta 
T4N 6R2
Phone: (403) 343-4529RH L
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PLASTIC SURGEON: ON — Applications are 
invited for the position of plastic surgeon at The 
Victoria Hospital Corporation, London, Ontario. 
The applicant must be certified in plastic sur­
gery by The Royal College of Physicians and 
Surgeons of Canada and have a minimum of 
one and preferably two years of post residency 
training in some aspect of plastic surgery. The 
position includes the management of a six bed 
burn unit. The applicant must express a primary 
interest in burn care. The position carries an 
academic rank within the department of surgery 
at the University of Western Ontario. As such, 
the applicant must express an interest in ongo­
ing basic research. The appointment is available 
as of July 1, 1988. Send enquiries to: Dr. R.M. 
McFarlane, Department of Surgery, Victoria 
Hospital, 391 South St., London, ON N6A 
4G5. -S 8 8 -2 0
OSHAWA GENERAL HOSPITAL
PLASTIC RECONSTRUCTIVE 
AND HAND SURGEONS
The Oshawa General Hospital invites applications 
for a position in plastic reconstructive and hand 
surgery on the medical staff for 1988. Canadian 
fellowship and certificate of specialty competence 
is required.
The Oshawa General Hospital is a 650-bed regional 
community hospital located 48 km east of Toronto.
Please contact:
Dr. D.G. Pierson,
Chairman, Department of Surgery 
Oshawa General Hospital 
24  Alm a St.,
Oshawa, ON L1G 2B 9 -S 88 -23
ORTHOPEDIC SURGEON: US -  Excellent 
opportunity to develop orthopedic surgery 
program affiliated with modern, regional 
hospital. Excellent guarantee plus full fringe 
benefits. Beautiful rural area one hour from 
Canadian metropolitan centre. Enjoy Ameri­
ca's most scenic sailing waters. For further 
information call: Lianne Harris, President, 
New England Health Search. 63 Forest 
Ave., Orono, Maine US 04473. Tel: 
(207) 866-5680 or 866-5685. -S88-21
ACADEMIC APPOINTMENT: ON -  Applica­
tions are invited for a full-time position in the 
Department of Urology at Queen's University. 
The successful applicant will have responsibility 
for teaching in an established postgraduate 
program involving clinical practice and adminis­
tration. There are excellent opportunities for 
basic and clinical research. The applicant must 
be able to conduct independent research. In 
accordance with Canadian immigration require­
ments, this advertisement is directed to Canadi­
an citizens and permanent residents of Canada. 
Candidates of either sex are equally encouraged 
to apply. Please send curriculum vitae and the 
names of three referees to the attention of: 
Mrs. S. Perry, Administrative Assistant, De­
partment of Urology, Queen's University. 
Kingston, ON K7L 2V6. -S88-22
See page 205for 
Classified ad numbers S88-17, 
S88-19, S88-24.
NOTICE OF CHANGE OF ADDRESS /
AVIS DE CHANGEMENT D’ADRESSE
To ensure that you continue to receive the Canadian Journal o f  Surgery without 
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Avant de demenager, assurez-vous de recevoir sans interruption le Journal cana- 
dien de chirurgie en completant le formulaire suivant.
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